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Introduction 
Chronic pancreatitis is an ongoing inflammation of the pancreas leading to permanent 
alterations in the structure and function of the pancreas Structural abnormalities include 
irregular dilated main pancreatic ducts, areas of stricture, inflammation and fibrosis m the gland, 
resulting in a mass, and pseudocyst formation Functional derangements are endocrine 
dysfunction advancing to insulin dependent diabetes mellitus and exocrine dysfunction 
manifesting as steatorrhoea and weight loss Pain is the most disabling symptom of chronic 
pancreatitis 
Rokitansky (1804-1878) was the first to describe chronic inflammation of the pancreas 
"resulting in enlargement or shrinkage of the gland" (Rokitansky 1842) Leopold Oser (1839-
1910) distinguished two forms inflammation of the entire gland and focal inflammation (Oser 
1898) Chronic pancreatitis was identified as a distinctive disease in 1946 following the 
description of Comfort et al (Comfort et al 1946) Based on observations, they defined the 
clinical features of chronic pancreatitis, delineated its association with alcohol intake and 
introduced the term "chronic relapsing pancreatitis" Notably, the association between chronic 
alcohol abuse and chronic pancreatitis was already known at the beginning of the twentieth 
century (Gruber 1929, Weichselbaum 1912) 
From 1950 up to recently several classifications have been made of this disease based on clinical, 
etiological and/or morphological criteria in an attempt to gain uniformity in reports on chronic 
pancreatitis and to provide guidelines for treatment The Marseille classifications in 1963, 1984 
and 1988 described morphological, seventy and etiological characteristics The Cambridge 
classification in 1984 defined, among others, the severity of the disease based on imaging criteria 
(Sarner and Cotton 1984) Both these classifications have drawbacks due to the fact that clinical 
signs often did not match with morphological abnormalities The M-ANNHEIM classification 
has been advocated incorporating multiple risk factors, the disease severity, the different stages of 
the disease and criteria of previous classification systems (Schneider et al 2007) The complexity 
of this classification however, will render its clinical application difficult Recently, a clinically 
based classification in analogy with the Child-Pugh liver cirrhosis classification has been 
proposed, based upon clinical signs, morphology and pancreatic function, which appears to be 
more adapted to clinical use (Buchler et al 2009) The many attempts to classify chronic 
pancreatitis reflect the complexity of the disease and its various manifestations Even the most 
experienced specialist in chronic pancreatitis is frequently puzzled by patients having severe 
typical pancreatitis pain with normal pancreatic morphology or patients with numerous 
intraductal stones and parenchymal calcifications without pain (see Figure 1) 
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I CT scan of a patient with severe pain and almost normal morphology of the pancreas CT scan of a patient without pain and gross pancreatic abnormalities 
Incidence of chronic pancreatitis 
Incidence rates of chronic pancreatitis in Western Europe countries and the United States is 
estimated to be 3-8 patients per 100.000 with a prevalence of 25-75 cases per 100.000 (Levy et 
al. 2006; O'Sullivan et al. 1972; Dite et al. 2001). The malerfemale ratio depends of the type of 
pancreatitis, and ranges from 8-9:1 in alcohol chronic pancreatitis (Amman et al. 1987; Lankisch 
2001) to 1-2:1 in tropical and non alcohol chronic pancreatitis (Lankisch et al. 1995b). There is 
a difference between countries mostly attributed to the variation in prevalence of risk factors 
such as alcohol abuse and genetic predisposition (Dite et al. 2001). There are no accurate time 
trends available regarding the incidence of CP. The hospital admission rates for patients with 
chronic pancreatitis seem to have increased over the last decades (Spanier et al. 2008b). 
Aetiology of chronic pancreatitis 
The aetiology was traditionally divided in alcohol, idiopathic and "others". Later, systems to 
categorize causes and risk factors were more elaborated. Etiologic risk factors (risk modifiers) are 
listed most systematically in the TIGAR-O classification (Etemad and Whitcomb 2001) and the 
M-ANNHEIM multiple risk factor classification (Schneider et al. 2007) Although many factors 
are known to be related to the development of chronic pancreatitis, the mechanisms of action 
have not all been unravelled and there are still patients in whom the cause has not been found. 
Introduction | 15 
E l Incidences of chronic pancreatitis in Western European countries (Andersen et al. 1982: Dite et al. 2001: Spanier et al. 
I 2008a: Tinto et al. 2002: Schmidt 1991: Beger and Pap 1991; Dzieniszewski andjarosz 1991: Capitaine 1991: 
I Jaakkola and Nordback 1993) I In the Netherlands, like all Western countries, the major cause of chronic pancreatitis is alcohol abuse (Spanier et al. 2008a). Genetic predisposition, however, seems important too, given the 
fact that in some Western countries with high alcohol abuse, incidence of chronic pancreatitis is 
relatively low compared with others (Figure 2). Furthermore, although alcohol is unmistakably a 
contributing factor, only 2% of the men with known alcohol abuse suffer from pancreatitis 
related disease (Ahmed et al. 2006). 
Natural course of chronic pancreatitis 
The natural course of chronic pancreatitis can be divided into that of pancreatic function, pain, 
progression to pancreatic malignancy and mortality. An accurate description of the natural 
course is difficult because the underlying causes, the genetic predisposition and anatomical 
complications differently influence the evolution of chronic pancreatitis (DiMagno et al. 1993; 
Ahmed et al. 2006). For example, continuation of alcohol and smoking accelerate the disease 
course (Maisonneuve et al. 2005; Maisonneuve et al. 2006). 
From a recent prospective study by Mulhaupt et al. the median age at onset of alcohol 
pancreatitis was 36 years, 23 years in early onset idiopatie pancreatitis, 62 years in late onset 
pancreatitis and 10 years in hereditary pancreatitis (Mullhaupt et al. 2005). 
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Disabling pain is present in approximately 80% of patients (Layer et al. 1994). The natural 
history of pain in chronic pancreatitis is matter of debate. Extinction of pain following 
progression of pancreatic fibrosis and atrophy and increasing loss of pancreatic function has been 
reported, called the 'burn out phenomenon' of the pancreas (Amman et al. 1984; Kalthoffet al. 
1984; Lankisch 2001; Layer et al. 1994; Mullhaupt et al. 2005; Lankisch et al. 1995a). The time 
period of spontaneous pain relief varies between a few years to up to three decades and is highly 
unpredictable for the individual patient. 
Chronic pancreatitis is associated with a 15-50 fold increased risk of pancreatic cancer especially 
in alcoholic and hereditary pancreatitis (Lowenfels et al. 1993; Lowenfels et al. 2001; Lowenfels 
and Maisonneuve 2005). Life expectancy of patients with chronic pancreatitis is reduced, mostly 
due to alcohol abuse and smoking related non-pancreatic diseases (Mullhaupt et al. 2005; 
Lowenfels et al. 1994; Levy et al. 1989). 
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Pain in chronic pancreatitis 
Pain is the main reason for which patients with chronic pancreatitis seek medical help. Chronic 
pain is the most important predictor of health-related quality of life in these patients. The pain is 
typically located in the midepigastric region with referral to the back, particularly at the left side. 
Patients present with a heterogenous pain pattern ranging from relapsing episodes to persistent 
pain of varying severity (see figure 3). Pain patterns differ among the types (causes) of chronic 
pancreatitis, probably due to different pain mechanisms. 
Persistent pain with slight 
fluctuations 
Pain attacks without pain 
between them 
ÎVi Persistent pain with pain attacks Pain attacks with pari between them 
I Pain patterns according to the Pain-Detect Qttestionaire 
With progression of the disease, pain attacks become more frequent and severe. Most patients 
develop continuous pain during the course of the disease (type Β pain), a smaller number 
continue to have intermittent attacks (type A pain) (Cruciani and Jain 2008). 
There are two main complimentary theories explaining the pathogenesis of pain in chronic 
pancreatitis patients; the neurogenic theory and the increased intraductal/intraparymchymal 
pressure theory. According to the neurogenic theory there are alterations of pancreatic/ 
peripancreatic nerves as a result of exposure to noxious substances and/or activated immune 
cells, thereby generating pain ('neuroimmune interaction')(Vera-Portocarrero and Westlund 
2005; Hegde and Bhatia 2005). This pain theory accords well with the theories explaining so 
called neuropathic pain in somatic nerves. The increased intraductal/intraparenchymal pressure 
theory postulates that the pain is generated as a result of increased pressures in the pancreatic 
ductal system and/or parenchyma due to obstruction by strictures, stones or inflammation 
(Hellender and Laugner 1993; Klöppel 1990). This theory resembles that of the classic 
compartment syndrome. The intraductal/intraparenchymal pressure theory is strongly supported 
by the good results of surgical and endoscopical drainage procedures in many - but not all -
chronic pancreatitis patients. 
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Other possible explanations for pain are pancreatic ischemia, oxygen-free radical production, 
attacks of acute pancreatitis and complications of chronic pancreatitis including pseudocysts, 
common bile duct stenosis or duodenal obstruction (Cruciani and Jain 2008; Sakorafas et al. 
2007). All these entities fit well into both pain theories and should - for reasons of clarity - not 
be considered as separate pain mechanisms. 
Standard treatments of chronic pancreatitis pain 
Patients with chronic pancreatitis pain are treated by conservative, endoscopic or surgical means 
or combinations hereof. A broadly accepted treatment algorithm has been published in 1999 by 
the American Gastroenterology Association (AGA) (see Figure 4). 
Although it is advised to individualize treatment, most patients are initially treated by 
conservative means when other causes of pain like pseudocysts, bile duct obstruction, peptic 
ulcer or maldigestion have been excluded. 
The conservative management consists of stopping alcohol consumption and smoking, dietary 
adaptations, pancreatic enzyme supplements and analgesics. Alcohol abstinence reduces the pain 
in many patients. In a series of studies, Trapnell found that 75% of the patients who stopped 
alcohol intake experienced pain relief (Trapnell 1979). 
Despite this favorable finding, the effect of alcohol stop on pain relief remains controversial 
(Strum 1995). Dietary measures such as avoidance of high fat content foods have been reported 
as reducing pain, but this result is not very well documented (van Esch et al. 2006) Pancreatic 
enzyme supplements aim to decrease intraductal pressure by reducing pancreatic secretion via a 
negative feedback mechanism. Although the concept is plausible, the effect on chronic pain is 
not evident (Shafìq et al. 2009). Initially, non-opiate analgesics like acetominophen with or 
without codeine phosphate and NSAIDS are prescribed to combat pain. Patients with acute 
relapses of pancreatitis often need opioid treatment in a clinical setting. Many patients with 
chronic pancreatitis progress to daily opioid use despite optimal conservative treatment. 
Endoscopic treatment is indicated in selected patients who have intraductal stones and/or 
strictures causing duct dilatation. Initial results of endoscopic treatment were promising showing 
about 75% pain relief (Huibregtse et al. 1988). However, recent prospective randomized 
comparative trials have highlighted the limitations of endoscopic lithotrypsy and ductal stenting 
and better alternatives. Extracorporeal shock wave lithotripsy gave similar pain relief as 
endoscopic lithotripsy without stent placement (Dumonceau et al. 2007). Endoscopic drainage 
of the pancreatic duct was inferior to surgical drainage in a recent randomized trial of 
longstanding chronic pancreatitis with large stones and multiple strictures of the main pancreatic 
duct (Cahen et al. 2007). 
Surgery of the pancreas has consistently been recognized as an effective treatment of unrelenting 
chronic pain. About 60% of all patients with chronic pancreatitis pain will eventually need 
pancreatic surgery (Mullhaupt et al. 2005). There are two types of surgical procedures 
corresponding with the two pain hypotheses: drainage procedures in case of a dilated main 
pancreatic duct and pancreatic resection when a (inflammatory) mass is present (Bradley 1982). 
A pancreaticojejunostomy is the most common surgical method to drain the pancreatic duct. 
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Chronic pancreatitis with pain 
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S \ 
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AGAflow chart, adapted from American Gastroenterological Association Medical Position Statement (1998) 
The technique evolved from a distal retrograde drainage (Puestow & Gillesby) to a side-to-side 
longitudinal pancreaticojejunostomy after completely deroofing (decompressing) the pancreatic 
duct (Partington & Rochelle) (Puestow and Gillesby 1958; Partington and Rochelle 1960) (see 
Figure 5). Reported pain relief after a drainage procedure is about 70% (Carter 1993; Beger et 
al. 2005). Pain relief after pancreatico-jejunostomy seems to be not only the result of duct 
decompression but also of decreased parenchymal pressure, restoration of pancreatic blood flow 
and reduced influx of inflammatory mediators across the damaged perineurium of 
intrapancreatic nerve fibers (Holmberg and Isaksson 1985; Sakorafas et al. 2007). The principle 
of the V-shape excavation of the pancreas according to Izbicki with suturing of the pancreatic 
remnant to a jejunal limb is based on parenchymal pressure relief. 
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This technique is advocated for patients with an irregular but no gross dilatation of the 
pancreatic ducts (Izbicki et al. 1998; Yekebas et al. 2006). Pancreatic resections for pain are 
based on the neurogenic theory e.g. that the inflammatory mass involves the pancreatic nerves 
causing pain. Most resections, however, also decompress the main pancreatic duct. Classical 
procedures are a standard Whipple's operation, a pylorus-preserving pancreaticoduodenectomy 
or a distal pancreatectomy (left pancreatic resection). Beget et al. introduced the duodenum 
preserving pancreatic head resection to avoid the morbidity associated with duodenal resection 
and abnormal gastro-intestinal continuity. More recent procedures combine a resection of the 
pancreatic head with drainage of the main pancreatic duct. Examples are the Frey procedure 
consisting of'coring-out' the pancreatic head followed by a longitudinal pancreaticojejunostomy 
(Frey and Smith 1987) (see Figure 5) and the modified Beget procedure (Beget et al. 1985) 
Figure 3 Α-B Drawing and operative picture of the two types of procedures used at the Department of Surgery, Radboud 
University Nijmegen Medical Centre: I Frey procedure: the head of the pancreas is cored out (dark arrow) and a longitudinal pancreaticojejunostomy is created (light arrow) Longitudinal pancreaticojejunostomy over a dilated duct according to Partington Rochelle (light arrow) 
Resection procedures seem to have a slightly better long-term pain relief (about 80%) than the 
dtainage procedures, but are associated with a higher morbidity ( 2 0 ^ 0 % ) . A Frey procedure 
might have little advantage ovet the Beget regarding operative difficulty and complications 
(Izbicki et al. 1995). 
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A prospective randomized comparison between the two procedures, however, revealed no 
differences in pain relief, mortality, pancreatic function and quality of life at 9 years follow-up 
(Strate et al. 2005). 
Surgery fails in approximately one third of patients. Higher failure rates have also been reported 
depending of the type of procedure (Beger et al. 2005; Schnelldorfer et al. 2006). Treatment 
failure may in part be due to disease exacerbation. 
Patients with alcohol and nicotine abuse who have difficulty stopping drinking and smoking, 
show disease progression and persistence of pain (Maisonneuve et al. 2005; Maisonneuve et al. 
2006; Strum 1995; Trapnell 1979; Talamini et al. 1999). However, in the majority of cases, 
there is no proper explanation for the persistence or relapse of pain and little is known regarding 
the fate of patients after failed initial surgery. Twenty years ago Imrie proposed an algorithm for 
the management of recurrent pain following surgery. The complexity of this algorithm illustrates 
the difficulty understanding the mechanism of pain persistence and recurrence (Imrie 1990). 
Since then, surgeons have made little effort to study treatment failure and alternative treatment 
options (Alexakis et al. 2004; Bradley, III et al. 1998; Keus et al. 2003). Only a few studies 
addressed the feasibility of reoperation unfortunately without extensive discussion of the results 
in terms of pain control (Schnelldorfer et al. 2006). In a retrospective study Prinz et al found 
"substantial pain relief' in 11 out of 14 patients after a re-drainage procedure performed 2 
months to 18 years after an initial drainage procedure (Prinz et al. 1986). Results of re-resection 
are scarce and contradictory (Markowitz et al. 1994; Brinton et al. 1984). Total or near-total 
pancreatectomy has been done as a salvage procedure, but is controversial because of the partial 
success in pain relief and the occurrence of disabling pancreatic endocrine insufficiency (Alexakis 
et al. 2003; Muller et al. 2007). Reluctance to do re-drainage surgery or re-resection is 
understandable given the unpredictable outcome and the high morbidity of these procedures. In 
order to provide further help less invasive procedures such as surgical nerve ablation are offered 
to patients with persistent or recurrent pain. 
Denervation for chronic pancreatitis pain 
According to the AGA guidelines (surgical) denervation procedures should be considered when 
patients with small duct disease who need opioids and have had no perceived benefit from 
maximal conservative therapy or endoscopy (Warshaw et al. 1998) (see Figure 4). Several 
approaches exist, all attempting to extrinsically denervate the pancreas (1998; White 1943). The 
older techniques were rather complicated including intraoperative chemical splanchnicectomy, 
surgical splanchnicectomy and ganglionectomy, selective pancreatic denervation and (segmental) 
pancreatic autotransplantation. Despite initial enthusiasm most procedures did not provide 
long-term pain relief. Good results, however, have been achieved by open surgical 
splanchnicectomy with or without ganglionectomy (Sastre et al. 1992; White et al. 1966). This 
procedure is based on the concept that the majority of nociceptive input from the pancreas is 
processed via the autonomic splanchnic nerves that run from the celiac plexus into the 
sympathie cord between Th5-Thl2 (Mallet Guy et al. 1949; Mallet Guy 1983; White 1943; 
Naidoo et al. 2001). This open surgical procedure has not been performed on a wide scale 
because it was technically demanding and had major complications. 
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The rise of minimally invasive surgery caused renewed interest in splanchnicectomy to treat 
chronic pancreatitis associated pain. That the procedure could be successfully performed by 
video assisted thoracoscopy with a low morbidity was demonstrated first by Cushieri et al. in 
1994 (Cusdueri et al. 1994). 
Only a few groups perform thoracoscopic splanchnicectomy on a routine basis for patients with 
chronic pancreatitis pain (Ihse et al. 1999; Howard et al. 2002). Different approaches have been 
described varying from unilateral (Makarewicz et al. 2003), two step bilateral (Kusano et al. 
1997; Kusano et al. 1997; Mäher et al. 1996) and one step bilateral splanchnicectomy (Buscher 
et al. 1999; Andrén-Sandberg et al. 1996). Short term results of thoracoscopic splanchnicectomy 
were encouraging in many aspects; 80% pain relief, no mortality, a low morbidity and a short 
hospital stay (Cuschieri et al. 1994; Mäher et al. 1996; Kusano et al. 1997) (see table 2) 
Short term results ofBTS in the various series. N= number of patients 
Cushieri et al.(Cuschieri et al. 1994) 
Mäher et al.(Maher et al. 1996) 
Kusano et al.(Kusano et al. 1997) 
Sandberg et al.(Andrén-Sandberg et al. 1995) 
Buscher et al.(Buscher et al. 1999) 
Bradley et al.(Bradley, III et al. 1998) 
Lekowski et al.(Leksowski 2001) 
Ν 
5 
15 
9 
13 
26 
16 
20 
Success rate 
60% 
79% 
78% 
100% 
58% 
80% 
7 5 % 
Median Follow up 
8 
18 
14 
9 
14 
23 
6 
'months) 
Long term pain relief however, was questionable and in any case seemed less than short term 
pain relief (Baghdadi et al. 2008). Similar to failure after drainage procedures and pancreatic 
resection, surgeons made little effort to understand why patients do not respond to 
splanchnicectomy other than pointing at the heterogeneous patient groups including patients 
who had failed other treatments (e.g pancreatic surgery). Mechanistically, a persistent cause of 
pain or progression of pancreatic disease should not adversely affect the outcome of 
splanchnicectomy as transecting the afferent nerves stops the nociceptive input from the diseased 
organ. Thus, other pathogenic mechanisms or conditions must be present explaining therapy 
resistance and pain persistence after nerve ablation. 
Treatment failure in chronic pancreatitis pain 
Persistence of the cause of pain and progression of disease could well explain unsuccessful 
pancreatic surgery but are only marginally elaborated in surgical literature, as mentioned earlier. 
Alexakis et al. found the presence of chronic opioid use to be a predictor of unsuccessful 
pancreatic surgery. The unfavorable outcome was attributed to opioid addiction without going 
into detail regarding pathogenic mechanisms involved (Alexakis et al. 2004). Other factors 
contributing to treatment failure were also reported, including long duration of chronic 
pancreatitis pain and (multiple) previous unsuccessful therapies (Howard et al. 2002). 
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An important explanation for treatment failure, highly under-discussed in pancreatic literature, 
is the potential of patients with chronic pain to develop visceral hyperalgesia and central nervous 
sensitization (Pregni et al. 2007). 
Central sensitization in chronic pain 
To understand the development of visceral hyperalgesia and central sensitization it is necessary 
to know the neurophysiological pain pathways involved in the transmission of visceral afferent 
nociceptive information (see Figure 6). 
Visceral nociceptive input starts in the pancreatic organ by stimulating the local nerve endings. 
The pancreas contains multiple interpancreatic ganglia/neural cell bodies receiving neurons from 
projecting neurons to different structures in the pancreas such as vasculature, acini, islets and 
ducts. Primary visceral afferent fibres run through the celiac plexus along with the splanchnic 
nerves and terminate in the dorsal horn, predominantly in lamina I, II , V and X Visceral 
nociceptive spinal input is characterised by its multisegmental nature. Although visceral afferent 
inflow in the spinal cord constitutes approximately 10% of all spinal inflow, their nerve endings 
diverge extensively to second order spinal neurons with in the spinal cord. This extensive 
widespread of visceral input may explain the poor viscerotopic localisation of visceral pain 
compared to somatic pain (Knowles and Aziz 2009). Furthermore, this viscerosomatic 
convergence in the dorsal column accounts for the referral of pain, typically experienced in 
visceral pain (Gebhart 2000). Spinal afférents ascend in the spinal cord through two pathways: 
via the spinothalamic tract and lateral leminiscus to the thalamus, or via the dorsal column to 
the nucleus gracilis and cuneatus and from there via the medial leminiscus to the thalamus. 
Further processing of nociception on a supraspinal level takes place in the somatosensory cortex I 
and II (SI and SII), the insula, cingulate gyrus and thalamus for somatic pain. The insula and SII 
are of importance for processing visceral pain (Apkarian et al 2005) (Figure 6). 
Repeated nociceptive input as in chronic pancreatitis pain results in altered sensory processing by 
the central nervous system called neuroplasticity. Neuroplasticity which is characterized by both 
peripheral and central sensitization has an important role in pain that becomes chronic and 
abnormal in nature (Woolf 2000). 
Peripheral sensitisation is defined by lowered thresholds, increased rates of action potentials 
(enhanced responsiveness) and an expansion of the receptive field of the neuron. These processes 
are triggered by inflammatory mediators via direct (substance P, glutamate, serotonin) or 
indirect stimulation (interleukines, nerve growth factor, norepinephrine) (Byers and Bonica 
2001). The sustained activity of primary afférents occurring after peripheral sensitisation 
amplifies the synaptic transmission from the afferent to the dorsal horn neuron, as a result of 
facilitated excitatory responses or depressed inhibition called central sensitisation (D'Mello and 
Dickenson 2008; Dickenson 1995; Anand et al. 2007). 
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Neurophysiologicallanatomicalpathway with ascending and descending nerves. 
These processes are largely mediated by activated NMDA receptors (D'Mello and Dickenson 
2008). Not only peripheral and spinal processes but also supraspinal (i.e. descending and 
ascending) pathways influence the afferent nociceptive input (Urban and Gebhart 1999; Sarkar 
et al. 2001) (Figure 6). Central sensitization has been described in functional gastrointestinal 
disorders with visceral hyperalgesia such as irritable bowel disease and dyspepsia (Cervero 1995; 
D'Mello and Dickenson 2008; Sarkar et al. 2006; Sarnelli et al. 2004). 
Persistent or recurrent pancreatic inflammation in chronic pancreatitis is likely to induce 
ongoing or repetitive nociceptive input, leading to central sensitization and visceral hyperalgesia. 
The continuing visceral nociceptive input might at some point lead to changes in central pain 
processing that are so pathological that central pain perception becomes autonomous and thus 
independent of peripheral pain inputs. This may explain pain chronificadon and the therapy 
resistance in patients with chronic pancreatitis (Cervero 2000; Rössel et al. 2001). 
Although nerve inflammation has received more attention as important mechanism of pain in 
chronic pancreatitis (neuropathic pain), data are scarce regarding the neuroplastic effects on the 
central nervous system and the role of the central nervous system in the persistence of pain in 
patients with chronic pancreatitis (Sakorafas et al. 2007; Di Sebastiano et al. 2003). In addition, 
the modulating effect of opioid analgesics and surgery for chronic pancreatitis pain on 
neuroplasticity has not been addressed in literature to date. 
Ü 
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This thesis 
This thesis focuses on a series of patients who underwent bilateral thoracoscopic 
splanchmcectomy for disabling chronic pancreatitis pain We started doing bilateral 
thoracoscopic splanchmcectomy in 1996 Since then over 100 procedures have been performed 
at our centre, one of the largest series in the world We refined the technique initially described 
by Cushien et al by dissecting not only visible nerves through the intact parietal pleura but all 
potential nerve bearing tissue between T5 and T12 and replacing electrocautery by the harmonic 
scalpel as dissection device We also researched more in detail the effects of transecting elements 
of the sympathetic system on systemic adrenergic responses and vital signs 
The majority of patients referred to our centre had longstanding disease, continuous pain for 
many years, were opioid dependent, and often had failed previous surgical, endoscopic and/or 
percutaneous interventions First results were encouraging, adequate pain relief in the majority 
of patients after a minimally invasive and short lasting surgical procedure with low morbidity 
and a short hospital stay Our initial enthusiasm was tempered when analyzing the long-term 
results showing a marked decrease with time in percentage of patients with permanent pain 
reduction This led to a more in depth search for the causes of unsuccessful surgical therapy, the 
alterations in pain processing present in patients with longstanding chronic pancreatitis pain and 
opioid use, and the effects of splanchmcectomy on pain processing 
The major tool we used to measure pain processing in this group of patients with chronic 
pancreatitis pain was Quantitative Sensory Testing (QST) QST is a much used technique in 
pain research, in which different standardized stimuli of different modalities (e g electric, 
mechanical, thermal or chemical) can be applied with variable intensities to measure thresholds 
from non-painful to painful (Greenspan 2001, Zaslansky and Yarmtsky 1998) QST has thus far 
mainly been used in measuring patients with somatic pain syndromes, before and after an 
operation or to quantify analgesia - but less for measuring pain processes in patients with 
chronic visceral pain (Kosek and Ordeberg 2000, Stawowy et al 2002, Stawowy et al 2004, 
Wilder-Smith et al 1996, Wilder-Smith et al 2003) For our thesis, we obtained unique data 
using QST, giving new insights into pain processing in patients with chronic pancreatitis pain 
Aims of this thesis 
The aim of this thesis is to provide more insight into the role of bilateral thoracoscopic 
splanchmcectomy (BTS) in the treatment of patients with chronic pancreatitis and severe pain 
Firstly, to study technical aspects, feasibility and complications a small group of patients with 
proven chronic pancreatitis were treated with BTS (Chapter 2) Splanchnic nerves not only 
convey the primary afferent nerves but also include a majority of sympathetic nerves The 
question was raised whether BTS 1 e sympathectomy exerts clinical relevant effects on 
sympathetic activity (Chapter 3) For studying long-term effects of BTS on pain we treated a 
larger group and prolonged the median follow to36 months (range 12-60 months (Chapter 4) 
Despite deafferantation, pain persists or returns in a substantial part of the patients We 
subsequently looked for and analyzed the possible role of predefined factors in predicting the 
success or failure of BTS (Chapter 5,7) 
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Furthermore we studied the treatment options when BTS failed, and an attempt was made to 
determine its place in the treatment algorithm of CP (Chapter 5). 
With QST the presence of neuroplasticy (i.e. generalized hyperalgesia) and the effect of BTS on 
these neuroplastic alterations accompanying the pain of chronic pancreatitis were studied 
(Chapter 6 -7). We also looked to see if we could find evidence for alterations in central pain 
processing independent of peripheral nociceptive input (Chapter 8). It is known that in some 
chronic pain syndromes the autonomous nervous system may interacts with the somatosensory 
nervous system, and that this crosstalk may lead to hyperalgesia. We thus also attempted to 
demonstrate a possible relationship between sympathetic activity and pain processing in chronic 
pancreatitis patients with pain (Chapter 9). To find out if the neuroplastic changes can be 
reversed, patients with therapy resistant pain were treated with low dose Ketamin, a NMDA 
antagonist (Chapter 10). 
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Background: 
Intractable pain, the most prominent feature of chronic pancreatitis, causes the patient great 
disability, and its treatment poses a difficult problem for gastroenterologist and surgeon alike 
The main goal of treatment is to provide sufficient and lasting pain relief without the use of 
opiates When these measures fail, surgery is often unavoidable Indications, effect on pam relief, 
morbidity and mortality of drainage and resection procedures are described Bilateral 
thoracoscopic splanchnicectomy, a newly developed operation to alleviate pain irrespective of the 
type of anatomic abnormality, is outlined in more detail Early encouraging results of pain relief 
in patients with chronic pancreatitis after thoracoscopic splanchnicectomy are presented 
Intractable pain is the main problem in patients with chronic pancreatitis and poses a 
therapeutic challenge The goal of treatment is to provide sufficient and lasting pain relief 
without the use of opiates The treatment should be safe with a low morbidity and mortality risk 
and should not lead to deterioration of pancreatic function A conservative approach has long 
been advocated based on studies of the natural history of pancreatitis, suggesting a progressive 
'burning out' of the pancreas and eventually complete pain alleviation (Amman et al 1987, 
Amman et al 1988) Recently, this therapeutic conservatism has been criticized because of the 
impact of pain on patient and society and the substantial number of patients with progressive 
disease without attenuation of pam (Malferthemer et al 1994, Frey et al 1989) In such 
patients, and particularly in those who have intractable and disabling pain and who become 
opiates-dependent, more aggressive surgical approaches arc warranted Traditionally, two types 
of operation are used for pain relief in patients with chronic pancreatitis drainage procedures 
and resection procedures The indication for one or the other depends on the nature of the duct 
abnormality or the presence of an inflammatory mass A newly developed operation to alleviate 
pain, irrespective of the type of anatomic abnormality, is thoracoscopic splanchnicectomy, which 
in theory fulfils therapeutic purposes In the following, pain management of chronic pancreatitis 
is discussed, with emphasis on operative techniques blocking afferent pain stimuli A series of 
patients with chronic pancreatitis who underwent thoracoscopic splanchnicectomy is presented 
Conservative Treatment 
The conservative management includes stopping alcohol consumption, introducing dietary 
measures, pancreatic enzyme suppletion and analgesics Anatomic substrates like pseudocysts, 
bile duct obstruction or peptic ulcer should be excluded before starting conservative treatment 
Alcohol abstinence reduces the pain in many patients (Trapnell 1979) In a series of studies, 
Trapnell found that 75% of the patients who stopped experienced pain relief Despite this 
finding, reduction of alcohol intake and its effect on pain relief remains controversial (Trapnell 
1979) Dietary measures such as avoidance of high fat content foods are recommended for pain 
reduction, although well-documented studies are lacking It is hypothesized that a negative 
feedback of enzyme suppletion by proteases reduces intraductal pressure which is presumed to be 
related to pain (DiMagno et al 1993, Leahy and Carter 1991) Beneficial effects of this 
treatment (Layer and Holtmann 1994) as well as total absence of effect have been reported 
(Brown et al 1997, Halgreen et al 1986) 
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Initially, pain should be treated with non-opiate analgesics like acetominophen with or without 
codeine phosphate In many cases more potent analgesics, such as narcotics, are needed 
Approximately 30% of patients with chronic pancreatitis fail conservative treatment and 
undergo surgery (KalthofTet al 1984) 
Operative Treatment 
Surgical procedures in general include drainage and resections The effect of drainage procedures 
is based on the hypothesis that pain is most likely caused by ductal obstruction leading to 
pancreatic duct dilation and ductal hypertension (Bradley 1982, Leahy and Carter 1991) 
Endoscopic drainage combined with stone removal or stent placement has found wider 
application and is of particular use in the treatment of complications of chronic pancreatitis, 
such as biliary obstruction or pancreatic pseudocyst (Huibregtse et al 1988, McCarthy et al 
1988, Smits et al 1995, Smits et al 1996) This technique may also be used to test if surgical 
drainage will alleviate pain Endoscopic drainage is promising because of its low morbidity and 
mortality but it appears to be more successful in patients with relapsing attacks of pancreatitis 
(Kozarek 1993) Pancreaticojejunostomy is the most commonly used surgical method for 
draining the dilated pancreatic duct It was first applied by Du Val as retrograde drainage into a 
Roux loop after resection of the tip of the pancreas (Du Val 1954) The technique evolved to a 
side-to-side pancreaticojejunostomy over a completely deroofed pancreatic duct by Puestow & 
Gillesby (Puestow and Gillesby 1958) and Partington & Rochelle (Partington and Rochelle 
1960) Reported pain relief after this procedure is about 70-80%, with a mortality of 3% (Frey 
et al 1989, Carter 1993) and a morbidity of 10-30% (Howard et al 1995, Prinz and Greenlee 
1981, Delcore et al 1994, Evans et al 1997) With longterm follow-up, Holmberg et al showed 
that drainage does not necessarily correlate with pain relief (Holmberg and Isaksson 1985) 
Nealon et al reported that surgical drainage slows the progression of the disease (Nealon et al 
1988) In contrast, an increase in incidence of diabetes mellitus from 26% to 50% after 
longitudinal pancreaticojejunostomy has been demonstrated (Eckhauser et al 1984) It is very 
likely that progression of the disease rather than drainage procedures causes impairment of 
pancreatic function Most resections also improve drainage Based on the hypothesis of an 
inflammatory mass involving pancreatic nerves and causing the pain, the main objective of these 
procedures is to resect the diseased pancreatic tissue Different techniques have been developed 
over the years such as left (subtotal) pancreatectomy (Gebhardt 1993), the standard or pylorus 
preserving Whipple procedure (Rossi et al 1987) and, more recently, the duodenum preserving 
pancreas head resection according to Beger (Beger et al 1989, Beger et al 1985) or Frey (Frey 
and Smith 1987) Because of the high incidence of pancreatic endocrine and exocrine 
insufficiency, 80-95% pancreatectomy (Keith et al 1989) and total pancreatectomy (Russell 
1993) are seldom indicated The Whipple procedure or a duodenum preserving pancreatic head 
resection is performed when there is an inflammatory mass in the head of the pancreas with or 
without a dilated duct leading to intractable pain When complications of chronic pancreatitis 
are present, or in the case of high suspicion of a malignant process, these procedures are in fact 
preferred The choice for Whipple procedure or Beger (Frey) resection is still the subject of 
debate Similar effects on pain relief are reported 
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However, it seems that long-term results, e g , weight gain and bowel motility, are better after 
Beger resection Furthermore, the incidence of endocrine insufficiency is higher after 
pancreatoduodenectomy than after duodenum preserving resection (Izbicki et al 1995, 
Schoenberg et al 1993) 
The resection procedures show a slightly better pain relief (80-90%) than the drainage 
procedures, but have a higher complication rate (20^40%) with an equal mortality rate (Eddes 
et al 1996, Beger et al 1989, Evans et al 1997, Howard et al 1995, Izbicki et al 1995) 
Complications are less after Freys resection, which combines resection and drainage (Izbicki et 
al 1995) 
Nerve Blockade 
Neural and perineural changes caused by the inflammatory process are held responsible for pain 
in chronic pancreatitis (Boekman et al 1988, Boekman 1994) Afferent pain stimuli are 
transmitted centrally via the celiac plexus, which receives fibers from the left and right greater, 
lesser and least splanchnic nerves present at the level of T5 to Tl 1 (Martin et al 1943, Mallet 
Guy et al 1949) In the literature, results of nerve blockade are difficult to evaluate since a 
variety of surgical and percutaneous techniques have been used to treat upper abdominal or 
pancreatic pain, and no large series exist In pancreatic cancer, celiac plexus blockade for severe 
secondary pain is well accepted (Saltzburg and Foley 1989) In chronic pancreatitis the pain 
relief is not as effective and lasts only 3-6 months (Pap et al 1990, Leung et al 1993, Myhre et 
al 1989, Bengtsson and Lofstrom 1990) Therefore, celiac plexus blockade is not advised in 
chronic pancreatitis White et al and later Mallet Guy reported good long-term results after 
splanchmcectomy in combination with celiac ganghonectomy (Mallet Guy 1983, White et al 
1966) Success was shown in 113 of 127 patients (89%) with chronic pancreatitis (Mallet Guy 
1983) Transhiatal bilateral splanchmcectomy relieved pain in 80-100% of patients with 
unresectable pancreas carcinoma and chronic pancreatitis (Sastre et al 1992, Michotey et al 
1983) Unilateral or bilateral transthoracic splanchmcectomy with vagotomy achieved pain relief 
in 90% of the patients with a follow-up of 16 months (Stone and Chauvin 1990) These surgical 
procedures, however, are very complicated and accompanied by marked morbidity A few 
authors have reported their initial experience with unilateral (Maher et al 1996) and Bilateral 
Thoracoscopic Splanchmcectomy (Maher et al 1996, Cuschieri et al 1994, Andren-Sandberg et 
al 1995) 
Thoracoscopic Splanchnicectomy 
Thoracoscopic sympatectomy was first described by Wittmoser in 1969 (Wittmoser 1969) This 
technique has been applied for hyperhydrosis palmans (Lin 1992) or arterial insufficiency 
(Claes et al 1994) Worsey and associates, encouraged by the good results of thoracic 
splanchnicectomy, were the first to apply thoracoscopy to denervate the pancreas in a patient 
suffering from pancreatic cancer (Worsey et al 1993) Cuschieri performed bilateral 
splanchmcectomy in 6 patients with chronic pancreatitis in the full prone position, which offers 
the opportunity to cut the splanchnic nerves on both sides without the need to change the 
patient's position (Cuschieri et al 1994) 
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We have been performing bilateral thoracoscopic splanchnicectomy since 1995 to treat pain in 
patients with chronic pancreatitis and pancreatic cancer. Early results of patients with chronic 
pancreatitis are presented. 
Surgical Procedure 
We use a technique similar to that described by Cuschieri et al. (Cuschieri et al. 1994). In 
summary, the procedure is performed under general anaesthesia with double lumen intubation 
for single lung ventilation. The patient is placed in the full prone jackknife position. The 
operating thoracoscope is introduced in the second intercostal space beneath the angle of the 
scapular bone (Fig. 1). A second trocar is introduced one intercostals space superiorly and a few 
inches towards the spine. The pleural space is opened from the 5th (T 5) to the 12th thoracal 
vertebra (T 12), and the splanchnic nerves and all the potentially nerve-bearing tissue on each 
side are transsected using electrocautery or the harmonic scalpel (Ultracisionl). Constant 
awareness of the variable anatomy and of the possibility of crossing nerve branches is mandatory 
(Fig. 2). At the end of the procedure the lungs are reinsufflated and the trocar sites are closed, 
without routinely leaving chest drains. 
I I Full prone position of the patient. Insertion of the I trocars (see text). 
Patients and Methods 
Twenty-six patients underwent bilateral thoracoscopic splanchnicectomy (17 men, 9 women) in 
the period August 1995 to October 1997. Mean age was 41 years, ranging from 15 to age 63 
years. All patients had chronic pancreatitis, diagnosed by means of endoscopic retrograde 
cholangiopancreatography, computer tomography and/or magnetic resonance cholangio-
pancreatography. The presence of pseudocysts was ruled out. Thirteen of 26 patients (50%) had 
no dilated duct or an inflammatory mass in the head of the pancreas. Patients who used opiates 
and were referred from other hospitals were treated with splanchnicectomy irrespective of the 
'anatomical' substrate of pancreatitis (dilated duct or inflammatory mass). 
I lntra-operative view of the right hemithorax. I. Splanchnic nerves. 2. Sympathie chain. 3. Right lung. 4. Intercostal branches. 5. Azygos vein. 
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Mean interval between onset of pancreatitis and operation was 3.3 years (range 1.6—11.1). In 
most patients alcohol abuse was the cause of pancreatitis (Table 1). Eleven patients had 
undergone one or more surgical or endoscopic intervention (Table 2). Data of patients were 
collected prospectively. Pain was scored with the visual analog score for pain (VAS, 0 is no pain, 
10 is intractable pain). The mean preoperative VAS was 9 (range 7-10). Twenty-one patients 
(81%) required opiates. Four patients had both endocrine and exocrine pancreatic insufficiency 
and three had only exocrine insufficiency. Although with intervals, seven patients were at work 
before operation. Remaining patients were on social welfare and unable to work. Pain scores 
before and after operation were compared using a paired t test. A Ρ value less than 0.05 was 
considered statistically significant. 
I Aetiology of chronic pancreatitis of patients who 
I underwent bilateral thoraeoscopic 
Ε ϊ β splanchnicectomy 
I Etiology Patients (%) 
Alcohol 13 (30) 
Gallstones 1 (4) 
Familial 3(10) 
Trauma 2 (8) 
Pancreas divisium 2 (8) 
Results 
In all but two procedures splanchnic denervation was technically successful (92%). Two patients 
had severe pleural adhesions on the left side due to prior lung complications after necrotizing 
pancreatitis and distal pancreatectomy, respectively. After adhesiolysis, splanchnic nerves were 
difficult to visualize and complete denervation was uncertain. Transient intercostal pain related 
to the thoracoscopy was experienced by almost all patients, which lasted for 1 to 3 days. In three 
patients intercostal neuralgia persisted for a longer period of time but was successfully managed 
by carbamazepine. One patient had a major complication. He stayed for 2 days in the ICU for 
respiratory failure caused by preoperative aspiration. Minor complications were encountered in 
three patients. One pneumothorax had to be drained. One patient had a wound infection and 
one a pneumonia. Twenty-one patients (81%) had no complications at all. Mean (range) 
hospital stay was 3 (1-7) days. 
Pain Relief 
At follow-up 6 months after operation, pain scores were significantly lower (P < 0.01) than 
preoperative values (mean ± SD VAS; 2.6 ± 3.2 versus 9.1 ± 0.7). In 6 patients (23%) pain 
recurred and these procedures were considered as failures One of the patients who failed 
splanchnicectomy subsequently underwent a Beger resection, but did not become pain free. The 
two patients who had pleural adhesions belonged to the group of failures. Fourteen patients 
(54%) had no pain medication, six patients (23%) were treated with NSAIDs (Table 3).The 
seven patients who were previously at work could completely resume their job. 
I Previous interventions for pain in chronic pancreatitis Procedure 
Bcger resection 
Distal resection 
Papillopiasty 
Stent 
Nerve block 
Patients (%) 
4(15) 
6(23) 
2(8) 
4(15) 
1 (4) 
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I l'airi medication before and at six months after bilateral thoracoscopic spianchnicectomy Before (%) 6 months (%) 
Opioids 21(81) 12(23) 
Non Opioids 5(19) 6(23) 
No analgesics 0 14(54) 
Discussion 
Management of pain in chronic pancreatitis is troublesome, particularly in those patients who 
become dependent on opiates. Surgical procedures such as Whipple, Beger or Frey resections 
have good results in these patients. There is, however, great reluctance to undergo these large 
operations due to the marked morbidity and risk of mortality (Beger et al. 1989; Eddes et al. 
1996; Evans et al. 1997; Izbicki et al. 1995; Rossi et al. 1987). Bilateral thoracoscopic 
spianchnicectomy has several advantages in comparison with other types of surgery for chronic 
pancreatitis: this method is minimally invasive, it is suitable for patients with diffuse forms of 
pancreatitis (no dilated duct, no inflammatory mass in the head of the pancreas) and may be 
used when other surgery has failed (salvage procedure). We performed a bilateral thoracoscopic 
spianchnicectomy, transsecting all potentially nerve-bearing tissue between Τ 5 and 12, in full 
prone position with double lumen intubation and single lung ventilation. Our previous 
experience with unilateral left thoracoscopic spianchnicectomy was disappointing. Only one of 
six patients had temporary pain reduction, which finding corresponds with that of Maher et al. 
(Mäher et al. 1996). Experimental data on the location of nerves transmitting afferent pain 
stimuli from the pancreas support a bilateral approach (Bliss et al. 1950). Excision of all 
potentially nerve bearing tissue may have favorably influenced results of the bilateral approach. 
In some patients up to seven splanchnic nerve branches were found after the pleura between T5 
and T12 had been opened. When focused only on the greater, lesser and least splanchnic nerves, 
splanchnic denervation might have been incomplete. It seems that in the full prone position the 
use of a double lumen tube is not absolutely necessary to obtain a good view of the operative 
field and should be abandoned (Cuschieri et al. 1994). We experienced optimal view with single 
lung ventilation only, especially in the left hemithorax. Since the time taken to place a double 
lumen tube is hardly greater than for a single lumen tube, and complications did not occur, we 
will continue to use the double lumen intubation technique. Local damage to intercostal nerves 
by retractors or trocars may be responsible for the intercostal neuralgia experienced by patients 
who underwent thoracotomy or thoracoscopy (Yim and Liu 1996). In the present series, 
electrocautery of the splanchnic nerves may have caused thermal injury to the adjacent 
intercostals nerves. Using the harmonic scalpel to dissect the splanchnic tissue, no cases of long-
lasting neuralgia have been encountered. Introduction of smaller trocars (5 mm) and 
instruments may further diminish the occurrence of postoperative intercostals neuralgia. In the 
present study, about 75% of patients had reduction of pain after operation. Cushieri et al., 
Andrén-Sandberg et al. and Kusano and associates reported similar early results in 6, 13 and 9 
patients with chronic pancreatitis, respectively (Cuschieri et al. 1994; Andrén-Sandberg et al. 
1995; Kusano et al. 1997). 
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With regard to the low morbidity rate and the effectiveness in pain management bilateral 
thoracoscopic splanchnicectomy seems an attractive alternative to more invasive surgical 
approaches. A criticism, however, may be that long-lasting pain relief has not been demonstrated 
so far. Three patients who were recently evaluated more than 2 years after splanchnicectomy 
were still pain-free without the use of pain medication.Bilateral thoracoscopic splanchnicectomy 
is promising in the treatment of pain in patients with chronic pancreatitis. Its precise role needs 
to be determined when long-term results become available. 
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Abstract 
Background & objectives: Bilateral Thoracoscopic Splanchnicectomy (BTS) is a well known 
technique to alleviate intractable pain in patients with chronic pancreatitis. BTS not only 
disrupts afferent fibres from the pancreas that mediate pain but also postganglionic sympathetic 
fibres which originate in segments T5-T12 and which innervate the vasculature of the liver, 
pancreas and the adrenal gland. 
The aim of this study was to assess whether and how BTS affects sympathetic noradrenergic and 
adrenomedullary function in patients with chronic pancreatitis. 
Methods: Sixteen patients with chronic pancreatitis for at least one year, underwent autonomic 
function testing before and 6 weeks after BTS for intractable pain. Testing was carried out 
during supine rest and during sympathetic stimulation when standing. 
Results: Supine and standing systolic and diastolic blood pressure were significantly lower post 
BTS as compared to pre BTS (P=0.001). One patient showed orthostatic hypotension after 
BTS. Baseline plasma norepinephrine levels and plasma norepinephrine responses to 
sympathetic activation during standing were not reduced by BTS. In contrast, supine plasma 
epinephrine levels and responses during standing were significantly reduced (P<0.001). 
Parasympathetic activity was unaffected by BTS as shown by unaltered Valsalva ratio, I-E 
difference and AHRmax. 
Conclusion: BTS for pain relief in patients with chronic pancreatitis reduced adrenomedullary 
function, due to disruption of the efferent sympathetic fibres to the adrenal gland. BTS did not 
affect noradrenergic sympathetic activity although blood pressure was lower after the 
sympathectomy. 
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Introduction 
Chronic pancreatitis is a fibro-inflammatory disease of the pancreas Pain is the mam reason for 
these patients to seek medical help Aim of surgical therapy is to alleviate pain, preferably 
without morbidity or mortality and with preservation of pancreatic function In the absence of 
an anatomical substrate or when previous surgery hasn't been successful, nerve interruption such 
as celiac blockade or splanchnicectomy are recommended (Warshaw et al 1998) Bilateral 
thoracoscopic splanchnicectomy (BTS) is a minimal invasive surgical procedure dissecting 
splanchnic nerves through a thoracoscopic approach BTS has the advantage of a low morbidity 
without reported mortality (Buscher et al 2008) 
The splanchnic nerves predominantly consist of sympathetic fibres and the contribution of 
visceral pain afférents, which accompany the sympathetic nerves is relatively small (Cervero and 
Foreman 1990) Sympathetic fibres, originating in segments T5—T12, synapse in the celiac 
ganglia from where postganglionic splanchnic fibres innervate the pancreatic and intestinal 
vasculature (Boekman 1993) and the adrenal glands (Li et al 1999) A potentially undesired 
effect of BTS is an impairment of cardiovascular homeostasis particularly in chronic pancreatitis 
patients who often have cardiovascular and respiratory comorbidity Since the splanchnic 
vascular bed has an important capacitance function, interrupting its noradrenergic innervation 
by BTS might reduce the return of venous blood to the heart, thus predisposing the patient to 
orthostatic hypotension In addition, dissecting the sympathetic nerve to the adrenal gland 
might affect adrenomedullary function The aim of this study was to assess the effects of BTS, 
performed in patients with chronic pancreatitis on sympathetic noradrenergic and adrenal 
medullary baseline function before and after sympathetic stimulation 
Patients and Methods 
Sixteen patients, (10 men and 6 women), with chronic pancreatitis for at least one year, 
undergoing bilateral thoracoscopic splanchnicectomy (BTS) for disabling pain were studied for 
the effects of sympathectomy on sympathetic activity Median age was 49 (range 32-68) years 
All patients had chronic pancreatitis, diagnosed by means of endoscopic retrograde 
cholangiopancreaticography, computed tomography and/or magnetic resonance 
cholangiopancreancography, according to standard criteria (Imrie et al 1999) Thirteen patients 
had small duct disease, three patients had a slightly dilated main duct with duct size less than 5 
mm Fifteen patients were on daily opioid medication and were not able to stop this medication 
because of (or fear for) pain relapse Patients treated for hypertension, or patients with 
medications directly interfering with the sympathetic nervous system were excluded 
Demographic data and medication are listed in Table 1 All patients gave their written informed 
consent for this study The medical ethical committee waved the need for protocol review 
Splanchnic denervation 
We used a technique for BTS slightly modified from that described by Cuschien et al 
(Cuschieri et al 1994) In summary, the procedure is performed under general anaesthesia with 
double lumen intubation for single lung ventilation 
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The patient is placed in a full prone position with the arms stretched along the head. The 
thoracoscope is introduced two intercostal spaces below the angle of the scapula, and a second 
trocar is introduced one intercostal space above and a few inches towards the spine. The parietal 
pleural space is opened from the 5th to the 12th thoracic vertebra. To ensure complete 
denervation, the splanchnic nerves and all the potentially nerve-bearing tissue on each side as 
well as the sympathetic chain itself at level T5 are carefully transsected using the harmonic 
scalpel (Ultracision®, Johnson & Johnson Medicals, Amersfoort, The Netherlands). At the end 
of the procedure the lungs are re-expanded and the trocar sites closed without routine use of 
chest drains. 
Demographic data and medication of the pancreatitis patient. 
(*Opioid medication has been converted to Morphine Equivalents (MEq) using the Narcotic Analgesic Converter 
(Version 2.0, GlohalRPh©Inc.: uiww.GlohalRPh.com)) 
Demographics 
Patients 
Sex (M/F) 
Age (median, range in years) 
Onset of pancreatitis (median, range) 
Etiology 
alcohol 
idiopathic 
hereditary 
hypertriglyceridemia 
Use of Opioids 
Morphine Equivalents (mg, Mean (range)) 
Use of Sedatives 
Diabetes Mellitus 
Ν 
16 
10/6 
49 (32-68) 
5.5(1.0-21.7) 
7 
7 
1 
1 
15 
146 (0-520) 
2 
4 
Autonomic Function Testing 
Sedative medication, which remained unaltered after the operation, was stopped the day before 
testing, while analgesic treatment was continued. All patients underwent non-invasive 
measurement of blood pressure and heart rate by the Finapres device (TNO, The Netherlands, 
model 5) before and 6 weeks after BTS (Wesseling 1996). Blood pressure and heart rate were 
measured after supine rest for 20 minutes. Thereafter, the following tests for autonomic function 
were performed: 
Standing up manoeuvre. Patients were asked to stand up within 5 seconds and to remain in the 
upright position for 2 minutes. The systolic (SBP) and diastolic blood pressure (DBP) responses 
to the upright position were calculated from the blood pressure values between 50-80 seconds 
after standing up as compared to those of the supine rest position. Orthostatic hypotension was 
defined as a decrease of systolic blood pressure of more than 20 mmHg after standing. The 
difference between the maximal heart rate at standing (between 15-20 seconds after standing up) 
and the supine heart rate was calculated and expressed as AHRmax. The quotient between 
maximal heart rate and minimal heart rate after standing up was calculated as T/B ratio 
(tachycardia/bradycardia ratio) (Wieling and Karemaker 1999). 
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Forced breathing. Each patient performed six maximal respirations in one minute in the supine 
position and both inspiration and expiration were synchronized with the program clock on the 
computer. Heart rate was computed from the RR-interval and the difference between maximal 
and minimal heart rate during each cycle of 10 seconds was measured and averaged for the six 
respiratory cycles (I-E difference) (Wieling and Karemaker 1999) 
Valsalva manoeuvre. All patients were instructed to maintain an expiratory pressure of 40 mmHg 
for 15 seconds by means of forced expiration into a mouthpiece connected to a manometer. The 
manoeuvre was performed in triplicate. The maximum heart rate during the manoeuvre was 
divided by the minimum heart rate after the manoeuvre (Valsalva ratio) (Baldwa and 
Ewing 1977) 
Plasma catecholamines 
After voiding, a cannula was inserted in an antecubital vein and a blood sample was drawn after 
20 minutes of supine rest. To assess the effects of mild sympathetic stimulation, a second blood 
sample was drawn after 5 minutes of standing. Blood samples were collected into chilled tubes 
containing heparin and were immediately placed on ice. All samples were centrifuged (at 4 oC) 
within 1 hour after blood sampling and plasma samples were stored at -80 oC until assayed for 
concentrations of norepinephrine (NE) and epinephrine (EPI), using high performance liquid 
chromatography (Willemsen et al. 1995). All samples of each patient were assayed within the 
same run. Intra-assay coefficients of variation were 1.9% for NE, 3.0% for EPI. Inter-assay 
coefficients of variation were 6.5% for NE, 11.4% for EPI. 
Statistical analysis 
For all variables non-parametric tests were used. Pre- and post operative data of the entire group 
were compared using the paired Wilcoxon signed rank sum test. Relative and absolute 
differences between baseline and standing NE and E levels (Δ) were calculated. We performed 
statistical analysis using SPSS for Windows (Release 13.0, SPSS Inc., Chicago, II, USA). 
Demographic data are presented as median and range and all other data are presented as median 
and interquartiles (IQR). Differences were considered statistically significant when Ρ < 0.05. 
Results 
In all sixteen patients BTS was technically successful, meaning that all potentially nerve-bearing 
tissue on each side had successfully been transsected. 
Hemodynamic effects of BTS 
After BTS, supine as well as standing, both median systolic and diastolic blood pressures were 
significantly lower than before BTS (P<0.01, Table 2). This effect was observed in all but two 
patients. The median supine systolic and diastolic blood pressures were 10.5 mmHg [IQR 4-
15.8 mmHg] and 7.5 mmHg [IQR 3-10.5 mmHg] lower postoperatively. During standing the 
median differences were 10.5 mmHg [IQR 7-27 mmHg] and 7.5 mmHg [IQR l-17mmHg], 
respectively. 
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DBP increased significantly with standing both before and after the operation (2.5 mmHg [IQR 
-1-11 mmHg], P=0.012, and 3 mmHg [IQR -1-7 mmHg], P=0.049) whereas SBP did not. One 
patient demonstrated orthostatic hypotension before BTS which persisted after the procedure. 
One patient who had no orthostatic hypotension before BTS demonstrated asymptomatic 
orthostatic hypotension after BTS. Heart rate showed a similar increase with standing both pre 
and post BTS. 
i Results of the autonomic function testing pre and postoperatively, depicted as Median (IQR) Ρ'- Ρ post BTS vs. pre BTS, P# = Ρ standing vs. supine preoperatively and P$= Ρ standing vs. supine post operativel 
Valsalva ratio 
IE_difFerence 
Δ Hrmax 
T/B ratio 
SBP supine (mmHg) 
SBP standing (mmHg) 
DBP supine (mmHg) 
DBP standing (mmHg) 
MAP supine (mmHg) 
MAP standing (mmHg) 
HR supine (beats/min) 
HR standing (beats/min) 
Pre BTS 
1.26(1.13- 1.54) 
10.0(8.4-17.1) 
2 2 ( 1 6 - 3 1 ) 
1.11 (1.07-1.23) 
108(100-120) 
1 0 9 ( 9 5 - 1 2 4 ) 
6 3 ( 5 0 - 7 2 ) 
6 7 ( 5 9 - 7 9 ) 
78 (69 - 86) 
78 (74 -95) 
66 (62 - 75) 
8 3 ( 7 0 - 9 7 ) ' 
Ρ' 
0.856 
0.012 
<0.001 
Post BTS 
1.22(1.17-1.88) 
1 2 . 0 ( 6 . 7 - 15.8) 
1 8 ( 1 6 - 2 5 ) 
1.10(1.06-1.16) 
1 0 2 ( 9 1 - 115) 
9 7 ( 8 2 - 1 0 8 ) 
5 7 ( 5 1 - 6 5 ) 
60 (48 - 72) 
7 2 ( 6 5 - 8 1 ) 
71 (60 - 83) 
67 (61 - 75) 
8 9 ( 7 1 - 1 0 3 ) 
P' 
0.450 
0.701 
0.308 
0.181 
0.028 
0.010 
0.005 
0.016 
0.009 
0.013 
0.477 
0.026 
pt 
0.074 
0.016 
0.001 
Autonomic function tests 
In all patients the Valsalva ratio, the I-E difference and the AHR max were within normal limits 
before BTS and were unaffected by BTS. The postoperative T/B ratio did not differ signiPicantly 
from the preoperative ratio (Table 2). 
Plasma catecholamines 
In two patients both plasma EPI and NE levels after BTS could not be measured for technical 
reasons. 
PUsma Norepinephrine levels 
Before BTS, five patients showed higher supine plasma NE levels than normal (upper limit NE 
3.0 nmol/L), ranging between 3.06 -7.68 nmol/L. During standing, the plasma NE levels of the 
entire group increased significantly from a median 2.0 nmol/L (IQR 1.37-3.49) to a median 
3.53 nmol/L (IQR 2.52-5.94; P=0.001). The median relative increment in plasma NE was 89% 
(48-119) (Figure 1A). 
After BTS, baseline supine plasma NE level was 2.17 nmol/L (IQR 1.16-3.18 nmol/L) and this 
was not significantly different from the pre-BTS plasma NE level (P=0.460). 
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In the upright position, plasma NE rose to 4.52 nmol/L (IQR 2.82-6.19 nmol/L; P< 0.001) and 
the median relative increment was slightly but significantly higher than before BTS (100 vs. 
89%; P= 0.011, Figure IB) 
Phsma Epinephrine levels 
Before BTS, all patients had supine plasma EPI levels that were within the normal range 
(median 0.08 nmol/L, IQR 0.04-0.13 nmol/L). During standing plasma EPI levels rose to 
median 0.12 nmol/L (IQR 0.06-0.16 nmol/L p<0.001). The relative increment of plasma EPI 
was 37% (IQR 21-66%) (Figure IB). 
Figure 1A Figure IB 
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Boxplots of plasma norepinephrine (NE, Figure 1A) and of plasma epinephrine (EPI, Figure IB) levels before (light 
boxes) and after (dark boxes) the Β TS. absolute is the absolute increment of NE or EPI afier standing, (pre = pre Β TS, 
post = post BTS). On the right Y-axis the relative increment relative) is depicted (%, right Y-axis) (Figure IA f 
P=0.00J. * P= 0.011, Figure IB tP=0.001, *P= 0.002, Wilcoxon signed rank sum test). Error bars represent Range 
(minimum-maximum) 
After BTS, median supine plasma EPI level was 0.03 nmol/L (IQR 0.01-0.04 nmol/L) and 
significantly lower than before BTS (P< 0.001). After BTS, plasma EPI levels did not increase 
after standing. In each individual patient both the supine and the standing plasma EPI levels 
were lower after BTS. Consequently, both the relative and the absolute increments in plasma 
EPI were significantly reduced after BTS (P=0.002 and P=0.001 respectively. Figure IB). 
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Discussion 
Interruption of sympathetic nerves by BTS for pain relief in patients with chronic pancreatitis 
reduces baseline and stimulated EPI plasma levels In contrast, there is no effect on sympathetic 
noradrenergic and parasympathetic function Furthermore, the blood pressure was significantly 
reduced after BTS 
Since the sympathetic nerves to the adrenal gland are interrupted by BTS and since the adrenal 
medulla is almost the sole source of circulating EPI, it is not surprising that adrenomedullary 
function is impaired as is reflected by the decrease in plasma EPI levels This effect has been 
shown before in animal studies and for the first time nowjn human subjects (Engeland 1998) 
The present study cannot answer the question whether this selectively impaired adrenomedullary 
function is of (patho-) physiological significance since we did not examine the plasma EPI 
responses to for instance strong stimuli, like hypoglycaemia, in these patients However, from 
animal studies it is known that insulin induced hypoglycaemia detected in the portal vem is 
mediated through spinal sympathetic afférents and subsequently suppressed by sympathectomy 
(Fujita and Donovan 2005, Fujita et al 2007) Theoretically, sympathectomy may thus have 
consequences for the detection and regulation of glucose metabolism in diabetic patients In our 
diabetic patients we did, however, not encounter such problems after BTS 
Furthermore, we know from adrenalectomized patients that depletion of EPI is tolerated well 
(Lenders et al 1988, van der Steen et al 1995) Although the adrenal cortex is also 
sympathetically innervated, the main and predominant regulator of adrenal cortical function is 
ACTH, released by the anterior pituitary gland Therefore, it is unlikely that adrenal cortical 
function is impaired after BTS 
Noradrenergic sympathetic nerves supplying the splanchnic vascular bed are also disrupted by 
BTS, but plasma NE levels were unaltered suggesting that overall sympathetic nervous function 
is unimpaired Though the splanchnic vascular bed is richly innervated by sympathetic nerves 
and the hepatic-mesentenc spill-over amounts to about 40%, a relatively low fraction of 
circulating plasma NE is coming from the mesenteric organs like pancreas and liver (Esler et al 
1990) In addition, circulating plasma NE is also derived from sympathetic nerves from other 
organs such as skeletal muscle and heart, therefore it is possible that the local effect of BTS on 
splanchnic derived NE is obscured To uncover this local effect, more selective and invasive 
measurements of NE spill-over of the splanchnic area would be necessary 
Variable effects on blood pressure have been reported after thoracic sympathectomy In contrast 
to Noppen et al (Noppen et al 1996) who found no effect, Kingma et al (Kingma et al 2002) 
and Papa et al (Papa et al 1986) demonstrated a decrease in resting BP after sympathectomy as 
we did From a physiological point of view the reduction can be attributed to vasodilatation due 
to a reduced vascular resistance (Kingma et al 2002) or to a decrease in cardiac output due to a 
decreased venous return The lack of a reflex-mediated increase in heart rate and plasma 
catecholamines after BTS argues against the possibility of substantial vasodilation A direct 
cardiovascular effect following denervation does not explain the hypotension in our patients 
because the majority of the cardiac sympathetic plexus receives cardiac branches from above T5 
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In patients undergoing sympathectomy for hyperhidrosis ganglia are transsected at the levels T2-
T4 through which the direct sympathetic nerves serve the heart, and more cardiovascular effects 
are expected than after BTS (Moak et al 2005, Kingma et al 2002, Papa et al 1986, Kawamata 
et al 2004, Noppen et al 1996) 
Increased renal sympathetic activity causes hypertension and sympathectomy is applied for the 
treatment of hypertension (Smithwick and Thompson 1953, Mornssey et al 1953, Krum et al 
2009) Since the renal plexus receives fibres from the lesser splanchnic nerves and the celiac 
plexus, disruption of this anatomical and functional relation might also explain the hypotensive 
effect of splanchmcectomy 
Only one patient demonstrated orthostatic hypotension after ΒIS but was asymptomatic 
Clinical significant orthostatic hypotension has only been reported in a minority of patients after 
both bilateral and unilateral thoracoscopic splanchmcectomy for pain in chronic pancreatitis 
(Basmski et al 2005, Mäher et al 2001) 
Reduction of pain may be held responsible for lowering blood pressure Stress caused by pain 
causes an increase in blood pressure, by increasing the muscle sympathetic nerve activity (Fagius 
et al 1989) However, the relation between chronic pain and blood pressure is less well 
understood and from some studies it appears that this normal "pain - blood pressure" 
relationship is absent or reversed in patients with chronic pain (Maixner et al 1997, Pickering 
2003) This is supported by the fact that all our patients were normotensive Therefore it is 
unlikely that reduction in pain is responsible for causing orthostasis or reduction in blood-
pressure in our group of patients Since variable effects of opioids on blood pressure (increase as 
well as decrease) in normotensive as well as hypertensive state have been reported, opioid use 
may have affected the blood pressure in our patients (Sun et al 1996, Wright and Ingenito 
2003) However the opioid dose expressed in Meq's was too diverse in our patients to explain 
the unequivocal blood pressure reduction measured in the majority of the patients 
Bilateral thoracoscopic splanchmcectomy is a surgical procedure in which the splanchnic nerves 
are dissected by a thoracoscopic approach After 6 months follow up 60 to75% of the patients 
have pain relief (Buscher et al 2002) Since at least 25% of the patients do not experience any 
pain relief at all after splanchnic deafferentation of the pancreas from the beginning, complete 
splanchnic transsection could be criticized in these patients The finding of low EPI levels in our 
cohort of patients in rest as well as after stimulation post BTS, suggests complete technical 
success Measuring EPI concentrations before and after BTS therefore might be a tool to verify 
complete denervation 
Bilateral splanchmcectomy does not seem to have significant clinical side-effects However, some 
caution is warranted regarding the hypotensive effect, especially in younger patients with a 
normal to low preoperative blood pressure In patients with hypertension, BTS may necessitate 
adjustments in the antihypertensive treatment 
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Abstract 
Background & Objectives: The management of pain in patients with chronic pancreatitis is 
troublesome The aim of this prospective study was to evaluate the early and long term pain 
relief of bilateral thoracoscopic splanchnicectomy 
Methods: From August 1995 until August 1999, forty-four patients with chronic pancreatitis 
underwent bilateral thoracoscopic splanchnicectomy Thirty-six patients required opioids Data 
were collected prospectively Pain intensity was registered preoperativeiy and at regular intervals 
after operation by means of the Visual Analogue Score (VAS) Use of analgesics (opioids, nsaids 
and aminocetophen, no analgesics or aminocetophen) was noted before and after 
splanchnicectomy Median (range) follow up was 36 months (12 to 60 months) 
Results: The procedure was technically successful in 40 patients Thirty six patients had no 
complications Eleven of twenty four patients who have been followed up for 24 months or 
more had a significantly reduced VAS score at two years (median (range) 8 5 (7-10) vs 2 5 
(0-5), p<0 01) The cumulative rate of pain relief was 46 per cent 48 months after 
splanchnicectomy 
Conclusion: Bilateral thoracoscopic splanchnicectomy alleviates pain in patients with chronic 
pancreatitis having low morbidity and no mortality Pain recurs in approximately 50 per cent at 
the long run The cause of pain recurrence remains to be elucidated 
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Introduction 
Pain in patients with chronic pancreatitis elicits a challenging problem for surgeons and 
gastroenterologists. Main goal of treatment is to provide sufficient and lasting pain relief without 
the use of opioids and deterioration of pancreatic function. Surgical as well as conservative 
approaches have been advocated to treat pain in these patients. The plea for long-standing 
conservative treatment is based on the assumption that chronic pancreatitis ultimately leads to 
complete fibrosis and that patients will become pain free (Amman et al. 1984; Amman et al. 
1987). However, 50 per cent of patients with chronic pancreatitis appear to suffer from relapsing 
pain attacks still after 10 years of observation. Moreover, 30-50 per cent of patients do not 
respond to conservative treatment and become opioid dependend (Lankisch et al. 1995). 
Surgery for pain relief comprises drainage and resection procedures. The choice between one of 
the procedures roughly depends either on the diameter of the main pancreatic duct and duct 
abnormalities or the presence of an inflammatory mass in the head of the pancreas. Both kinds 
of operations result in long-term pain relief in about 60-80 per cent of patients, however, they 
involve considerable morbidity and mortality (Carter 1993; Saeger et al. 1993; Delcore et al. 
1994; Beger et al. 1989; Warshaw et al. 1998) and therefore are carried out with reluctance. 
Thoracoscopic bilateral splanchnicectomy is an operative technique recently introduced to 
alleviate pain irrespective of the type of anatomic abnormality. Using a minimal invasive 
approach, nociceptive fibers originating from the pancreatic area, incorporated in the splanchnic 
nerves, are transected at the thoracic level where they enter the paravertebral sympathie chain. 
This minimal invasive technique seems to fulfill the therapeutic purpose of sufficient pain relief 
with low morbidity and low mortality, without deteriorating pancreatic function (Andrén-
Sandberg et al. 1995; Kusano et al. 1997; Buscher et al. 1999). Early results are promising, but 
prospective studies with a follow-up longer than one year have hardly been reported (Ihse et al. 
1999). Since August 1995 we have gained experience with this procedure. In this prospective 
study early and long-term effects of bilateral thoracoscopic splanchnicectomy on pain relief and 
complications in a large unselected group of patients with continuous pain in chronic 
pancreatitis are evaluated 
Patients and methods 
From August 1995 until December 1999, forty four patients underwent bilateral thoracoscopic 
splanchnicectomy (26 men, 18 women). Mean age was 41 years, ranging from 15 to 63 years. 
All patients had chronic pancreatitis, diagnosed by means of endoscopic retrograde 
cholangiopancreatography, computed tomography (CT) and/or magnetic resonance 
cholangiopancreatography, according to standard criteria (Imrie et al. 1999) The presence of 
pseudocysts was ruled out. Twenty one of forty-four patients neither had a dilated main 
pancreatic duct nor an inflammatory mass in the head of the pancreas. Four patients had a 
dilated duct (> 4 mm) and 5 patients had an enlarged pancreatic head on CT. Previous 
pancreatic surgery rendered accurate radiological interpretation of the pancreatic abnormalities 
difficult in the 14 remaining patients. 
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Twenty eight patients had undergone one or more surgical or endoscopic interventions for pain 
Five patients had previously undergone a Beger resection and three patients a Partington-
Rochelle procedure Nine patients underwent a resection procedure 
In eight patients the pancreatic duct had been drained endoscopically with a stent Papilloplasty, 
biliodigestive bypass and pseudocyst drainage had been performed in respectively three, two and 
in another three patients Two patients unsuccessfully underwent neurolytic celiac blockade 
Median interval between onset of pancreatitis and operation was 4 6 years (range 14-14 8 
years) In twenty four patients alcohol abuse was considered to be the cause of the pancreatitis 
Four patients had hereditary pancreatitis, four patients where known with a pancreas divisum 
and m two pancreatitis developed after trauma In the remaining ten patients the cause of 
chronic pancreatitis was unknown Thirty four patients were referred from other hospitals 
Twelve patients were (partly) at work before operation The remaining 32 patients were unable 
to work, on social welfare or capable to do only light housekeeping mainly due to complaints 
caused by pancreatic disease 
Data on pain and pain medication were collected prospectively during regular outpatient visits 
before and after splanchmcectomy Pain was scored by the visual analogue score for pain for one 
week on three months interval during the first 24 months and on six months intervals during the 
period thereafter (VAS, zero is no pain, ten is intractable pain) Use of medication was noted and 
divided into three groups No medication or acetaminophen, acetaminophen and/or (Non 
Steroidal Ann Inflammatory Drugs (NSAID's) and opioids with or without NSAID's Failure of 
treatment was defined as persistence of pain needing additional therapy after the procedure or 
recurrence of pain necessitating the same or increased amounts of analgesics compared to that 
before the operation 
The surgical procedure has been described previously (Buscher et al 1999) In short Under 
general anesthesia with one lung ventilation, the patient is in full prone position One trocar is 
introduced into the second intercostal space beneath the angle of the scapular bone and a second 
trocar a few inches towards the spine one intercostal space more superior The pleura is opened 
at the level of the 5th to the 12th thoracic vertebrae and all potentially nerve bearing tissue 
including visible splanchnic nerves are transected 
Nerves have been transected electrosurgically in the first twenty two patients Thereafter, 
patients were treated with the harmonic scalpel (Ultra-Osion®, Johnson & Johnson Medical, 
Amersfoort, The Netherlands) Chest tubes were not routinely placed after the procedure 
Postoperative pain was routinely managed by parenteral administration of opioids, usually 
morfine intravenously by patient controlled analgesic device (PCA) Gradual tapering of the 
opioids used preoparanvely could therefore be accomplished, leaving the patient in partial 
control of his pain complaints due to the PCA method used 
Statistical analysis 
Pain scores were compared with a Wilcoxon signed rank sum' test Data are presented as median 
(range) Differences were considered statistically significant when Ρ < 0 05 Pain relief was 
analyzed by life-table method Endpomts of follow-up were failure of treatment, death and end 
of the observational period 
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Results 
The median follow up was 36 months (12-60 months). Twenty four patients had a follow up of 
24 months or more. The median preoperative VAS was 8.5 (7-10). Thirty-six patients required 
opioids. Median use of opioids was 38 months, varying from 6 to 84 months. 
Early and late complications 
Splanchnicectomy was technically successful in 40 patients. Four patients had severe pleural 
adhesions on one or both sides due to prior pulmonary complications after necrotizing 
pancreatitis or after surgery for chronic pancreatitis. After adhesiolysis, splanchnic nerves were 
difficult to visualize and complete denervation was uncertain. Transient pain lasting for one to 
three days related to the trocar insertion was experienced by almost all patients. Three patients 
had intercostal neuralgia persisting for a longer period of time. This was successfully managed by 
carbamezapine. 
One patient stayed for two days in the ICU for respiratory failure caused by preoperative 
aspiration. No patient died. 
Minor complications were encountered in four patients. In two a pneumothorax had to be 
drained. One patient had a wound infection and one a pneumonia. Thirty-six patients had no 
complications at all. Median hospital stay was 4 (1-10) days. 
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Scattergram showing VAS before and β months after bilateral thoracoscopic splanchnicectomy 
Circles represent patients with opioid use and squares represent patients on NSAID. Open circles and squares represent 
patients who failed splanchnicectomy. 
Early pain relief 
Pain scores at 6 months after surgery were significantly lower than preoperative valuesP<0.01). 
Early results at 6 months are shown in Figure 1. 
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Pain medication at 6 months is listed in Table 1. In eleven patients pain persisted or recurred 
within 6 months and in another six between six and twelve months. In all four patients with a 
technically unsuccessful procedure pain recurred within six months. 
I Pain medication before and at 6 months afier bilateral thoracoscopic splanchnicectomy, and at end offollow-np Before 
(n=44) 
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(1 
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Non-failures 
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15 
Opioids 
NSA1D and acetaminophen 
No analgesics or acetaminophen 
Long term pain relief 
There were 5 patients with a long term failure at 15, 15, 18, 36 and 48 months after 
splanchnicectomy, respectively. Eleven of the twenty four patients who have been monitored for 
two years or more had a significantly reduced VAS score at (p<0.01). One patient died from a 
gastric carcinoma 1 year after splanchnicectomy. This patient had only mild epigastric 
discomfort at 9 month follow up in comparison with severe abdominal pain before operation. 
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There was no difference in failure rate between the nine patients with a dilated duct or an 
inflammatory mass in comparison with 21 patients without these features. 
Pain medication at median follow up of 36 months is listed in Table 1. 
In figure 2 the cumulative probability of pain reduction after splanchnicectomy is depicted. 
Most failures occur within the first year. There is a probability of 46 per cent of pain relief 4 
years after splanchnicectomy. 
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Discussion 
This report encompasses the largest study, as far as the authors could determine, on the pain-
relieving effect of bilateral thoracoscopic splanchnicectomy in patients with chronic pancreatitis. 
This minimal invasive procedure results in early pain relief in the majority of patients and is 
done without mortality, a low complication rate and a short hospital stay. Pain, however, recurs 
in about half of the patients at the long run. 
The management of pain in these patients before the splanchnicectomy was troublesome, as 
reflected by the high percentage of opioid use, the long history of pain and the significant 
number of failed previous operative and anesthetic procedures. Moreover, the large number of 
patients referred from other hospitals demonstrated the difficult pain management in this group. 
Was the thoracoscopic splanchnicectomy, at least in the beginning, perceived by patients and 
specialists as a "salvage" procedure, encouraged by the initial excellent results, the procedure 
became first choice as surgical intervention (Buscher et al. 1999). This alternative surgical 
approach did not influence early and late relapse of pain. Patients with a dilated main pancreatic 
duct or an inflammatory mass in the pancreatic head in particular, who were good candidates for 
either a drainage procedure or a duodenum preserving resection of the pancreas, did not have a 
worse outcome after splanchnicectomy compared to patients without these findings. 
The procedure aimed at complete splanchnic nerve transection with the least operative 
morbidity for the patient. Unlike other authors (Ihse et al. 1999; Imrie et al. 1999; Mäher et al. 
1996), we routinely opened the parietal pleura from the 5th to the 12th thoracic vertebral level, 
transecting all fatty tissue between the pleura and the intercostal vessels containing the main 
splanchnic trunks and their branches, assuring complete denervation. The vaporizing effect and 
low heat of the harmonic scalpel helped to meticulously dissect the subpleural tissue, leaving the 
vasculature uninjured ,and to keep clear visibility. We did not encounter severe bleeding needing 
thoracotomy as reported by Ihse using electrocautery (Ihse et al. 1999). Patients, in whom 
technical difficulties were encountered and complete denervation was uncertain, kept pain or 
had pain recurrence within six months, suggesting a correlation between technical success and 
pain relief. Seemingly in contrast no correlation was found between the number of cut nerves 
and the degree of pain relief in a recent series of 21 patients with chronic pancreatitis undergoing 
bilateral thoracoscopic splanchnicectomy (Ihse et al. 1999). 
Our early results are in agreement with those of others, reporting 60-80 per cent pain relief after 
six months (Table 2). The varying percentages are probably explained by differences in 
interpreting pain relief and in defining "failure". During follow-up half of the patients had 
recurrence of pain and were back on their initial daily dose of analgesics or even more. There 
may be several explanations for pain recurrence. First, other than sensory nerves that run from 
the pancreas to the semilunar ganglion and subsequently in the splanchnic nerves can take over 
nociceptive transmission of pancreatic impulses. 
The parasympatic innervation by the vagus may carry such pain signals from the pancreas. Based 
on this assumption, some authors advocate doing a vagotomy in addition to a splanchnicectomy 
(Stone and Chauvin 1990; Stone et al. 1985). The benefit of an additional vagotomy, however, 
has not been properly demonstrated. 
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We did not consider transecting the vagus in patients with relapse of pain fearing side effects. 
Second, pain recurrence is related to altered nociceptive sensory receptor function in and around 
the pancreas. There are two distinctive classes of nociceptors innervating internal organs: the 
high-threshold receptors, which nerve activity is entirely evoked by noxious stimuli, and the low-
threshold receptors, which have a range of stimulation intensity, from innocuous to noxious. 
Receptors that were unresponsive to certain stimuli may theoretically become activated. In the 
presence of inflammation for example, so-called silent nociceptors are activated and contribute 
to the perception of chronic visceral pain (Cervero 1994; Cervero 1995). According to this 
"neural mechanism" (episodes of) progressive inflammation during the course of chronic 
pancreatitis may induce recurrent pain. The observation that a few patients had an episode of 
acute pain attributed to a documented relapse of pancreatitis in the follow-up period after 
splanchnicectomy could be an example of this theory. 
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Third, recurrent pain may be related to previous opioid abuse. Backsliding in old habits such as 
alcohol and opioid use were signaled at follow-up visits during the process of gradual tapering 
pain medication, even longer time after splanchnicectomy. It seems that in subgroups of patients 
with chronic pancreatitis addiction problems interfere with the evaluation of the success of 
thoracoscopic splanchnicectomy. 
Fourth, splanchnicectomy has a placebo effect in some patients. This is supported by the 
relatively high number of patients with pain recurrence within one year. 
Fifty percent long term success rate is lower than that reported by others (Ihse et al. 1999), 
although a thorough comparison is not possible due to differences in study design and endpoints 
used. The higher percentage of preoperative opioid use and the number of previous unsuccessful 
surgical procedures in our series may have influenced this outcome. 
One might criticize leaving an enlarged head of the pancreas surgically untouched, with regard 
to the higher risk for pancreatic carcinoma, in patients with chronic pancreatitis 
(DiMagno 1993). 
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However, the overall incidence of carcinoma unexpectedly found after resection for chronic 
pancreatitis, is very low (Beger et al. 1989; Williamson and Cooper 1987). For this reason, we 
feel that bilateral thoracoscopic splanchnicectomy may be done in the presence of an enlarged 
pancreatic head. 
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Abstract 
Background: Bilateral thoracoscopic splanchnicectomy is a minimally invasive method of 
treating pain in chronic pancreatitis patients. It offers good short-term pain relief, but long-term 
success is difficult to predict. We analyze long-term results and identify factors predicting success 
of splanchnicectomy. 
Methods: Seventy-five consecutive chronic pancreatitis patients underwent bilateral 
thoracoscopic splanchnicectomy with long term follow-up (one year or more). Treatment 
success was analysed using Kaplan Meier method, and possible predictive factors (etiology, 
gender, onset of pancreatitis, previous pancreatitis related surgery, opioid use, pathology at 
imaging, technical success and post-splanchnicectomy complications) via Cox regression. We 
compared patients with long-term pain relief, patients who failed the procedure within one year, 
and those who had pain recurrence after more than one year. Further treatments after failed 
splanchnicectomy were evaluated. 
Results: Sixty six patients (89%) were on continuous opioids; 47 (62%) had prior pancreatitis 
related interventions. Treatment was successful in 52% of patients at 12 months, 38% at 24 
months, and 28 % at 48 months. Twenty-one patients (28%) reported pain relief at the end of 
follow-up, of whom thirteen were completely pain free without any additional treatment. 
Pancreatic surgery after failed splanchnicectomy relieved pain in only 13%. Technical success 
was the only independent factor significantly associated with successful splanchnicectomy 
outcome (P=0.03). Preoperative opioid use showed a strong tendency to be associated with 
unsuccessful outcome (P=0.07). 
Conclusion: Splanchnicectomy offers prolonged (>4 years) benefit in one out of four patients 
with severe chronic pancreatitis pain. Prior opioid use may adversely impact pain relief after 
splanchnicectomy 
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Introduction 
Chronic pancreatitis is the result of fìbro-inflammatory changes in the pancreas due to various 
etiologies. Intractable pain is the main reason for seeking medical help by patients with this 
disease (Gupta and Toskes 2005; Steer et al. 1995). Conservative treatment e.g. enzyme 
replacement, anti-secretory therapy, cessation of alcohol and tobacco intake has limited benefit 
for controlling pain (Khalid and Whitcomb 2002). The aim of surgery in patients with severe 
pain is to avoid the need for prolonged opioid intake. Surgical approaches depend on the 
pancreatic pathology. Resection is first choice in patients having an inflammatory mass of the 
pancreas. Duct drainage is performed when duct dilatation is apparent and ductal hypertension 
is held responsible for pain. Overall, reported pain relief varies between 50 and 90 percent, 
without significant difference between types of^qgeration (Beger et al. 1999; Bradley 1987; 
Evans et al. 1997; Frey et al. 1989; Gebhardt 1993; Howard et al. 1995; Izbicki et al. 1995; 
Schnelldorfer et al. 2007). Thoracoscopic splanchnicectomy has been proposed as a salvage 
surgical procedure for patients who have failed surgery and for those patients with no or minor 
pancreatic pathology on diagnostic imaging studies (1998; Warshaw et al. 1998). Short term 
pain relief has been reported in about 70% of patients (Andrén-Sandberg et al. 1996; Buscher et 
al. 1999; Mäher et al. 1996). Long-term results seem poorer but data are limited (Buscher et al. 
2002; Howard et al. 2002; Ihse et al. 1999; Mäher et al. 2001). These results question the 
therapeutic role of splanchnicectomy and may explain the limited use of this technique in most 
pancreatic centers. 
Little is known about possible pre-operative risk factors associated with successful pain relief 
after pancreatic surgery in general and splanchnicectomy in particular. Previous pancreatic 
surgery, opioid use prior to surgery, extent of the inflammatory mass in the pancreatic head and 
response to epidural infusion of local anesthetics have been investigated for their association with 
failure of surgery with equivocal results (Alexakis et al. 2004; Howard et al. 2002; Keus et al. 
2003; Schnelldorfer et al. 2007). 
In this study we report a large single centre experience with bilateral thoracoscopic 
splanchnicectomy for the treatment of pain in patients with severe chronic pancreatitis. We 
prospectively assessed early and long-term results of thoracoscopic splanchnicectomy with a 
focus on factors associated with success. In addition, we studied alternative interventions for pain 
in patients who did not benefit from splanchnicectomy. 
Patients and methods 
Patients 
Between August 1995 and July 2004 76 consecutive patients with chronic pancreatitis pain 
underwent bilateral thoracoscopic splanchnicectomy and participated in the study. Patients were 
recruited from the pancreatic surgery outpatient clinic, which functions as a tertiary and 
quaternary referral clinic for patients with chronic pancreatitis. The diagnosis of chronic 
pancreatitis was made based on clinical grounds, pancreatic functional insufficiency and 
morphologic changes detected by imaging studies e.g endoscopic retrogade 
cholangiopancreatography (ERCP), computed tomography (CT) and/or magnetic resonance 
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cholangiopancreatography (MRCP), according to Singer et al and Sarner and Cotton (Sarner 
and Cotton 1984; Singer et al. 1985). 
1. We followed the AGA guideline for treatment of pain in chronic pancreatitis to select 
patients for surgery(1998). Thus, patients with an enlarged pancreatic head, a dilated 
pancreatic duct or pancreatic tail pathology were selected for pancreatic head resection, 
a duct drainage procedure or left pancreatectomy, respectively. Bilateral thoracoscopic 
splanchnicectomy was offered to three categories of patients: 
2. Patients without or with minor morphological changes of the pancreas at imaging 
studies. 
3. Patients who had prior interventions including pancreatic surgery for pain without 
prolonged pain relief 
4. Patients with contra-indicadons for pancreatic surgery or who refused to undergo 
abdominal surgery and requested a less invasive procedure. 
Alcohol abstention for a period of at least six months was demanded before being selected for a 
splanchnicectomy and patients were encouraged to discontinue smoking. Written consent was 
obtained from all patients before participating in the study. 
Technique of Bilateral Thoracoscopic Splanchnicectomy 
The operative technique has been described previously (Buscher et al. 1999). In the first 22 
patients nerves were dissected electrosurgically and in the following 54 patients by a harmonic 
scalpel (Harmonic Scalpel*, Johnson & Johnson Medical, Amersfoort, The Netherlands). Chest 
drains were not left behind on a routine basis. Standard chest X-rays were performed two hours 
postoperatively and the day after. The following complications were scored: Infection (e.g. 
wound or pulmonary infection), intercostal neuralgia, bleeding and post-operative chest tube 
drainage for pneumothorax. 
Follow-up 
Patients visited the outpatient clinic at 3 month intervals in the first year after splanchnicectomy 
and at 3 to 6 months intervals thereafter. After one year the referring physician was asked to take 
over the follow-up visits but on patient request. Patients were asked to fill in a simple pain diary 
including pain scoring and corresponding physical activity three times a day and daily intake of 
analgesics during 5 days before each outpatient visit. At each visit, data on pain and pain 
medication, hospital admissions and all pancreatitis related interventions (i.e. surgery, feeding 
jejunostomy or jenunal tube and morphine pump) were documented. All patients with pain 
relapse after splanchnicectomy and visiting their physician as a result were again referred to our 
center for diagnostic and therapeutic counseling. Patients were contacted at the end of the study 
period to complete follow-up details on pain and pain medication. The referring physician was 
contacted to complete the medical information. 
Pain scoring 
Pain was scored by means of VAS (from 0 = no pain to 10 = unbearable pain) before 
splanchnicectomy and at follow-up visits (Buscher et al. 2002). The highest VAS score when 
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doing light physical activity (e.g cleaning, shopping) was noted from the diary. The highest VAS 
of the day of the outpatient visit was recorded in case a diary was not filled in. 
Medication 
Use of medication was divided into three groups: no medication, no opioids (NSAIDs and 
acetaminophen) and opioids (with or without NSAIDs). Opioids analgesic doses were converted 
into morphine-equivalents (MEq) using the Narcotic Analgesic Converter (Version 2.0, 
GlobalRPh© Inc.; http://www.Globalrph.com for comparison of preoperative and postoperative 
consumption of analgesics. The highest daily dose of analgesics listed in the diary or reported by 
the patient was noted. 
Success and failure 
Technical success was defined as success related to the surgical procedure. It was defined as all 
nerve bearing tissue having been recognized, together with certainty of complete splanchnic 
nerve dissection on both sides. 
Primary therapeutic success was defined as pain relief (VAS reduced by at least 2 points reduced 
combined with reduced intake of pain medication) at 1 year or more after splanchnicectomy. 
Primary failure of treatment was defined as persistence of pain or recurrence of pain (same or 
higher VAS, combined with same or increased intake of pain medication) within 1 year after 
splanchnicectomy. Secondary failure was pain recurrence after 1 year or more, needing 
additional therapy, and/or needing higher amounts of pain medication compared to the pre-
splanchnicectomy period. Definitive success was defined as primary success until end of follow-
up without subsequent interventions. 
Additional intervention 
Additional intervention was defined as any major invasive intervention done in order to reduce 
pain (pancreatic surgery, feeding tube, morphine pump, celiac blockade or epidural/intrathecal 
catheter) 
Predicting factors 
The following factors believed to predict clinical success were analyzed: etiology (Alcohol (A) vs. 
non-alcohol(NA)), gender (Male(M) vs. Female(F)), technical success (Yes/No), previous 
pancreatitis related surgery (Yes/No), medication (opioids vs. non-opioids), onset of disease (first 
symptoms less than 4 years vs. more than 4 years ago), pancreatic function (Diabetes Mellitus 
(DM) and/or exocrine insufficiency vs. normal endocrine and exocrine function), the presence 
of distinct pathology at imaging (defined as a pancreatic head > 3.5 cm in diameter or a dilated 
pancreatic duct with a diameter > 7 mm, (Yes/No)), post-operative complications (Yes/No) and 
dissection device (Harmonic scalpel vs. electrocautery). 
Statistical analysis 
Comparisons were initially made between patients with primary success and primary failure, 
followed by multiple group comparison between patients with primary failure, secondary failure 
and definitive success. Continuous variables were expressed as medians with (range) and were 
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analyzed using Mann-Whitney U test or Kruskal Wallis ANOVA for multiple group 
comparison. Nominal data were analyzed using 2 or Fisher's exact probability tests for the 
comparison between primary success and primary failures as well as for the multiple group 
comparison. Kaplan-Meier analysis was used to calculate the probability ot pain relief after 
spianchnicectomy in time. Endpoints of follow-up were primary or secondary failure, death, lost 
to follow-up and end of observational period. Subsequently, potential risk factors were analysed 
in a univariate manner using log-rank tests to identify predictors for pain relief. Cox regression 
analysis was performed on identified predictors (p <0.1 in the univariate analysis) to quantify the 
corrected effect of each previous determined factor on pain relief. Hazard Rates (HR) with 95% 
confidence intervals (CI) were used to describe the effect of the risk factors on the outcome. 
P<0.05 was considered statistically significant. All statistical analyses were performed with the 
statistical package SPSS®, version 12.01 (SPSS, Chicago, Illinois, USA) 
Results 
Demographics and follow-up. 
Seventy-five patients were eligible for analysis of success of spianchnicectomy. One female 
patient was excluded from further analysis because of death 8 months after splanchniccctomy 
due to gastric carcinoma. 
Patient characteristics are listed in Table 1. 
Comparison of patient characteristics and outcomes between the three groups: definitive success, primary and secondary 
failures. *Data are represented as median (range). # Meq= morphine equivalents 
Gender M/F 
Follow up 
VAS' 
Onset' 
Etiology (A/NA) 
Opioids 
M E q ' 
Pancreas pathology 
Patients with 
ptior intervention(s) 
Pancreatic sutgery 
Endoscopic 
Celiac block 
Technical failute (y/n) 
Intervention post-
splanchnicectotny (y/n) 
Ν interventions 
Opioids end follow-up{y/n) 
Total (n-75) 
45/30 
54(12-118) 
9(7-10) 
4.2(1.0-21.7) 
36/39 
66 
160(20-1080) 
16 
47 
Primary success (n=39) 
Definitive 
Success (n=21) 
11/10 
47(12-118) 
8(7-10) 
3.7(1.0-21.7) 
13/8 
17 
95 (30-1080) 
8 
13 
10 
3 
4 
1/20 
0/21 
0 
1/20 
Secondary 
failure (n=18) 
11/7 
72(15-104) 
9(8-10) 
5.9(1.5-19.2) 
8/10 
16 
180 (20-800) 
2 
12 
8 
4 
2 
5/13 
7/11 
7 
12/6 
Primary 
failure(n=36) 
23/13 
50(12-112) 
9(8-10) 
4.3(1.0-11.4) 
15/21 
33 
180(20-840) 
6 
22 
18 
5 
6 
9/27 
25/11 
39 
28/8 
P=0.682 
P=0.066 
P=0.322 
P=0.758 
P.0.361 
P=0.215 
P.0.833 
P=0.10() 
P.0.831 
P-0.549 
1>=0.849 
P.0.102 
P=0.042 
P=0.025 
P=0.002 
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There were 45 men and 31 women. Median age was 46 (range 15-72) years. Half of the patients 
had a history of alcohol abuse, and the majority of patients (88%) were on daily opioid 
medication at first referral. Forty-seven patients (62%) had undergone one or more previous 
surgical and/or endoscopic pancreatitis related interventions including celiac blockade. A total of 
69 interventions had been done comprising twenty pancreatic resections, eight drainage 
procedures, twelve endoscopic interventions, twelve celiac blockades and seventeen other biliary-
pancreatic surgeries such as bilio-digestive anastomosis, cyst drainage and papilloplasty. Sixteen 
patients showed pancreatic pathology at imaging studies such as a dilated duct or an 
inflammatory mass, but were reluctant to undergo major surgery. Twenty (27%) patients had 
pancreatic insufficiency, seven only endocrine, 4 only exocrine and 9 both endocrine and 
exocrine. 
Seven of the seventy-five patients (10 %) died during follow-up at 22, 33, 58, 72, 73, 84 and 96 
months, respectively. Four patients died from a cause unrelated to the pancreas, and one patient 
died due to massive bleeding after a repeat pancreatic head resection in another hospital. Cause 
of death was unknown in two patients. Two of seven patients were pain free at time of death. 
Median follow up period was 54 months (range 12 - 118 months). Four patients (5%) were lost 
to follow up after 13, 18, 44 and 51 months, respectively. 
Complete technical success was achieved in 60 patients (80%). The procedure was considered 
unsuccessful in 13 patients due to pleural adhesions caused by previous complicated surgery, 
attacks of pancreatitis or pulmonary infection. Incomplete lung collapse made clear visibility 
impossible and complete dissection uncertain in the remaining two patients. 
Ten patients (13%) suffered from eleven postoperative complications needing additional 
intervention, namely: aspiration followed by 2 days of mechanical ventilation (N=l), 
symptomatic pneumothorax needing chest tube insertion (N=6), and intercostal neuropathy 
needing nerve blockade (N=4). 
Thirty-nine splanchnicectomy patients (52%) achieved primary treatment success [complete or 
partial pain relief at twelve months; median (range) VAS 3(0-5)] and thirty-six patients (48%) 
primary treatment failure [no pain relief at twelve months; median (range) VAS 8(6-10)]. 
Splanchnicectomy ultimately failed in fifty-four patients (72%; both primary (N=36) and 
secondary failures (N=18), median follow up 61 months, range 12-112 months). Of the 
remaining twenty-one patients (28%) with primary success, thirteen (62%) were pain free and 
eight (38%) had little pain (median follow up 47 months, range 12 - 118 months) at the end of 
follow-up (Table 1). At the end of the observational period the number of patients on opioid 
medication had been reduced from sixty-six (88%) to forty-one (55%). 
The corrected percentage of patients with a successful splanchnicectomy (e.g. corrected for death 
and loss to follow-up) was 52% at 12 months, 38% at 24 months and 28 % at 48 months 
(Figure 1). 
Comparison of the three groups revealed no significance differences in demographic 
characteristics or in frequency of predictive factors (Table 1). A significantly higher proportion 
of patients with primary failure underwent significantly more interventions than patients with 
secondary failure. The number of patients on opioids at the end of follow-up was significantly 
lower in the definitive success group compared to other groups (Table 1). 
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splanchnicectomy. 
Predicting factors 
There were no significant differences between primary success and primary failure for any of the 
chosen factors. Comparison between primary and secondary failures did not reveal any statistical 
significant difference in the frequency of predicting factors either. 
Log rank analysis showed a statistically significant difference for the factor "procedure" in favor 
of technical success (P=0.036) and for opioid use in favor of non-opioids (P=0.049, Figure 2). 
Alcoholic etiology and the presence of distinct pancreatic pathology showed a tendency towards 
a more favourable outcome (P =0.074 and 0.090, respectively). There was no significant effect 
for the factors gender, prior surgery, time of onset, postoperative complications, pancreatic 
function and dissection device. 
Using Cox regression analysis, technical failure was the only independent factor for predicting 
the effect of splanchnicectomy (HR 0.50, 95%CI, 0.26-0.93; P=0.03). Opioid use tended to be 
a negative predictor of success (HR 2.92, 95%CI 0.90-9.45; P=0.07). The Hazard rates for the 
factors anatomic substrate and etiology were respectively 0.58 (95%CI, 0.24-1.4; P=0.23) and 
0.82 (95%CI, 0.34-1.55; P=0.55). 
Therapy for pain after failure of splanchnicectomy 
Thirty-two patients (32/54, 59%) who failed splanchnicectomy (25 primary and 7 secondary 
failures) underwent one or more subsequent interventions including pancreatic surgery, 
prolonged jejunal tube feeding and opioid pump insertion. Only three (13%) of 23 patients who 
underwent a surgical drainage or resection procedure after either primary or secondary failure 
had pain relief (Table 2). 
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I Log Rank analysis and Kaplan Meier curves for the possible predicting factors. (A= Gender, Β = Medication, C = Etiohgy, D = Technical success, E = Presence of distinct pancreas pathology, F - History, G • Onset and H = Complication). Numbers of patients at risk are similar to those in Figure 1 at each time point. 
Seventeen patients (53%) received permanent jejunal feeding of whom nine reported reduced 
pain. Three of these patients also had an opioid pump. Another three patients received 
continuous subcutaneous or intrathecal opioids and were stable regarding pain. Four (19%) of 
twenty-one patients, who failed splanchnicectomy and did not undergo a subsequent 
intervention, reported (spontaneous) pain relief in the 'pancreatic region' at the end of 
follow-up. 
Type and results of interventions following unsuccessful spUinchnicectomy (primary and secondary failures). 
1 Intervention 
1 Partington-Rochelle 
Whipple 
Ftey 
Beget 
Tail tesection 
Othet 
Faillite 
ptimaty 
4 
2 
3 
3 
2 
8 
secundaty 
1 
Follow up 
Pain tetutned within 1 ycat in all patients 
Pain ftee aftet 13 and 12 months 
Pain in patient within 3 months in two patients, 1 
patient died 9 months aftet the operation 
Procedures failed in all patients within 1 year 
Pain returned within 1 yeat in both patients 
Procedure failed in all patients, one patient died 
postoperatively 
Redo resection procedute failed, readmitted for 
pain 1 month after operation 
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Discussion 
Splanchnicectomy offers prolonged (more than 4 years) benefit in one out of four patients with 
severe chronic pancreatitis pain Previous opioid usage may adversely impact pain relief after 
splanchnicectomy In our group, patients who fail splanchnicectomy were likely to fail other 
subsequent surgical interventions 
Treatment of patients with constant pain due to chronic pancreatitis is challenging, and use of 
opioid medication is inevitable in the majority of patients No convincing results have been 
reported from conservative therapies, at least not in cases of severe pain (van Lsch et al 2006) 
Operative therapy is generally offered to patients with pancreatic duct dilatation or an enlarged 
pancreatic head or tail Success rates vary between 50% and 90%, with patient selection the 
most likely factor determining long-term effect of surgical treatment Patients with pain attacks 
and pain free periods, and not needing regular opioids also seem to do best after such surgery 
This view, however, should be treated with caution, as there is a paucity of proper studies 
identifying predictive factors for a favorable outcome after surgery to relieve pain m chronic 
pancreatitis (Alexakis et al 2004, Howard et al 2002, Keus et al 2003, Stefaniak et al 2007, 
Schnelldorfer et al 2007) 
Cushien et al published the first study on bilateral thoracoscopic splanchnicectomy to treat 
patients with pain due to chronic pancreatitis (Cuschien et al 1994) Since then only a few 
centers have systematically investigated the value of this technique as a pain therapy (Buscher et 
al 2002) It is apparent from these series that, in comparison with pancreatic resection and 
drainage series, thoracoscopic denervation is mostly applied as a salvage procedure in patients 
with severe pain and on opioid medication, m patients who have failed previous interventions, 
and in those who have no or minor pancreatic pathology on CT scanning, ERCP or MRCP In 
the present series 88% of the patients were on daily opioids, 63% had prior pancreatic 
interventions and only 2 1 % demonstrated gland enlargement or duct dilatation Such 
unfavorable patient selection might explain the disappointing long-term success of 28% we 
report here Conversely, one might argue that one out of four patients with severe chronic 
pancreatitis pain show long-term benefit from a minimally invasive procedure carrying low 
morbidity and no mortality 
One-third of failures occurred more than one year after splanchnicectomy and after initially 
being considered a success No patient, however, had recurrent pain after four years Both 
observations emphasize the necessity of long-term follow up studies to optimally evaluate the 
effect of pain treatment in chronic pancreatitis We, like others, previously reported more 
favourable results in patients with a short follow-up (Kusano et al 1997, Mäher et al 1996, 
Buscher et al 1999) One-year follow-up is necessary to properly define success in order to 
correct for a placebo effect, and to allow for a sufficient postoperative period to successfully deal 
with signs of opioid withdrawal The significant difference in outcome between technically 
successful and unsuccessful splanchmcectomies renders a pure placebo effect unlikely 
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It is, however, hardly surprising that technical success was identified as a significant predictor for 
clinical success. In contrast to others we completely incise the parietal pleura between thoracic 
level V and XII to dissect all nerve bearing tissue instead of selectively transecting visible 
splanchnic nerves. By doing so communicating and crossing nerves will not be missed and 
dissection is complete (Naidoo et al. 2001). 
Opioid use, previous surgery and distinct pancreatic pathology have been previously investigated 
on a small scale as predictive factors for treatment failure (Alexakis et al. 2004; Stefaniak et al. 
2007; Schnelldorfer et al. 2007; Keus et al. 2003). The present results support opioid use as an 
unfavourable predictor but not previous surgery or pancreatic pathology. This is in concordance 
with a recent study of Stefaniak et al, who also found pre-operative opioid treatment as the only 
predictive factor for pain recurrences after an unilateral splanchnicectomy (Stefaniak et al. 2007). 
Alexakis et al. reported patients using opioids to have more advanced disease than patients 
without opioids. Furthermore, these patients tended to have more disease related complications 
and a longer duration of symptoms, resulting in more hospital admissions (Alexakis et al. 2004). 
Patients with previous surgery also seem to have a longer and more severe disease course. In 
contrast, we did not find a relationship between more advanced disease, severity of pain and 
opioid use. 
The question arises as to which instruments are available to identify patients having benefit from 
any kind of pain relieving surgery. Howard et al. promoted epidural analgesic testing to 
differentiate between non-visceral pain, pancreatic pain and non-pancreatic visceral pain before 
doing splanchnicectomy. A drawback of this study was the lack of a control group consisting of 
patients with non-visceral or supposedly non-pancreatic pain undergoing splanchnicectomy 
(Howard et al. 2002). We had the expectation that Quantitative Sensory Testing (QST), an 
objective method to measure pain processing, could identify patients resistant to surgical 
intervention. However, no correlation was found between clinical success and results from QST 
in an earlier study of patients undergoing splanchnicectomy (Buscher et al. 2007). 
A further question is why a therapy directed at interrupting nociceptive inputs via the splanchnic 
afférents is not successful in reducing pain. Although vagal afferent nerves are considered not to 
convey noxious sensory information, primary visceral afferent nerves via the vagal nerve may 
contribute to the maintenance of chronic visceral pain states (Randich and Gebhart 1992; 
Gebhart 2000). Cutting the vagal nerve for pain relief has been done in the past but may have 
severe side effects such as delayed gastric emptying needing gastric bypass surgery (Stone and 
Chauvin 1990). There is growing evidence of morphological and functional changes in 
pancreatic sensory nerves explaining persistence of pain in chronic pancreatitis (Boekman et al. 
1988; Di Sebastiano et al. 2003; Buchler et al. 1992; Di Sebastiano et al. 2000). Nerve damage 
and nerve inflammation result in continuous visceral nociceptive input to the central nervous 
system, which ultimately may lead to changes in central pain processing that are so pathological 
that central pain perception becomes autonomous and thus independent of peripheral pain 
input (Cervero 2000; Pregni et al. 2007). In support of this line of thought, we recently found 
evidence for central hyperalgesia in chronic pancreatitis patients who used opioids daily 
(Buscher et al. 2006). 
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Pancreatic surgery following failed splanchmcectomy was less successful than primary pancreatic 
resections or duct drainage procedures (Beger et al 1989, Bradley 1987, Carter 1993, Cahen et 
al 2007) This is unlikely to be due to poor centre performance since patients had pancreatic 
surgery only in top, experienced centers throughout the country Unfavorable patient selection, 
e g multiple prior interventions with disappointing results and prolonged opioid usage, may 
explain the low rate of pain relief Accordingly, total pancreatectomy after previous pancreatic 
surgery was successful in only one-third of patients with chronic pancreatitis (Alexakis et al 
2003) As mentioned before, opioid usage may be associated with an autonomic state of pain 
processing in patients with chronic pancreatitis that might persist after surgical removal of the 
source of nociceptive input (Buscher et al 2006) 
Feeding into the jejunum is known to decrease abdominal pain and other gastrointestinal 
complaints in patients with chronic pancreatitis (Fang and DiSano 2004, Stanga et al 2005) 
Impaired gastric emptying may be one of the underlying mechanisms responsible for food intake 
related pancreatitis pain and the success of jejeunal feeding Although conforming to the 
definition of success in the present study, patients have difficulty accepting long-term jejunal 
tube feeding and no oral intake as a permanent therapeutic solution as it impairs their quality of 
life (Fitzsimmons et al 2005) 
Some patients who initially failed splanchmcectomy reported pain reduction and needed less 
medication during follow-up without any additional intervention Apart from other 
explanations, this might reflect the natural course of chronic pancreatitis with "burnout" of the 
inflammation as suggested by Amman et al (Amman et al 1984) but criticized by others 
(Lankisch et al 1995) 
No patient with spontaneous pain relief, however, had the progressive loss of exocrine and 
endocrine function that would be expected with complete pancreatic fibrosis 
It is concluded that splanchmcectomy has limited long-term effect in patients with severe 
chronic pancreatitis pain in whom alternative surgical therapies are not available Daily previous 
opioid usage is associated with an unsuccessful outcome Further studies are needed to answer 
the question whether splanchmcectomy offers a better outcome when done earlier in the course 
of this disease, particularly before starting opioid medication 
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Abstract 
Background & Objectives: The pain of chronic pancreatitis remains challenging to manage, 
with treatment all too often being unsuccessful. A main reason for this is lacking understanding 
of underlying mechanisms of chronic pain in these patients. 
Aim: To document, using somatic quantitative sensory testing, changes in central nervous 
system processing (neuroplasticity) associated with chronic pancreatitis pain and thus gain 
insight into underlying pain mechanisms. 
Methods: We studied 10 chronic pancreatitis patients on stable opioid analgesic medication. 
Ten matched surgical patients without pain served as controls. Pain verbal Numeric Rating 
Scores (NRS) and thresholds to electric skin stimulation and pressure pain were measured in 
dermatomes T10 (pancreatic area), C5, T4, LI and L4. 
Results: The pancreatitis patients had a median NRS pain score of 5 (range 3-8). Electric 
sensation and pain thresholds were significantly increased in the pancreatic region, tending to be 
more so in female pancreatitis patients. Pressure pain thresholds were significantly lower in 
pancreatitis patients than in controls, with men tending towards greater generalised relative 
hyperalgesia than women. 
Conclusions: Chronic pancreatitis patients show pronounced generalised deep hyperalgesia 
that is present despite opioid therapy. These signs, consistent with central sensitisation, appear 
relatively more prominent in men than women. There is also evidence suggesting that women 
may have a better segmental inhibitory response than men, possibly explaining their relatively 
less prominent generalized deep tissue hyperalgesia compared to men. 
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Introduction 
Chronic, relapsing pain in patients with chronic pancreatitis is a major therapeutic challenge, 
frequently leading to recurrent hospitalization, multiple medical interventions and opioid 
dependence. Surgery to alleviate pain by removing the inflamed mass in the pancreas or draining 
the dilated main pancreatic duct is a therapeutic option in about 50% of these patients. For the 
remaining patients there is no anatomic substrate for surgery — or pancreatic surgery has failed. 
In this second group, typical treatments such as celiac plexus blockade, thoracoscopic 
splanchnicectomy, pancreatic denervation operation and even total pancreatectomy fail to 
alleviate pain in a substantial percentage of patients (Buscher et al. 2002). 
There is thus a real need for better treatments for the pain of chronic pancreatitis. This will only 
be achieved on the basis of a better understanding of the underlying mechanisms (Woolf and 
Max 2001). It is now well-accepted that nociceptive input results in altered sensory processing 
by the central nervous system - neuroplasticity - , and that such neuroplasticity plays an 
important role in pain which becomes chronic and abnormal in nature (Woolf 2000). For the 
pain of chronic pancreatitis, two mechanisms could be postulated to be involved. Firstly, 
persistent pancreatic inflammation may result in ongoing nociceptive input, leading to central 
sensitization and visceral hyperalgesia. Secondly, continuing visceral nociceptive input might at 
some point lead to changes in central pain processing that are so pathological that central pain 
perception becomes autonomous and thus independent of peripheral pain inputs (Cervero 
2000;Rossel et al. 2001). 
Current typical methods of clinical pain assessment by means of visual analogue scores, pain 
questionnaires and analgesic consumption do not provide insight into pain mechanisms. Over 
the last years, quantitative sensory testing (QST) has been introduced as an important tool to 
make neuroplasticity visible and thus to gain insight into pain mechanisms in patients after 
surgery (Wilder-Smith 2000;Wilder-Smith et al. 2003), in the context of chronic pain (Kosek 
and Ordeberg 2000), or in patients with visceral pain syndromes (Giamberardino et al. 
1997;Rossel et al. 2001;Stawowy et al. 2002;Sarkar et al. 2003;Bajaj et al. 2003;Giamberardino 
et al. 2005). In the context of the latter, changes in visceral pain processing (i.e. visceral 
neuroplasticity) can be reflected in convergent somatic dermatomes, thus making visceral 
neuroplasticity accessible to somatic QST (Kosek and Ordeberg 2000;Stawowy et al. 
2002;Stawowy et al. 2004). 
The aim of this study is to document the changes in central processing present in patients with 
pain due to chronic pancreatitis using somatic quantitative sensory testing, and thereby to 
attempt to gain more insight into the mechanisms underlying pain in these patients. 
Patients and Methods 
Patients 
For this study, we recruited patients with chronic pancreatitis (CP) on stable opioid analgesic 
medication and without previous abdominal or pancreatic surgery. Our local institutional review 
board waived the need for formal ethics committee approval for the present purely observational 
study; patients gave verbal informed consent to participation. 
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Patients with complications of CP (e.g. biliary obstruction) and patients with other acute or 
chronic pain syndromes (e.g. irritable bowel syndrome, chronic regional pain syndrome) were 
excluded. Both patients and controls were negative regarding clinical criteria for fibromyalgia 
(Wolfe et al. 1990). Age- and gender matched patients without pain or pain syndromes, 
scheduled to undergo an operation for a benign gynaecologie or urologie disease, served as 
controls and were measured before surgery. 
The patients' medical and demographic data were obtained from the patient records. Opioid 
medication for each patient was converted to morphine equivalents using the Narcotic Analgesic 
Converter (Version 2.0, GlobalRPh© Inc.; www.GlobalRPh.com). Aetiology of the CP was 
reported as alcohol or non-alcohol, and evidence of endocrine or exocrine pancreatic 
insufficiency was documented. 
Clinical Pain Assessment 
The pain state at time of QST was documented via verbal numeric rating score (NRS, 0 = no 
pain and 10 = unbearable pain). 
Quantitative Sensory Testing 
Quantitative sensory testing took place in the mid-afternoon, using a standard temporal test 
sequence. Testing in females was not standardised with regard to phase of the menstrual cycle. 
Mechanical stimulation thresholds were tested using a pressure algometer with a 1.0 cm2 probe 
(Somedic Sales AB, Horby, Sweden). The pressure pain thresholds were measured for muscles 
overlying bone at the following sites: lower neck (C5 dermatome), thorax (T4 dermatome), 
pancreatic site (dorsal T10 dermatome), hip region (LI dermatome) and knee (L4 dermatome). 
Thresholds to electric constant current skin stimulation (Digistim*; Biometer A/S, Copenhagen, 
Denmark; tetanic stimulation at 100 Hz, 0.2-ms square waves, self-adhesive electrodes 3 cm 
apart) were measured on the right side of the body in the same dermatomes as for pressure pain 
threshold testing. Three thresholds were measured: sensation (stimulation just felt), pain 
detection (stimulation just becomes painful), and pain tolerance (painfulness of stimulation just 
becomes intolerable). 
Statistical analysis 
We performed statistical analysis using the Statistica for Windows Software Package (Release 
6.0, Statsoft Inc., Tulsa, OK, USA). We analysed QST results using a mixed model ANOVA 
with two between subjects factors ("patient group" = PATGRP, i.e. controls vs. pancreatitis; 
"gender" = SEX, i.e. male vs. female) and one within subjects factor ("site" = SITE, i.e. 
dermatome of QST measurement). Post hoc analysis of significant factors or their interactions 
was performed using Tukey's Honest Significant Difference Test. Testing involving NRS results 
was by Kruskal Wallis ANOVA. To examine the relationships between NRS, morphine 
consumption and QST results, we performed non-parametric correlation analysis (Spearman R). 
Statistical significance was set at P<0.05. 
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I Demographic data of the pancreatitis and control patient groups. NIA = not applicable Mean age (range) 
M/F 
Aetiology (alcohol/others) 
Diabetes Mellitus 
Pancreatic exocrine insufficiency 
Patients 
52.6(29.4-71.3) 
5/5 
9/6 
3 
2 
Control group 
50.1 (36.4-68.1) 
5/5 
NA 
0 
0 
Results 
Between February 2003 and March 2004 we tested ten patients (5 men and 5 women) 
presenting with pain and chronic pancreatitis, on stable opioid analgesic medication and without 
previous abdominal surgery. Ten patients (5 men and 5 women) scheduled to undergo an 
elective urologie or gynaecologie procedure for a non-malignant disease without pain or 
analgesic therapy served as controls. Demographic data of the pancreatitis and control patients 
are listed in Table 1. 
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Pressure pain tolerance thresholds for the controls (continuous line) and pancreatitis patients (dashed line) according to 
gender. Depicted on the Y-axis are the pain tolerance pressure thres-holds in kl'a. On the X-axis the different 
dermatomes with PAN as the pancreatic region are shown. Values are means and 95% confidence intervah. ANOVA 
analysis shows significant differences (P<0.05) for controls vs. pancreatitis, for male vs. female, and L4 vs. other sites. 
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Pain NRS and opioid use 
The median pain numeric rating score (NRS) of the pancreatitis patients was 5 (range 3-8, 
interquartile range (IQR) 4-6) and they consumed a mean of 135 mg (95% confidence interval 
= 19-251) Morphine Equivalents of opioids per day. There was no significant correlation 
between NRS and opioid consumption. 
Quantitative Sensory Testing 
Pressure pain thresholds 
Pressure pain thresholds were lower in the pancreatitis group (factor PATGRP, P=0.02) and in 
females (SEX, P=0.034). Thresholds at L4 were higher than in all other dermatomes (SITE, 
P<0.0001). There were no significant interactions, the results are summarised in Figure 1. 
Electric thresholds 
Sensation thresholds to electric skin stimulation were significantly higher in the pancreatic site 
than in the C5, T4 or L4 dermatomes (factor SITE, P=0.006). The interactions SITE * 
PATGRP (P= 0.023) and SITE * PATGRP * SEX (P=0.019; Figure 2A) were significant. 
C5 T4 PAN L1 L4 C5 T4 PAN L1 L4 =^= control 
^ j pancreaWis 
male female 
Electric sensation thresholds for the controls (continuous line) and pancreatitis patients (dashed line) according to 
gender. Depicted on the Y-axis are the electric sensation thresholds in mA. On the X-axis the different dermatomes 
with PAN as the pancreatic region are shown. Values are means and 95% confidence intervals. * = significantly 
different (P<0.05) vs. other dermatomes and vs. value for control group. ANOVA analysis shows significant 
differences (P<0.05)for the pancreatic site vs. C5, T4 and L4 sites. I 
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Post hoc testing for SITE * PATGRP revealed significantly higher thresholds for the pancreatic 
site than all other sites in pancreatitis patients. For the interaction SITE * PATGRP * SEX, post 
hoc testing demonstrated significantly higher thresholds in the pancreatic site than for all others 
in female pancreatitis patients. Pancreatic site thresholds in female pancreatitis patients were also 
higher than in control patients. 
Electric skin pain detection thresholds were significantly higher in the pancreatic (and LI) site 
than in the C5 dermatome (SITE, P<0.001). Significant interaction was present for SITE * 
PATGRP (P=0.012); the pancreatic site thresholds were higher than C5 and T4 in pancreatitis 
patients. The results are summarised in Figure 2B. 
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For electric skin pain tolerance thresholds, pancreatic (and LI) site thresholds were significantly 
higher than for the C5 and T4 dermatomes (SITE, P<0.001). The interaction SITE * PATGRP 
was significant (P=0.013; pancreatic site has higher thresholds than C5 in pancreatitis patients). 
Figure 2C summarises the results. 
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Correlations between QST results and pain NRS or morphine use 
For the pancreatitis patients we found no significant correlations between pain N R S or 
morphine use (expressed in daily morphine equivalents) and Q S T results. 
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Discussion 
As far as we are aware, this is the first study systematically investigating alterations in central 
nervous system processing in patients with pain and chronic pancreatitis using somatic 
quantitative sensory testing (QST). In this small pilot study, the pancreatitis patients show 
generalised hyperalgesia to pressure pain compared to controls despite considerable opioid 
consumption, and hyposensitivity to electric stimulation in the pancreatic segment. These results 
are suggestive of generalised central sensitisation and segmental (spinal) inhibition; there is some 
evidence that the neuroplasticity demonstrated may differ according to gender. 
More insight into pain mechanisms may permit more effective approaches to pain management 
(Woolf and Max 2001). In this context, QST has proven to be a valuable tool for studying 
mechanisms of chronic pain (Fields et al. 1998). Clinical and experimental studies have provided 
evidence of central sensitization resulting from chronic nociceptive input and altering pain 
perception in a variety of somatic and neuropatie pain syndromes. QST studies in patients with 
fibromyalgia demonstrate decreased pressure pain thresholds at the site of maximal pain as well 
as contralaterally, most likely due to central sensitization (Kosek et al. 1996). Although QST has 
been applied in visceral pain syndromes such as irritable bowel syndrome, post-cholecystectomy 
pain, dysmenorrhoea, endometriosis and urinary calculosis (Giamberardino et al. 1997;Rossel et 
al. 1999;Desautels et al. 1999;Giamberardino et al. 2001;Bajaj et al. 2003), QST has not so far 
been used to systematically study neuroplasticity in patients with pain due to chronic 
pancreatitis. 
It must be emphasised that the present study is a pilot study with a limited number of subjects, 
with attendant limitations regarding statistical power and hence generalisation of results. Clearly 
further and larger studies will be necessary to confirm the present observations. The importance 
of psychological factors in chronic pain is well-recognised. The present study was designed to 
study somatic aspects of pain via objective alterations in sensory processing. Hence it does not 
document subjects' psychological parameters or address their effects on QST. The increased 
affective distress of the pancreatitis patients vs. controls is self-evident (a screening Minimal Pain 
Inventory (Lousberg et al. 1999) for the subjects revealed affective distress scores of 10.0±1.0 vs. 
5.8±1.0 for pancreatitis vs. controls, P<0.05), and is documented in the literature (Wehler et al. 
2003;Fitzsimmons et al. 2005) 
QST is easily applicable and suitable for everyday clinical use as the method, equipment and 
protocols are not complicated and readily adaptable to clinical use (Zaslansky and Yarnitsky 
1998). The different but complimentary nature of information deriving from clinical pain report 
and QST need to be understood. Clinical pain report, highly multifactorial in nature, is the end 
result of a long serial CNS processing chain(Price 2000). QST formally assesses one aspect of 
pain, sensory discrimination, quantifying altered processing sensitivity via stimulus response 
curves for pain. Pain report is thus a symptom signalling the presence of a problem, but 
providing little insight into its underlying mechanisms. 
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QST permits objective and quantifiable insight into a major underlying mechanism of pain: 
altered sensitivity of sensory processing, the target of most pain therapies. 
It is generally acknowledged that dermatomes can converge between somatic and visceral 
neurons for nociceptive input (Jesseli and Kelly 1991). We chose the TIO dermatome as the 
main area reflecting pancreatic visceral neuroplasticity because it is accepted as being convergent 
with pancreatic viscerotomes. We performed QST in other dermatomes distant from the 
pancreatic area (C4, T4, LI and L4) to also assess more generalised (e.g. supra-spinal or glia-
based (Watkins and Maier 2003;Gebhart 2004)) alterations in sensory processing. 
Both mechanical stimulation and transcutaneous electric stimulation for QST have been 
validated extensively (Rollman and Harris 1987;Kosek et al. 1996;Kosek and Ordeberg 2000). 
QST by mechanical stimulation, such as pressure algometry used in our study, is well-validated 
and sensitive to excitatory neuroplasticity in more deeply situated tissues (e.g. bone and muscle) 
(Nikolajsen et al. 2000;Kosek and Hansson 2002). Cutaneous electric stimulation for QST, also 
well-validated, generally does not penetrate beyond cutaneous structures (Rollman and Harris 
1987). It will tend to stimulate peripheral nerve endings directly, bypassing nociceptors, and is 
thus considered to reflect central alterations of sensory processing more strongly than pressure 
algometry, which will reflect both peripheral and central contributions to neuroplasticity 
(Lautenbacher et al. 1994). Electrical skin threshold determinations sensitively reflect inhibitory 
neuroplasticity (Lautenbacher and Rollman 1997). 
Based on the above, we can suggest two reasons for the differing patterns of neuroplasticity 
found using electrical and pressure stimulation. Firstly, as already mentioned above, the two 
types of stimulation not only tend to stimulate different structures (skin vs. deep tissues), they 
also tend to reflect different aspects of altered sensory processing (central vs. peripheral). 
Secondly, cutaneous structures may be more easily subjected to inhibitory controls such as 
DNIC than deep tissues. Although we have found no literature directly addressing this topic, a 
comparison of the literature on the effect of DNIC on skin vs. literature about DNIC and 
deeper structures makes such dififerences conceivable (Cadden and Morrison 1991;Graven-
Nielsen et al. 1998;Svensson et al. 1999;Le Bars 2002;Lautenbacher et al. 2002). 
In this pilot study involving a small number of subjects, pancreatitis patients stable on opioid 
analgesia showed generalised hyperalgesia suggestive of central sensitisation caused by ongoing 
chronic visceral nociception (Cervero 1993;Cervero 1995;Giamberardino and Vecchiet 1995). 
This hyperalgesia could involve a number of mechanisms. One possibility is supraspinal 
descending facilitation originating in the rostral ventromedial medulla, which can contribute to 
chronic pain states, and which can be the result of long-term chronic visceral nociceptive inputs 
(Gebhart 2004). 
Impaired inhibitory controls, described as failing in a variety of chronic pain conditions (Kosek 
and Ordeberg 2000;Danziger et al. 2001a;Danziger et al. 2001b), and potentially inhibited by 
opioid medication, could also be a contributing factor (Le Bars et al. 1992). 
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A further option is the recently described phenomenon of glial activation, also manifest as 
extended and chronic hyperalgesia, and described as resulting from both neuronal and humoral 
(via proinflammatory cytokines) nociceptive inputs during pain and inflammation (Wieseler-
Frank et al. 2004). Another possible mechanism involves opioid-induced hyperalgesia, now well-
described in the context of acute as well as chronic opioid analgesic therapy (Xu et al. 2003). 
However, we found no correlation between opioid dosage and degree of hyperalgesia or pain, as 
might have been expected in this context. A final alternative or complement would be the 
presence of autonomous central sensitisation, i.e. sensitisation no longer dependent on 
peripheral nociceptive inputs (Cervero 2000;Rossel et al. 2001). To determine the possible or 
relative contribution of each of these mechanisms to the generalised deep tissue hyperalgesia 
observed is beyond the scope of the design of the present study. It would appear, though, that 
the visceral nociception in pancreatitis patients is aggressive and poorly controlled by 
opioid therapy. 
The pancreatitis patients also showed signs of segmental inhibition in the referred pancreatic 
dermatome. This would suggest the activation of segmental, most likely spinal, inhibitory 
mechanisms to modulate ongoing visceral nociceptive input (Sandkuhler 1996). It would appear 
that neither this inhibition nor the chronic opioid therapy succeed in blocking ongoing 
pancreatic nociceptive inputs in such a way as to completely prevent central sensitisation, as 
evidenced by the continuing generalised hyperalgesia in deep tissue less subject to inhibitory 
controls than skin. Interestingly, this hyperalgesia tends to be relatively less marked in women, 
who also tend to exhibit a more pronounced segmental inhibitory response. The mechanisms of 
such segmental inhibition are poorly understood and need further study. 
Gender specific differences in pain processing, also described in the literature (Berkley and 
Holdcroft 1999), are manifest in two ways in our study. Firstly, pressure pain thresholds are 
generally lower in women than in men for both groups in our study, consistent with previous 
investigations (Rollman and Lautenbacher 2001;Chesterton et al. 2003). Secondly, our study 
suggests differences in inhibitory control mechanisms between the sexes, with women appearing 
to exhibit better segmental inhibitory control than men, thus tending to exhibit less relative deep 
tissue hyperalgesia vs. controls. These differences need to be confirmed in larger studies. The 
exact mechanisms which could be responsible for such sex differences are still the subject of 
intense study. However, an important role is attributed to gonadal steroid hormones in the 
context of pain mechanisms, stress induced analgesia as well as opioid analgesia (Craft et al. 
2004;Fillingim and Gear 2004). Gender differences have also been discussed with regard to 
(supraspinal) descending noxious inhibitory controls (DNIC) (France and Suchowiecki 
1999;Staud et al. 2003). Animal experimental studies have found evidence for a female specific, 
non-opioid, stress induced analgesia mechanism (Mogil et al. 1997). However, we have found 
no published discussion on putative segmental inhibitory mechanisms in relation to gender. 
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In summary, the present study provides evidence of altered central processing of nociception — 
generalised hyperalgesia and segmental inhibition - in chronic pancreatitis patients with pain on 
long-term opioid therapy. The results are suggestive of ongoing central sensitisation, visible 
despite opioid medication, and probably due to continuing nociceptive input. Quantitative 
sensory testing may be a useful tool for gaining more insight into the mechanisms underlying the 
pain of chronic pancreatitis, thus hopefully providing the basis for future more successful 
mechanism-based therapeutic approaches to this refractory condition. Further studies 
investigating this topic are clearly indicated. 
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Abstract 
Background & Objectives: Central sensitisation due to visceral pancreatic nociceptive input 
may play an important role in chronic pancreatitis pain Using quantitative sensory testing 
(QST), this pilot-study investigates whether bilateral thoracoscopic splanchmcectomy (BTS), 
performed to reduce nociceptive visceral input, affects central sensitisation in chrome 
pancreatitis patients 
Methods: We studied 19 chronic pancreatitis patients (11 men, 8 women on stable opioid 
medication) and 18 healthy volunteers as preoperative controls Preopcratively and 6 weeks after 
BTS, pain numeric rating scores, opioid medication, and thresholds to electric skin stimulation 
and pressure pain (measured in dermatomes TlO (pancreas), C5, T4, LI, L4) were documented 
Treatment success was defined as cessation of opioids 6 weeks after BTS 
Results: Six weeks after BTS, neither pain nor opioid use had decreased significantly However, 
only 10 patients were still on opioids (P<0 05 vs preoperatively) and thresholds overall were 
significantly higher than preoperatively (pressure pain +25%, P<0 001, electric +55% 
[sensation], +34% [pain detection], +21% [pain tolerance], P<0 05) Gender-specific differences 
in hypoalgesia patterns were seen Preoperatively, BTS treatment successes consumed 
significantly less opioids than failures, without significant differences in preoperative patterns of 
neuroplasticity 
Conclusions: BTS for chronic pancreatitis pain resulted in fewer patients on opioids and 
overall increases in pain thresholds Our results suggest that BTS for reducing visceral 
nociceptive input may be effective in reducing resulting central sensitisation Although patients 
benefiting from BTS consume less opioids preoperatively, we were unable to clearly link 
treatment success with specific perioperative patterns of neuroplasticity such as the presence or 
absence of hyperalgesia 
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Introduction 
Pain in patients with chronic pancreatitis is one of the most severe types of chronic visceral pain. 
Treatment poses a therapeutic challenge for both gastroenterologists and surgeons. 
Independently of the treatment chosen, pain frequently relapses, leading to the need for ongoing 
analgesia and frequently to opioid dependence. 
In the presence of anatomical substrates for pancreatic pain, surgery is often considered for pain 
relief. Typical indications include pancreatic duct dilation, pseudocysts and inflammatory 
masses. However, in many patients with chronic pancreatic pain these indications do not apply, 
or previous surgery has failed. In such patients, pancreatic denervation may be considered, 
particularly if pain is poorly controlled by conservative means. One such surgical option is 
bilateral thoracoscopic splanchnicectomy (BTS), a minimally invasive procedure associated with 
low morbidity rates (Buscher et al. 1999). 
Nociceptive input is now accepted to result in alterations of central sensory processing (Woolf 
and Salter 2000). Nociceptive input such as local inflammation or nerve damage will initially 
lead to central sensitisation, but - if persistent - ultimately carries the risk of chronic 
abnormalities of sensory processing (Coderre 1993, Woolf 2000). Ultimately, central 
sensitization may become independent of peripheral nociceptive input, thus providing a 
plausible mechanism for the maintenance of chronic pain states in visceral pain patients (Cervero 
2000;Rossel et al. 2001). 
Using quantitative sensory testing (QST) in patients with chronic pancreatitis, we recently 
demonstrated significant hyperalgesia of central origin, present despite opioid therapy in 
substantial doses (Buscher et al. 2005). These results suggest that central sensitisation due to 
visceral pancreatic nociceptive input plays an important role in the pain of chronic pancreatitis, 
and that this process is not effectively impacted by chronic opioid therapy (Buscher et al. 2005). 
The aim of the present study is to investigate, using QST, whether bilateral thoracoscopic 
splanchnicectomy, aimed at reducing pancreatic nociceptive visceral input, affects the central 
sensitisation present in chronic pancreatitis pain patients. 
Patients and Methods 
Patients 
We prospectively recruited patients with chronic pancreatitis (CP) on stable medication 
including analgesics, and scheduled for pain-relieving pancreatic surgery, i.e. bilateral 
thoracoscopic splanchnicectomy (BTS). All these patients suffered severe continuous or 
intermittent pancreatic pain (NRS>7) necessitating continuous opioid medication for the last six 
months. During this time, all had undergone several unsuccessful attempts to discontinue - or at 
least reduce - their opioid medication. 
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Age and gender-matched controls for preoperative comparison were recruited from hospital staff 
and healthy surgical patients without pain or other major disease. Our local institutional review 
board waived the need for formal ethics committee approval for the present purely observational 
study; subjects gave informed consent to participation. Patients with complications of CP (e.g. 
biliary obstruction, pseudocysts) and patients with other acute or chronic pain syndromes (e.g. 
irritable bowel syndrome, migraine, CRPS I, fibromyalgia) were excluded. 
The patients' medical and demographic data were obtained from the patient records. Opioid 
medication for each patient was converted to morphine equivalents using the Narcotic Analgesic 
Converter (Version 2.0, GlobalRPh® Inc.; www.GlobalRPh.com). We documented evidence of 
endocrine or exocrine pancreatic insufficiency together with CP aetiology (i.e. alcohol or non-
alcohol) (Table 1). 
Demographic details of patients included in study. * NRS measured during QST 
Mean age (range) 
M/F 
Aetiology 
Alcohol 
Others 
Mean NRS* (range) 
Mean onset CP (range) 
Regular opioid medication 
Morphine equivalents (Meq) in mg (range) 
Diabetes Mellitus 
Pancreatic exocrine insulfìciency 
BTS 
50.7(31.0-68.7) 
11/8 
'I 
9 
5 (0-8) 
4.4 yrs (1.2-21.7) 
19 
153(20-520) 
4 
4 
Bilateral thoracoscopic splanchnicectomy 
We use a technique similar to that described by Cuschieri et al. (Cuschieri et al. 1994). In 
summary, the procedure is performed under general anaesthesia with double lumen intubation 
for single lung ventilation. The patient is placed in the full prone jack-knife position. The 
operating thoracoscope is introduced in the second intercostal space beneath the angle of the 
scapula. A second trocar is introduced one intercostal space above and a few inches towards the 
spine, and the pleural space opened from the 5th to the 12th thoracic vertebra. To ensure 
complete denervation, the splanchnic nerves and all the potentially nerve-bearing tissue on each 
side as well as the sympathetic chain are carefully transsected using the harmonic scalpel 
(Ultracision®, Johnson & Johnson Medicals, Amersfoort, The Netherlands). Constant 
awareness of the variable anatomy and of the possibility of crossing nerve branches is mandatory. 
At the end of the procedure the lungs are reexpanded and the trocar sites closed, without routine 
chest drains. Technical success is defined as 1) definitive visual identification of the splanchnic 
nerve branches between C5 and T12, the sympathetic chain, and the relevant nerve bearing 
tissue, and 2) complete transection under visual control of these tissues. 
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No specific tests were performed to prove loss of sympathetic nerve function with the goal of 
confirming complete nerve transection. We defined clinical success of the surgical procedure as 
cessation of chronic opioid therapy by six weeks postoperatively. 
Measurements 
Measurements were performed one day preoperatively and approximately six weeks after BTS. 
The pain state was documented via verbal numeric rating scores (NRS, 0 = no pain and 10 = 
unbearable pain) obtained at the beginning of testing. Pressure pain thresholds were determined 
for paraspinal muscles overlying bone at following left-sided sites: lower neck (C5 dermatome), 
thorax (T4 dermatome), pancreatic site (dorsal T10 dermatome), hip region (LI dermatome) 
and knee (L4 dermatome) using a pressure algometer with a 1.0 cm2 probe and a ramping rate 
of ca. 50 kPa/s (Somedic Sales AB, Horby, Sweden). Thresholds to electric constant current skin 
stimulation (Digistim"; Biometer A/S, Copenhagen, Denmark; tetanic stimulation at 100 Hz, 
0.2-ms square waves, self-adhesive electrodes 3 cm apart) were measured in the same 
dermatomes as for pressure pain threshold testing on the right side of the body. Three thresholds 
were measured: sensation (stimulation just felt), pain detection (pricking pain just felt), and pain 
tolerance (intolerable burning pain just felt). These QST techniques in relation to pancreatitis 
have been described in detail previously (Buscher et al. 2005). 
Statistical analysis 
We performed statistical analysis using the Statistica for Windows Software Package (Release 
7.0, Statsoft Inc., Tulsa, OK, USA). Testing involving NRS results was by Kruskal Wallis 
ANOVA or Wilcoxon. Analysis of QST results was performed separately for preoperative 
measurements and for the overall course of QST results in time. The following analyses were 
thus performed: 
1) Preoperative baseline results comparing patients with controls, analysed using a mixed 
model ANOVA with two between subjects factors ("gender" [SEX, i.e. male vs. female] 
and "patient group" [GROUP, i.e. pancreatitis patients vs. controls]) and one within 
subjects factor ("site" [SITE, i.e. dermatome of QST measurement]) 
2) Time course of QST results, analysed using a double repeated measured ANOVA with 
two between subjects factors ("gender" [SEX, i.e. male vs. female] and "treatment 
success" [EFFECT, i.e. failures vs. successes]) and two within subjects factors ("time" 
[TIME, i.e. pre and post operative] and "site" [SITE, i.e. dermatome of QST 
measurement]) 
Post hoc ANOVA analysis was performed using Fisher's LSD Test. To examine the relationships 
between NRS, morphine consumption and QST results, we performed non-parametric 
correlation analysis (Spearman R). Statistical significance was set at P<0.05. 
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Results 
Between September 2002 and June 2004 we studied 19 consecutive patients with pain and 
chronic pancreatitis scheduled for bilateral thoracoscopic splanchmcectomy (BTS, 11 men and 8 
women) Mean age at the time of testing was 51 years (range 31 to 69 years) Demographic data 
of the patients are listed in Table 1 
Clinical Pain Measures 
The median preoperative pain numeric rating score (NRS) of all pancreatitis patients was 5 
(range 0-8, interquartile range [IQR] 3-6) Six weeks after BTS the median pain NRS was 3 
(range 0-8, IQR 0-5, P=0 052 vs preoperatively) Preoperative morphine consumption was 146 
mg morphine equivalents (Meq) vs 115 mg Meq postoperatively (N S ) The number of 
patients on regular morphine was significantly reduced from 19 preoperatively to 10 
postoperatively (X2 test, P<0 05) The treatment failure group (ι e still on opioids six weeks 
post-BTS) underwent a non-significant reduction in pain NRS from a median of 5 (range 0-8, 
IQR 4-6) to 3 (range 0-7, IQR 0-5) In the treatment success group, pain NRS reduction was 
also non-significant from 4 (range 0-8, IQR 3-6) to 3 (range 0-8, IQR 0-5) Opioid reduction 
from preoperatively to postoperatively was significant in the success group (from a mean of 72 
Meq to 0 Meq) but not in the failure group (214 Meq vs 217 Meq) Preoperative opioid 
consumption was significantly higher in the failure vs the success group (214 Meq vs 72 Meq, 
P=0 007) However, preoperative NRS for pain was similar in failure and success groups (5 
[range 0-8, IQR 4-6] vs 4 [range 0-8, IQR 3-6]) 
Quantitative Sensory Testing 
Pre-operatwe pressure pain thresholds: controL· vs. patients 
ANOVA analysis of the preoperative pain thresholds just failed to show significant effects of 
controls vs patients (GROUP, P=0 068) or their interaction with gender (CROUP'SFX, 
P=0 062) The pressure pain thresholds were statistically different for gender (SEX, P=0 025, 
post hoc men had higher thresholds than women), between sites (SITE, P=0 001, post hoc 
thresholds in patella higher than rest, pancreatic site higher thresholds than C5 and T4) and for 
the interaction SITE*SEX (P=0 026, post hoc threshold for patella higher than others for males 
and females, pancreatic site has higher threshold than C5 and T4 only in females) The results 
for preoperative pressure pain thresholds are summarised in Figure 1 
Pre-operative electric thresholds: controL· vs. patients 
In the preoperative comparison between controls and patients, sensation thresholds to electric 
skin stimulation were significantly affected by the factor SITE (P=0 001, post hoc pancreatic 
site had higher thresholds than C5 and T4), with no further significant effects The same holds 
true for preoperative electric pain detection and tolerance thresholds, where the factor SITE 
showed a significant effect (P<0 001), with post hoc testing demonstrating that the pancreatic 
site had significantly higher pain tolerance thresholds than the C5, T4 and L4 dermatomes 
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Perioperative time course for pressure pain thresholds: patients only 
Double repeated measured ANOVA analysis of the pre and postoperative pain thresholds 
showed significant effects for the factor TIME (P=0.005; post hoc: post operative thresholds 
were significantly higher; +21%) and the factor SITE (P<0.001; post hoc: thresholds at the 
pancreatic site significantly lower than the LI and L4 site). Furthermore the thresholds showed 
significant interactions of site with treatment effect (SITE*EFFECT; P=0.005; post hoc: 
pancreas site had lower threshold than the patella only in the treatment failure group) and with 
gender (SITE*SEX; P=0.028; post hoc: pancreas had lower thresholds than LI in men and lower 
thresholds than L4 in women). Also significant were the interactions SITE*EFFECT*SEX 
(P=0.04, post hoc: pancreatic thresholds were significantly lower than L4 in women in the 
treatment failure group) and the interaction T1ME*SITE*SEX (P=0.001, post hoc: only in men 
were the pancreatic thresholds significantly lower than LI and L4 post-operatively). 
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For the interaction T1ME*SITE*EFFECT*SEX (P=0.05), post hoc analysis suggests that i) in 
men with failed treatment, post operative thresholds were higher than preoperatively at C5 and 
L4; ii) in men with successful treatment, postoperative thresholds were higher than 
preoperatively at LI and L4; and iii) in women with treatment success, postoperative thresholds 
were higher than preoperatively at T4 and LI. Furthermore, the pancreatic site was hyperalgesic 
compared to L4 both preoperatively and postoperatively in women with treatment failure, and 
only postoperatively in men both for treatment failure or success. The results for the time course 
of the pressure pain thresholds are summarised in Figure 2. 
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Perioperative time course for electric thresholds: patients only 
For all three electric thresholds, values taken overall were significantly higher postoperatively 
than preoperatively (TIME, P<0 05, +55% for sensation, +34% for pain detection, +25% for 
pain tolerance thresholds) For pain detection and pain tolerance thresholds, the interaction 
TIME*SITE was also significant (P<0 015, post hoc values significantly higher postop vs preop 
a tC5, T 4 a n d L l ) 
Correlations between Clinical Pain Measures and Q S T 
There were no significant correlations between pain NRS changes and threshold changes due 
to BTS 
Discussion 
To our knowledge, this is the first report studying sensory and pain processing after pain 
relieving surgery in chronic pancreatitis We found that bilateral thoracoscopic 
splanchmcectomy (BTS) in chronic pancreatitis patients is associated with significant increases 
in sensory and pain thresholds six weeks postoperatively For men, who exhibited a trend to 
generalised preoperative pressure hyperalgesia, BTS resulted in generalized hypoalgesia 
irrespective of treatment outcomes Only female BIS treatment successes tended to show 
segmental hypoalgesia postoperatively The number of patients using opioids was significantly 
reduced after BTS, however without significant pain score reduction BTS treatment success was 
associated with significantly lower preoperative opioid consumption, but preoperative patterns of 
neuroplasticity did not predict BTS treatment success 
Several studies have evaluated the effects of BTS in chronic pancreatitis pain based on clinical 
measures such as surgical complications, pain visual analogue scores (VAS), and/or medication 
use They report good early results for BTS (up to 6 months after surgery) - but only moderate 
long term results (Andren-Sandberg et al 1996,Mäher et al 1996,Bradley, III et al 1998, 
Buschererai 1999,Ihse et al 1999,Maher et al 2001,Buscher et al 2002,Howard et al 2002) 
Visual analogue or numerical rating scores are considered reliable for measuring the symptom 
pain and alterations thereof, but clearly do not suffice for assessing its multifactorial nature or 
providing insight into underlying mechanisms in the context of complex chronic pain 
syndromes such as chrome pancreatitis 
We have found no studies evaluating changes in sensory and pain processing after treatment in 
pancreatitis patients Also using quantitative sensory testing (QST), we were recently able to 
demonstrate generalized hyperalgesia in chronic pancreatitis patients, more pronounced in men 
(Buscher et al 2005) The preoperative QST results in the present study are compatible with 
these results, with differences in significance and patterns of neuroplasticity between our two 
studies probably being due to the small patient samples and the fact that - in contrast to the 
earlier study - the present study includes patients with previous abdominal surgery and resulting 
scars, which could be expected to influence sensory processing 
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Chronic pancreatitis is associated with intense nociceptive input due to pancreatic tissue as well 
as nerve damage Boekman et al provide convincing evidence that, in chronic pancreatitis, direct 
pancreatic nerve inflammation and damage accompanies pancreatic tissue inflammation 
(Boekman et al 1988,Boekman 1994) Other studies also support such nerve damage as a 
mechanism for pain generation in chronic pancreatitis Shrikhande et al found increased levels of 
NK-1 synthesis as a sign of increased neural activity in the pancreas caused by inflammation 
(Shrikhande et al 2001) Increased levels of substance Ρ have also been found in the pancreatic 
nerves of chronic pancreatitis patients (Di et al 2000), further supporting nerve damage as an 
important source of pain in these patients Thus we would suggest that it is the combination of 
visceral nociceptive and neuropathic noxious inputs which makes the pain of pancreatitis so 
intense, aggressive and difficult to treat 
Chronic ongoing nociceptive input causes alterations in central nervous processing such as 
central sensitisation (Woolf and Salter 2000), expressed as hyperalgesia As could be expected 
from the intense nociceptive input due to inflammation and nerve damage in chronic 
pancreatitis, such patients have indeed been shown to exhibit generalized hyperalgesia (Buscher 
et al 2005) If such central sensitisation in pancreatitis patients is dependent upon ongoing 
nociceptive input, then one might expect that interruption of this input would result in 
reduction of central sensitisation expressed as hyperalgesia The effectiveness of such an approach 
has been demonstrated in patients with severely painful chronic hip osteoarthritis, where 
subsequent pain relieving hip surgery reversed the previously present hyperalgesia (Kosek and 
Ordeberg 2000) Of interest is the fact that, in parallel, normalisation of the previously 
dysfunctional DNIC responses occurred, suggesting that inhibitory controls dysfunction may 
also be maintained by chronic nociceptive input Congruently with this line of thought, our 
study demonstrates overall reversal of hyperalgesia after BTS in painful chronic pancreatitis 
However, hyperalgesia reversal was not clearly associated with positive treatment effect The 
power of the study is evidently limited by its relatively small size, particularly in view of the 
gender-related differences in the pattern of BTS effect In men, the generalised hypoalgesic effect 
of BTS would appear to be similar in failures and successes Female chronic pancreatitis patients 
do not seem to undergo such a generalised antihyperalgic effect, with female BTS successes 
appearing to exhibit hypoalgesia mainly in the penpancreatic segments Clearly, further research 
is needed with larger patient collectives 
Half of our patients did not stop opioids after BTS Several explanations should be considered in 
this context Firstly, pancreatic deafferentation may not have been effective The greater and 
lesser splanchnic nerves provide the major afferent innervation for the pancreas (Cervero 1994), 
which also includes enteric nervous system fibres running along the mysentenc plexus (Salvioli et 
al 2002) All of these pathways should have been interrupted by our surgical technique -
something difficult to test in practice (Ihse et al 1999) Even assuming complete transection, it 
remains conceivable that alternative pathways could have been recruited to transmit nociception, 
as has been suggested to explain the recurrence of pain observed after myelotomy or chordotomy 
(Whitworth and Feler 2002) 
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Secondly, ongoing nociceptive input caused by inflammation and nerve injury may have led to 
irreversible (or autonomous) supraspinal changes Thus cortical reorganisation may have resulted 
in autonomous central sensinsation independent of nociceptive input (Cervero 2000,Rössel et 
al 2001 .Apkarian et al 2004) If this were the case in our chronic pancreatitis patients, this 
would also render deafferentation ineffectual Thirdly, the act of deafferentation itself could also 
have caused further central sensitisation in these patients Nerve destruction leads to increased 
spontaneous dorsal horn neural activity, resulting in increased central excitation and inhibition 
of descending inhibition and ultimately central sensinsation and visceral hyperalgesia (Woolf 
and Salter 2000,Gebhart 2000,Gebhart 2004) Finally, it should be remembered that BTS does 
not remove the nociceptive focus, ι e the inflamed pancreas, leading to continued secretion of 
bioactive substances such as cytokines and interleukins into the bloodstream (Bhatia et al 2000) 
This produces a maintained neuro-humoral response mediated by the penspinal glia cells, and 
results in a generalized hyperalgesic state (Watkins and Maier 2003,Wieseler-Frank et al 2004) 
Such a humoral nociceptive input will of course not be susceptible to nerve ablation 
In conclusion we found an overall increase in electric and pressure pain thresholds six weeks after 
bilateral thoracoscopic splanchmcectomy (BTS) in patients with painful chronic pancreatitis, 
with gender-specific differences in patterns of change These results in combination with the 
previously demonstrated generalized hyperalgesia suggest that changes in central nervous system 
function play an important role as a pain mechanism in this presently therapy-resistant group of 
patients However, we were unable to identify preoperative differences in neuroplasticity 
predictive of successful BTS outcome in this small study, although it is worth noting that BTS 
treatment successes consumed lower doses of opioids preoperatively than BTS failures Caution 
should therefore be exercised in assuming that all centrally sensitised pancreatic pain patients will 
benefit from BTS or other surgical pain reducing treatments Larger studies formally testing the 
effects of such pain-relieving surgery are clearly called for 
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Abstract 
Background and Objectives: Central sensitisation due to visceral pancreatic nociceptive 
input may play an important role in chronic pancreatitis pain. We investigated whether bilateral 
thoracoscopic splanchnicectomy (BTS) to reduce nociceptive input in chronic pancreatitis 
patients (CPP) with poor pain control affects supraspinal and spinal sensitisation. 
Methods: Seventeen CPP were studied preoperatively and 6 weeks after BTS. Pressure pain 
thresholds (PPT) were measured in clavicle and pancreatic dermatomes reflecting supraspinal 
and spinal central sensitisation. Patients with increased PPT after BTS (hypoalgesic) were 
compared to those without (hyperalgesic). 
Results: After BTS, ten patients showed C5 PPT increases (hypoalgesic; median change 
87 kPa), 7 patients had unaltered or lower PPT (hyperalgesic; -135 kPa). Preoperative pain NRS 
was similar between groups (4 vs. 5, P=0.2). After BTS hypoalgesic group NRS was lower (1 vs. 
6; P=0.008) and NRS change greater (-2 vs. 0; P=0.005). 
Whole group NRS and C5 PPT change correlated significantly and negatively (r=0.53; P<0.05). 
This was not so for pancreatic PPT. 
Conclusions: Reduced supraspinal - but not spinal - central sensitisation after BTS was 
associated with significantly reduced pain scores in a majority of CPP. A subgroup showed no 
reductions in supraspinal central sensitisation after BTS, coupled to no significant pain NRS 
reduction. Our results suggest that a subgroup of CPP with chronic pain has altered central pain 
processing this may be independent of ongoing peripheral nociceptive input, resulting in 
persisting pain despite BTS. If confirmed, these results indicate the importance of sensory testing 
for indications and management of interventional pain treatments. 
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Introduction 
Chronic pancreatitis is a disease characterized by progressive inflammation and irreversible 
fibrosis leading to destruction of pancreatic tissue (Steer et al. 1995). Pain is the leading 
symptom in patients with chronic pancreatitis and the main reason for seeking medical help. 
Pancreatic surgery is often considered for pain relief when an anatomical substrate such as 
pancreatic duct dilation, pseudocyst and inflammatory mass are present (Andersen and Frey 
2010). Independently of the surgical treatment chosen, pain persists or relapses in 30% of the 
patients, leading to the need for ongoing analgesia and frequently to opioid dependence 
(Andersen and Frey 2010; Andren-Sandberg et al. 2002). In these patients, pancreatic 
deafFerentation, interrupting nociceptive input may be considered (Buscher et al. 2002). Such a 
minimally invasive procedure is bilateral thoracoscopic splanchnicectomy (BTS), which has high 
initial success rates and low morbidity rates (Buscher et al. 1999). 
Ongoing nociceptive input, such as local inflammation or nerve damage, is now accepted to be 
one of the mechanisms that results in alterations of central sensory processing (Woolf and Salter 
2000). Loss of descending inhibitory control mechanisms or activation of descending facilitation 
favours nociceptive input and will lead to central sensitization, initially spinal and later on 
supraspinal (Cervero 2000; Drewes et al. 2008). Ultimately, central sensitization may become 
independent of peripheral nociceptive input, thus providing a plausible mechanism for the 
maintenance of chronic pain states in visceral pain patients.(Cervero 2000) Other mechanism 
could be opioid induced hyperalgesia especially in patients on long term opioid treatment 
(Simonnet and Rivat 2003). 
Using quantitative sensory testing, we demonstrated that patients with chronic pancreatitis 
requiring long-term opioid therapy did have more central sensitization and generalized 
hyperalgesia than healthy controls (Buscher et al. 2006). These results suggest that central 
sensitization, due to visceral pancreatic nociceptive input, plays an important role in the pain of 
chronic pancreatitis, and that this process is often not effectively impacted by chronic opioid 
therapy (Buscher et al. 2006). There is evidence that BTS to reduce pancreatic nociceptive input 
may be effective in reducing central sensitization in such patients (Buscher et al. 2007). 
However, the fact that such deafFerentation is not effective in all patients could imply that in 
some patients, such neuroplastic changes are independent of peripheral nociceptive input 
(Apkarian et al. 2009; Baghdadi et al. 2008). 
The aim of the present study is to investigate, using quantitative sensory testing (QST), whether 
such independence of neuroplastic central alterations from ongoing peripheral nociceptive input 
exists. Our hypothesis is that pain in some chronic pancreatitis patients is related to alterations in 
pain processing, explaining the failure of splanchnicectomy in some chronic pancreatitis pain 
patients. 
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Patients and Methods 
Patients 
At our unit we prospectively collect clinical and QST data from all chronic pancreatitis (CP) 
patients admitted. The present study is part of a clinical cohort of chronic pancreatitis patients 
scheduled for bilateral thoracoscopic splanchnicectomy and collected over the course of ten 
years. All these patients suffered severe continuous pancreatic pain (average daytime numeric 
rating scores (NRS) > 5) necessitating continuous opioid medication for the last six months. 
During this time, all had undergone several unsuccessful attempts to discontinue - or at least 
reduce - their opioid medication. Only patients on stable opioid therapy were selected to permit 
meaningful before vs. after surgery comparison. 
In our hospital the performance of QST is part of routine clinical diagnostics and monitoring 
for the management of complex pain patients e.g. chronic pancreatitis. Thus QST cannot be 
considered an intervention in the sense of an action that imposes extra risk or burden to the 
patient for study purposes. Hence no extra approval was necessary by our ethics committee 
(CMO region Arnhem-Nijmegen) because the study did not involve the collection of any extra 
data which was beyond standard clinical practice for our unit. Patients did provide informed 
consent for use of their clinical and quantitative sensory testing data for study and 
publication purposes. 
Patients with complications of CP (e.g. biliary obstruction, pseudocysts) and patients with other 
acute or chronic pain syndromes (e.g. irritable bowel syndrome, migraine, CRPS I, fibromyalgia) 
were excluded. In cases of doubt an expert in chronic pain was consulted. 
The patients' medical and demographic data were obtained from the patient records. Opioid 
medication for each patient was converted to morphine equivalents using the Narcotic Analgesic 
Converter (Version 2.0, GlobalRPh© Inc.; www.GlobalRPh.com). We documented evidence of 
endocrine or exocrine pancreatic insufficiency together with CP aetiology (i.e. alcohol or 
non-alcohol). 
Bilateral Thoracoscopic Splanchnicectomy 
We used a technique adapted from that described by Cuschieri et al. (Cuschieri et al. 1994). In 
summary, the procedure is performed under general anaesthesia with double lumen intubation 
for single lung ventilation. The patient is placed in the full prone jack-knife position. The 
operating thoracoscope is introduced in the second intercostal space beneath the angle of the 
scapula. A second trocar is introduced one intercostal space above and a few inches towards the 
spine, and the pleural space opened from the 5th to the 12th thoracic vertebra. To ensure 
complete denervation, the splanchnic nerves and all the potentially nerve-bearing tissue on each 
side as well as the sympathetic chain are carefully transected using the harmonic scalpel 
(Ultracision®, Johnson & Johnson Medicals, Amersfoort, and The Netherlands). At the end of 
the procedure the lungs are re-expanded and the trocar sites closed, without routine chest drains. 
Technical success was defined as 1) definitive visual identification of the splanchnic nerve 
branches between C5 and T12, the sympathetic chain, and the relevant nerve bearing tissue, and 
2) complete transection under visual control of these tissues. 
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AU patients were treated according to a standard protocol for this intervention. So pre-, peri- and 
postoperative care was the same for every patient, as well for anaesthetics used. 
Clinical pain assessment and quantitative sensory testing 
Measurements were performed one day preoperatively and six weeks after BTS. The clinical pain 
state was documented via verbal numeric rating scores (NRS, 0 = no pain and 10 = unbearable 
pain) obtained at the beginning of testing. 
Pressure pain thresholds were determined for paraspinal muscles overlying bone at following left-
sided sites: clavicle site (C5 dermatome) and pancreatic site (dorsal TIG dermatome) using a 
pressure algometer with a 1.0 cm2 probe (Somedic Sales AB, Horby, Sweden). The clavicle site 
(the most remote from the pancreatic region) was chosen as reflecting generalized changes in 
pain processing, i.e. supraspinal central sensitization. The pancreatic site was chosen as site 
reflecting spinal segmental hyperalgesia. These QST techniques in relation to chronic 
pancreatitis have been described in detail previously (Buscher et al. 2006). 
I Demographic and baseline data of the chronic pancreatitis group Results are demographic details of patients included in this study. All are medians and interquartile ranges unless otherwise specified. * numeric rating scores (NRS) measured during quantitative sensory testing. 
Age (yr) 
Sex ratio M-H (no.) 
Diabetes mellitus (no.) 
Pancreatic exocrine insufficiency (no.) 
Aetiology (no.) 
Alcohol 
Other 
Median NRS* 
Mean onset chronic pancreatitis 
Regular opioid medication (no.) 
Morphine equivalents (Meq) in mg 
Patients (n=17) 
47 (45 - 56) 
1 0 - 7 
4 
4 
6 
11 
4 ( 3 - 6 ) 
4 years ( 1 - 6 ) 
17 
90 (35 - 133) 
Statistical analysis 
We performed statistical analysis using the Statistica for Windows Software Package (Release 
7.0, Statsoft Inc., Tulsa, OK, USA). For all analysis non-parametric tests were used. The clavicle 
site was compared with the pancreatic site to visualize differences and changes in central spinal 
and supraspinal central sensitization. Change in pain processing due to BTS was quantified by 
calculating the difference between preoperative and postoperative clavicle site or pancreatic site 
PPT. Patients were divided in two groups based on the direction of changes in clavicle site or 
pancreatic site PPT due to BTS: Group 'hypoalgesic' was the group which experienced an 
increase in PPT after BTS (suggesting a reduction in hyperalgesia with splanchnicectomy, and 
group 'hyperalgesic' was the group not experiencing such an increase. 
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Analysis for hypoalgesic vs. hyperalgesic groups was performed based on both clavicle site and 
pancreatic site changes in PPT values. Pre- and post operative data within the group were 
compared using a Wilcoxon signed rank sum test; group comparisons (hypoalgesic vs. 
hyperalgesic for clavicle site and pancreatic site) were done using the Mann-Whitney U test. To 
examine the relationships between the NRS change and clavicle site and pancreatic site PPT 
change perioperatively, we performed non-parametric correlation analysis (Spearman R). 
Statistical significance was set at P<0.05. 
Results 
We studied 17 consecutive patients (10 men and 7 women) with pain and chronic pancreatitis 
scheduled for thoracoscopic splanchnicectomy. Median age at the time of testing was 47 years 
(interquartile range (IQR) 45 to 56 years). Demographic data of the patients are listed in 
Table 1. All BTS procedures were technically successful. One patient had a postoperative 
pneumothorax that was treated with a chest tube. Five patients had postoperative neuralgia in 
the area of the upper abdomen, this was treated conservatively and diminished in the weeks after 
operation. These complications are common for this procedure and were mostly transient. 
Pain levels and pain scores per group before and after intervention 
Pressure pain tolerance thresholds (PPT) and numeric rating scores are all medians with interquartile ranges. PPT is in 
kPa. Clavicle and pancreas are the dermatomes of measurements. Preoperative values were not significantly different 
between groups. 
* numeric rating scores (NRS) measured during quantitative sensory testing. 
PPT clavicle site 
Hypoalgesic 
Hyperalgesic 
PPT pancreas site 
Hypoalgesic 
Hyperalgesic 
NRS* clavicle site 
Hypoalgesic 
Hyperalgesic 
NRS* pancreas site 
Hypoalgesic 
Hyperalgesic 
Preoperative 
404(318-500) 
468 (363-800) 
508 (345-642) 
518(431-626) 
4 (3-5) 
5 (4-6) 
5 (4-5) 
4(3-6) 
Postoperative 
510(394-568) 
351 (267-527) 
593 (476-760) 
396 (309-525) 
1 (0-3) 
6 (5-7) 
4 (0-5) 
2 (0-6) 
Clinical Pain Measures 
The median preoperative pain numeric rating score (NRS) of all pancreatitis patients was 4 
(IQR 3-6). Six weeks after BTS the median pain NRS was 3 (IQR 0-5; P=0.097 vs. 
preoperatively). No significant difference in preoperative PPT or pain NRS could be found for 
the hypoalgesic group vs. the hyperalgesic groups as based on clavicle and pancreatic site PPTs. 
All pre- and postoperative NRS and PPT are given for hypoalgesic and hyperalgesic group in 
clavicle site and pancreas site in Table 2. For baseline data only age was significantly different 
(P=0.04) between the hyperalgesic and hypoalgesic group for the pancreatic site (Table 3). 
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Clavicle site Pressure Pain Thresholds and NRS 
Ten patients (6 men and 4 women) had clavicle site PPT increases after BTS compared to 
preoperative values (hypoalgesic group; 87 kPa IQR 40-120; P=0.0006); in 7 patients clavicle 
site PPT was unaltered or lower (hyperalgesic group; -135 kPa IQR -193- -31; P=0.003). The 
postoperative NRS was significantly lower in the clavicle site hypoalgesic group (P=0.008). The 
change in NRS was significantly greater in the clavicle site hypoalgesic group vs. preoperatively 
(Figure 1 LEFT; -2, IQR -4-0 vs. 0, IQR 0-1; P=0.005). The NRS in the hypoalgesic group was 
significantly reduced with BTS (P=0.03), compared with a non-significant increase in NRS in 
the hyperalgesic group (P=0.1). 
Demographic and baseline data of chronic patients per outcome group 
Results are demographic details of patients included in this study described per outcome group. All are medians and 
interquartile ranges unless otherwise specified. NS means non-significant 
Age (yr) 
Sex ratio M-F (no.) 
Diabetes Mellitus (no.) 
Pancreatic exocrine 
insufficiency (no.) 
Aetiology (no.) 
Alcohol 
Other 
Mean onset chronic 
pancreatitis 
Regular opioid 
medication (no.) 
Morphine equivalents 
in mg 
Hyperalgesic 
clavicle 
(n-7) 
31 (41-56) 
4 - 3 
0 
1 
3 
4 
3(1-5) 
7 
120(60-131) 
Hypoalgesic 
clavicle 
(n-10) 
47 (47-55) 
6 - 4 
4 
3 
3 
7 
4(1-6) 
10 
50(28-141) 
P-value 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Hyperalgesic 
pancreas 
( n = l l ) 
49 (47-57) 
6 - 5 
2 
4 
3 
8 
3(1-6) 
11 
60(20-131) 
Hypoalgesic 
pancreas (n=6) 
45 (36-49) 
4 - 2 
2 
0 
3 
3 
4 (2-5) 
6 
111 (55-240) 
P-value 
(1 . (1 -1 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Pancreatic site Pressure Pain Thresholds and NRS 
Regarding pancreatic PPT changes, 6 patients had an increase (hypoalgesic; 4 men, 2 women; 
127 IQR 86-142, P=0.028), and 11 patients did not (hyperalgesic; 6 men, 5 women; -113 IQR 
-132- -65. P=0.003). The postoperative NRS was similar in both groups (P=0.8). The change in 
pain NRS after BTS was not significantly greater in the pancreatic hypoalgesic group vs. 
preoperatively (Figure 1 RIGHT; 0, IQR -3-1 vs. 0, IQR -2-0; P=0.5). In neither group was 
NRS significantly reduced with BTS (hypoalgesic P=0.47 and hyperalgesic P=0.11). 
Correlations between Clinical Pain Measures and Q S T 
There was a significant negative correlation between the change in NRS and the PPT changes at 
clavicle site due to BTS for the group as a whole (r=0.53; P<0.05) (Figure 2). There was no 
significant correlation between the change in NRS and the PPT changes at the pancreatic site. 
Also no significant correlation could be observed between the clavicle site and the pancreatic site 
(Table 3). 
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Box plots of the change in numeric rating scores (NRS) and change in pressure pain thresholds (PPT) after bilateral 
thoracoscopic splanchnicectomy (BTS). 
A: The change in NRS after BTS was significantly greater (marked with an asterisk) in the clavicle site hypoalgesic 
group vs preoperatively (median = -21QR [-4 - 0] vs. 0 IQR [O-JJ; P=0.005). 
B: The change in NRS after BTS was not significantly greater in the pancreatic hypoalgesic group vs preoperatively 
(median 0 IQR -3-1 vs. -2-0; P=0.5) 
Hypoalgesic group was the group which experienced an increase in PPT after BTS (suggesting a reduction in 
preoperative hyperalgesia), and hyper algesic group was the group not experiencing such an increase. 
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On they-axis the change in pain numeric rating score (NRS) preoperatively vs. postoperatively has been mentioned. On 
the x-axis the change in pressure pain thresholds (PPT) preoperatively vs. postoperatively in clavicle site has been 
mentioned. A significant correlation was found between the change in NRS and PPT (r=0.53; P<().05). This 
correlation shows that an decrease in pain is correlated with an increase in pressure pain thresholds. PPT is in kPa. 
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Discussion 
Only few published studies describe changes in central pain processing in patients with chronic 
pancreatitis after thoracoscopic splanchnicectomy (Buscher et al 2007) We found that an 
increase in pressure pain thresholds (PPT) at the clavicle site after bilateral thoracoscopic 
splanchnicectomy (BTS), distant from the pancreas and thus reflecting supraspinal processing 
(Buscher et al 2006), was associated with a significant reduction in pain scores six weeks 
postoperatively This was not the case for the pancreas site, reflecting more segmental spinal 
processing (Buscher et al 2006) In patients in whom BTS did not show any effect on clavicle 
site PPT, pain scores were unaltered 
These results suggest that in the latter group, central changes in pain processing might have 
become independent of ongoing peripheral nociceptive input, resulting in persisting pain despite 
nociceptive deafferentation via BTS (Buscher et al 2008) 
Sensitization of the nervous system is a cardinal feature of most chronic pain disorders (Woolf 
and Salter 2000) Peripheral nociception at the site of the pancreas can be expected to spread via 
ascending pathways of the spinal cord to supraspinal structures including the cortex (Apkanan et 
al 2009, Baghdadi et al 2008) Due to ongoing nociceptive input the dorsal horn of the spinal 
cord undergoes neuroplastic changes, resulting in an increase in neuronal excitability and, 
synaptic strength and neuronal reorganization (Drewes et al 2008), characterized by segmental 
hyperalgesia at the site of injury (Cervero 1995) Ultimately ongoing nociceptive drive on 
secondary neurons will lead to spreading and generalized hyperalgesia, caused by 
hyperexcitabihty and firing of supraspinal neurons at lower thresholds (Drewes et al 2008) 8 
Failure of activation of diffuse noxious inhibitory controls (DNIC) in turn depresses nociceptive 
activity in dorsal horn neurons, experienced by patients as a reduction in pain (Le Bars et al 
1979, Gebhart 2000) All these changes carry the potential of independence from peripheral 
nociceptive input, where pain and hyperalgesia will then be present even when there is no 
peripheral nociceptive input (Cervero 1995) 
We found that deafferentation of the pancreas by BTS did not lead to a decrease in NRS or an 
increase in distant pain thresholds in a subgroup of pancreatitis patients Thus it would appear 
that we may have identified a subgroup of pancreatic pain patients where supraspinal central 
sensitization is no longer dependent on peripheral nociceptive input, resulting in absence of pain 
reduction This would be the first time this phenomenon has been demonstrated in chrome 
pancreatitis pain patients, and may explain the relatively large proportion of such patients who 
fail to respond to typical surgical or pharmacological treatments designed to reduce nociceptive 
input (Buscher et al 2008) Conversely, this study also suggests there is a subgroup of chronic 
pancreatitis pain patients in whom supraspinal changes in pain processing do depend on 
peripheral nociceptive input, and in these patients peripheral nociceptive deafferentation via 
BTS appears effective in reducing both pain and central sensitization 
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Methodological considerations 
Alternative explanations for the failure of BTS to improve hyperalgesia or pain need to be 
considered. Technical failure due to difficult identification of all the splanchnic branches, 
variations in morphology, alternative pathways and localisation of the greater and lesser 
splanchnic nerves have all been described in the literature (Baghdadi et al. 2008; Buscher et al. 
2008). However, during our procedures all nerves and branches were visualized in all patients 
and all procedures were classified as technically successful. The operation of itself could have 
caused further central sensitization due to nerve destruction resulting in increased central 
excitation and facilitation via descending pathways, where finally an autonomous state of 
chronic pain can be present (Woolf and Salter 2000). However, in our study only a minority of 
patients showed this phenomenon, and in fact almost two thirds of our chronic pancreatitis 
patients showed pain reduction due to deafferentation (Buscher et al. 2002). 
Another possible explanation for BTS failure is that BTS does not treat the cause of the pain 
itself; the pancreatitis (Wieseler-Frank et al. 2004). Again, however, the question is why this 
should be true of some pancreatitis patients and not others. An explanation for the difference in 
pain sensation after the operation by imperfections in the QST protocol is also unlikely. The 
QST protocol we used is well-standardised and reliable and is generally accepted in the literature 
as an appropriate and effective method to measure and follow-up pain processing in multiple 
disorders and patient groups (Buscher et al. 2006). 
In contrast to our previous study we were now able to positively link our QST lesults (presence 
or absence of hyperalgesia) to clinical effect (Buscher et al. 2007). As clinical effect, we used pain 
scoring by NRS, which is an easy and reliable method of evaluating pain state in patients. In our 
previous study, success was defined as ceasing opioids within 6 weeks after the treatment 
(Buscher et al. 2007). However it would have been more appropriate to correlate differences in 
pain processing, measured by QST, to changes in NRS or VAS, rather than opioid usage, which 
is influenced by a multitude of factors. Many of these factors are only weakly related to changes 
in pain processing which can be expected to occur in the first weeks after nociceptive 
deafferentation. 
An important limitation of this study is the sample size, therefore important differences in 
baseline or postoperative measurements could have been missed. Due to the use of a single pain 
assessment instead of multiple assessments like questionnaires we may also have missed 
important outcomes. In this study we only used one modality (mechanical pressure) for the 
quantitative sensory testing, because central sensitization is best reflected by mechanical (e.g. 
pressure) pain thresholds. Other modalities e.g. thermal pain thresholds mainly reflect peripheral 
sensitization or nerve damage. Our data might have been different if we used an even more distal 
site, e.g. the trigeminal dermatome, rather than the clavicle site as distant reference site reflecting 
generalised central sensitisation. However the use of the clavicle site for determining central 
sensitization has been described before and is more patient friendly (Bouwense et al. 2011). 
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Clinical implications 
This study has shown that there may be groups of patients with chronic pancreatitis that do not 
benefit from analgesic treatment and surgery that deafferents the pancreas to control pain It 
appears important to identify such patients, who are likely to have autonomous changes in 
supraspinal processing of pain, and might need specific treatment of central sensitization to 
control their chronic pain As suggested in other studies, QST can be used to demonstrate 
central changes in pain processing and to predict patients that are likely to have no benefit from 
common therapies modulating nociceptive input such as opioids (Buscher et al 2006, Wilder-
Smith et al 2003) These data suggest that a local nerve block test (e g celiac plexus blockade or 
differential epidural anaesthetic) (Howard et al 2002) in combination with a pre-and post 
blockade QST before performing a BTS might be predictive and save these patients an 
unnecessary operation, but this needs confirmation by future studies 
Pain control for chronic pain patients resistant to peripheral nociceptive deafferentation can 
likely be achieved by using medication influencing central changes in pain processing, e,g 
tricyclic depressants and gabapentmoids (Drewes et al 2008, Olesen et al 2011, Finnerup et al 
2005) Interestingly gabapentin has shown to potentiate the effect of opioids in an animal model 
of pancreatitis (Smiley et al 2004) Blockade of the NMDA receptor, which plays a central role 
in central sensitization, with ketamine has been proven to be effective in treating central 
sensitization and hyperalgesia (Woolf and Salter 2000, Coderre et al 1993) However, more 
research is needed on the use of ketamine, antidepressants and gabapentoids in treating therapy 
resistant chronic pancreatic pain patients (Bouwense et al 201 1) 
In summary, pain scores were unaltered in chronic pancreatitis pain patients in whom BTS did 
not increase distant PPTs These results suggest that in this group, central changes in pain 
processing might have become independent of ongoing peripheral nociceptive input, resulting in 
persisting pain despite BTS If confirmed in larger studies, these results indicate the importance 
of sensory testing in the interpretation of unsuccessful interventional pain treatments 
Ultimately, the ability to identify patients who have autonomous pain processing will be key to 
achieving improvements in the management of the disabling pain of chronic pancreatitis 
patients More research is needed to achieve greater insight into the alterations of central pain 
processing accompanying the pain of chronic pancreatitis and thus to treat this pain more 
effectively 
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Abstract 
Background & Objectives: Pain treatment in chronic pancreatitis patients is difficult, with 
pain frequently relapsing or persisting Recent studies suggest that altered central nervous system 
pain processing underlies the chronic pain state in these patients There is evidence that 
increased sympathetic activity may also play a role in some chronic pain syndromes This study 
assessed sympathetic nervous system activity and its relation to pain processing in patients with 
severe painful chronic pancreatitis We postulated that chronic pancreatitis patients with more 
sympathetic activity exhibit more generalised hyperalgesia 
Methods: In sixteen chronic pancreatitis patients, sympathetic activity was measured via 
venous plasma norepinephrine (NE) levels (supine, standing) Pain processing was quantified via 
pressure pain tolerance thresholds (PPT) in dermatomes 1 10 (pancreatic area), C5, T4, I 1 
Results: Five patients showed increased supine plasma NL· levels (NE >3 0 nmol/1) PPT were 
lower in patients with increased NE levels (INE) compared with patients with normal NF 
(NNE) (means [95% CI] INE 402 kPa [286-517] vs NNE 522 kPa [444-600], P=0 042) 
Conclusion: In severe chronic pancreatitis patients, increased sympathetic activity and 
hyperalgesia appear associated, suggesting that sympathetic activity may also play a role in these 
patients' pain 
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Introduction 
Pain is the leading sign in patients with chronic pancreatitis and is present in 80-90% of the 
patients. In many of these patients the pain is caused by the classical complications of 
pancreatitis like pseudocysts, biliary or duodenal obstruction, the presence of an inflammatory 
mass or the presence of a dilated duct as a sign of pancreatic duct hypertension. However, not 
infrequently, pain relapses after surgical treatment of these complications, even in the absence of 
noticeable anatomical substrates. 
The pain and nociception in chronic pancreatitis appears to be particularly aggressive for several 
reasons. Chronic pancreatitis is a visceral pain syndrome with its different, typical features as 
opposed to somatic pain syndromes (Gebhart 2000). Furthermore, both persistent inflammation 
and nerve damage are present in chronic pancreatitis, thus synergistically acting on sources of 
nociception, its transmission and modulation. Indeed, pathological studies have found evidence 
of nerve damage caused by chronic inflammation in chronic pancreatitis (Boekman et al. 1988; 
Boekman 1994). Büchler et al found a significant increase of the neuropeptides calcitonin gene-
related peptide (CGRP) and substance-P/tachykinins nerve fibers in and around the pancreatic 
acini in patients with chronic pancreatitis as a sign of neuropathic damage (Büchler et al. 1992). 
Similarly, an increased gene expression of neurokinin-1 was found in the pancreas which 
correlated significantly with the pain experienced by these patients (Shrikhande et al. 2001). In 
concordance with these findings, Drewes et al. recently reported changes in 
electroencephalogram patterns consistent with neuropathic pain mechanisms in patients with 
chronic pancreatitis patients with intermittent pain attacks (Drewes et al. 2008). 
Such ongoing, aggressive nociceptive input will quickly alter processing in the central nervous 
system and rapidly lead to central sensitization (Woolf and Salter 2000). In recent studies in 
patients with chronic pancreatitis the presence of altered pain processing in the central nervous 
system, i.e. generalized hyperalgesia and changed cortical projections, has been found (Buscher et 
al. 2006; Dimcevski et al. 2007). 
The abdomen and its viscera have an extensive autonomic nervous innervation, the enteric 
nervous system, which does not primarily play a role in nociception (Hansen 2003). It is 
conceivable that the nerve damage in chronic pancreatitis not only affects visceral nociceptive 
neurons, but also neurons of the autonomic nervous system. It is known that in some chronic 
pain syndromes the autonomic nervous system interacts with the somatosensory nervous system, 
and that this crosstalk may lead to hyperalgesia (Raja et al. 1999). Furthermore increased 
sympathetic activity and catecholamines can activate primary afferent nociceptors and enhance 
pain (Baron et al. 1999; Nackley et al. 2007). 
The aim of this study was to assess sympathetic nervous system activity in patients with chronic 
pancreatitis and to study whether evidence exists for "cross-talk" between pain processing and 
sympathetic activity in patients with severe pain caused by chronic pancreatitis. 
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The hypothesis tested was that chronic pancreatitis patients with higher levels of sympathetic 
activation should have more generalized hyperalgesia. 
Patients and Methods 
Sixteen patients who had severe chronic pancreatitis for at least one year (10 men and 6 women, 
mean age 51, range 37-68 years) were studied. All patients had chronic pancreatitis, diagnosed 
by means of endoscopic retrograde cholangiopancreaticography, computer tomography and/or 
magnetic resonance cholangiopancreaticography, according to standard criteria (Imrie et al. 
1999). All patients, bar one, were on opioid medication. No patients used alpha or beta-
blockers. Demographic data and medication are listed in Table 1. For clarity the opioid 
medication has been converted to Morphine Equivalents (MEq) using the Narcotic Analgesic 
Converter (Version 2.0, GlobalRPh® Inc.; www.GlobalRPh.com). The pain state was 
documented via verbal Numeric Rating Scores (NRS, 0 = no pain and 10 = unbearable pain) 
obtained just prior to the test. The study was approved by our regional medical ethical 
committee. All patients gave their written informed consent. 
Demographic data of the patients 
Demographics 
Patients 
Sex (M/F) 
Age (median, range in years) 
Onset of the pancreatitis (median, range) 
Etiology 
Alcohol 
Unknown 
Patients on Opioids 
Patients on Sedatives 
Diabetes Mellitus 
Morphine Equivalents (mg, Mean (range)) 
NRS (Median (IQR)) 
Ν 
16 
10/6 
51 (37-68) 
5.5(1.0-21.7) 
10 
6 
15 
2 
4 
146(0-520) 
4 (3-6) 
Quantitative Sensory Testing (QST) 
Pressure pain thresholds (PPT), defined as the pressure at which the painfulness of stimulation 
just becomes intolerable, were determined for paraspinal muscles overlying bone at following 
left-sided sites: lower neck (C5 dermatome), thorax (T4 dermatome), pancreatic site (dorsal T10 
dermatome) and hip region (LI dermatome) using a pressure algometer with a 1.0 cm2 probe 
and a ramping rate of 50 kPa/s (Somedic Sales AB, Horby, Sweden). Our QST techniques in 
relation to pancreatitis have been described in detail previously (Buscher et al. 2006). 
Plasma catecholamines 
After voiding, a blood sample was drawn after 20 minutes of supine rest after insertion of a 
cannula in an antecubital vein. To assess the effect of mild sympathetic stimulation, a second 
blood sample was drawn after 5 minutes of standing. 
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Blood samples were collected into chilled tubes containing heparin and were immediately placed 
on ice. All samples were centrifuged (at 4oC) within 1 hour after blood sampling and plasma 
samples were stored at -80 0 C until assayed for concentrations of norepinephrine (NE), using 
high performance liquid chromatography (Willemsen et al. 1995). All samples of each patient 
were assayed within the same run. 
Statistical analysis 
Based on NE levels, we defined two groups: patients with increased NE supine levels i.e. 
increased sympathetic activity (NE > 3.0 nmol/L, INE group) and patient with normal supine 
NE levels (NE < 3.0 nmol/L, NNE group). Pressure pain thresholds were analysed using 
repeated measures analysis of covariance (ANCOVA), with the factor CATEGORY-NE (INE 
vs. NNE) and the repeated measures factor SITE of PPT measurement. As covariate we took the 
increase in NE levels from supine to standing (ΔΝΕ). Correlations between NRS and NE levels 
(absolute or change on standing) and PPT were calculated using the Spearman Rank order 
correlation test. To exclude effects of alcohol or diabetes mellitus on pain processing (e.g. 
neuropathy) differences in pain thresholds were screened between the groups using Mann 
Whitney U testing. We performed statistical analysis using the Statistica for Windows Software 
Package (Release 7.0, Statsoft Inc., Tulsa, OK, USA). 
Data are presented as means ± 95% confidence intervals except when stated differently. 
Differences were considered statistically significant when Ρ < 0.05. 
Results 
All patients completed the study without incident. 
Catecholamines 
In one female patient, catecholamine assay was not done due to technical failure. Five patients (4 
men and 1 woman) showed increased supine plasma NE levels (NE >3.0 nmol/1) ranging 
between 3.06 —7.68 nmol/1. In the remaining 10 patients (6 men and 4 women) supine plasma 
NE levels were within normal range (ranging from 0.84 to 2.68 nmol/L). Plasma NE levels were 
not significantly correlated to pain NRS. 
Plasma NE levels increased significantly during standing (P=0.008, Table 2). 
Results of the nor-epinephrine measurements (Means (95%CI)} in supine position and afier standing, with the absolute 
and relative difference (Δ) between supine and standing measurements, for the entire group, the INE and NNE group 
separately 
• P< 0.01 vs. supine NE values. 
•• P<0.002 vs. INE group, NS non significant vs. INE group) 
Norepinephrine 
NE supine (nmol/1,) 
NE standing (nmol/L) 
Δ NE (nmol/L) 
Δ NE (%) 
INE (n=5) 
4.72(2.41 -7.04) 
7.66(3.80.-.11.53) 
2.94 (0.03 - 5.85) 
67 (-9-144) 
N N E (n=5) 
1.66(1.29-2.04.)" 
3.21 ( 2 . 3 9 - 4 . 0 3 ) " 
1.53(0.97.-2.12) NS 
98 (65-130) NS 
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Pressure pain thresholds 
Mean pressure pain thresholds (PPT) were 445 kPa [95% CI 348-542 kPa] for C5; 473 kPa 
[95% CI 360-585 kPa] for T4; 434 kPa [95% CI 359-510 kPa] for T10 and 497 kPa [95% CI 
428-566 kPa] for LI dermatome. ANCOVA analysis of the pressure pain thresholds showed 
significant effect for the factor CATEGORY-NE (NNE: mean PPT 522 kPa [95% CI 444-600] 
vs. INE: 402 kPa [95% CI, 286-517]; P=0.042) (Figure 1). No other single factor, covariate or 
their interactions showed any significance. 
There were no differences in pain thresholds in the absence or presence of DM or alcohol use. 
There was no significant correlation between PPT and pain NRS. 
700 
600 
500 
400 
2 η η 
100 
I 
normal NE 
increased NE 
Pressure pain thresholds (PPT; means and 95% CI) in patients for the groups with normal norepinephrine values 
(NNE) or increased norepinephrine values (INE) (ANCOVA: P=0.042). Dermatomes in which the PPT were 
measured are labelled along the X-axis. 
Pain scores 
There were no differences in NRS, opioid use (expressed as morphine equivalents) and types of 
medication between the groups NNE and INE 
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Discussion 
To our knowledge this is the first report relating sympathetic activity to pain and pain processing 
in patients with chronic pancreatitis. Signs of increased sympathetic activity were found in one 
third of patients with pain caused by chronic pancreatitis; such increased activity was associated 
with generally lower pressure pain thresholds. 
It is generally accepted that alterations in sympathetic activity can influence pain processing and 
pain experience (e.g. sympathetically maintained pain). Physiological stimulation of the 
sympathetic nervous system significantly increases spontaneous pain in patients with complex 
regional pain syndrome (CRPS) (Baron et al. 2002). Conversely, sympathetic blockade has been 
successful in reducing pain trrup to 70 % of patients with CRPS type 1 (Schattschneider et al. 
2006a; Torebjork et al. 1995). Catecholamines and sympathetic activity are known to influence 
pain processing for instance in arthritis in animals (Coderre et al. 1990), or fibromyalgia in 
humans (Torpy et al. 2000; Martinez-Lavin et al. 2002). Furthermore, cutaneously applied NE 
evokes more pain in capsaicin induced hyperalgesia, in patients with neuralgia and in patients 
with sympathetically maintained pain (Ali et al. 2000; Schattschneider et al. 2007; Torebjork et 
al. 1995). In this context, tissue and/or nerve damage with or without inflammation are 
postulated to disturb the functional separation between the sympathetic efferents and afferent 
nerves that is present under physiological conditions (Jänig et al. 1996; Jänig and Häbler 2000). 
These postulations have not been subject of study to date in the context of chronic pancreatitis, 
neither in animal nor in human studies. There are several possible reasons for considering 
increased sympathetic activity as a contributing factor for pain in chronic pancreatitis. Chronic 
pancreatitis is a fibro-inflammatory process with involvement of nerves including the autonomic 
nerves, which are extensively present in the pancreas (Boekman et al. 1988; Boekman 1994). 
Consequently, perineural sheaths are damaged and an interaction between the post ganglionic 
sympathetic nerves and afferent nerves in chronic pancreatitis might occur. Whether this 
'coupling' occurs directly, in which NE released from sympathetic efferents directly binds to the 
adrenoreceptor located on the sensory afferent, or 'indirectly', in which NE triggers the release of 
other mediators (e.g.prostaglandins) sensitizing the sensory afférents is still a matter of debate. 
However, Schattschneider et al. consider a direct action of NE to be the most likely mechanism 
of increased adrenosensitivity in capsaicin induced hyperalgesia (Schattschneider et al. 2007; 
Schattschneider et al. 2007). Therefore higher levels of NE could aggravate the hyperalgesic state 
found in patients with chronic pain due to chronic pancreatitis (Buscher et al. 2006). 
Sympathetic activity was studied by means of venous plasma NE levels to assess pathologically 
altered sympathetic activity (Izzo 1996). However, plasma NE levels only reflect global 
sympathetic activity and may miss local changes in sympathetic activity. This might explain why 
only a third of the patients showed globally increased NE levels. Local changes in activity would 
have better been detected by microneurography or microdialysis in the splanchnic area. Such 
testing is technically very demanding, difficult to reproduce and invasive (Izzo 1996). 
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Another explanation for only one third of the patients showing increase NE levels might be that 
underlying disease such as diabetes or chronic alcoholism, which were frequently present in our 
group, might cause parallel neuronal degeneration and regeneration, and that this might lead to 
decline in NE sensitivity and activity (Schattschneider et al. 2006b). Pain thresholds, however, 
appeared not to be affected by these factors in our series. Finally, it should be emphasized that 
the number of subjects in the present study is relatively small, thus further studies with more 
patients are indicated. Such studies should include additional measures of sympathetic activity 
(e.g. muscle sympathetic activity as measured by microneurography) as well as serial 
measurements to see if the relationship between pain and sympathetic drive remains stable over 
time. The cutoff value of 3 nmol/L for normal norepinephrine levels is based on the normal 
values of our laboratory and is also supported by the literature (Jacobs et al. 1997; Lenders et al. 
1992). Lenders et al cite a mean supine norepinephrine concentration of 0.98 nmol/L for 
healthy volunteers which increases to a mean of 2.16 nmol/L on standing; thus the cutoff value 
of 3 mmol/L represents an increase twice that associated with standing up in healthy volunteers 
(Lenders et al. 1992). 
In summary we found that increased sympathetic activity is associated with generalized lowering 
of pain thresholds in patients with severe chronic pancreatitis. Although there is growing 
evidence of the involvement of the autonomic nervous system in the sense of altered pain 
processing in patients with somatic pain syndromes, this connection has not so far been 
described for visceral pain or more specifically for chronic pancreatitis. Clearly more research 
needs to be done to further elucidate the role of the autonomic nervous system in pain 
processing in these patients. 
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S-Ketamine modulates central nervous hyperalgesia in pancreatitis pain | 
Abstract 
Background and Objectives: Upper abdominal pain is a dominant feature of chronic 
pancreatitis. A key phenomenon in this context is hyperalgesia, typically associated with N-
methyl-D-aspartate (NMDA) receptor activation. This exploratory study evaluates acute effects 
of S-ketamine, a non-competitive NMDA antagonist, in modulating generalized hyperalgesia in 
chronic pancreatitis pain. 
Methods: In a blinded cross-over trial 10 chronic pancreatitis pain patients received S-
ketamine for 3 hours at 2 microgr/kg/min or placebo infusion at an equivalent rate in 
randomized order. Clinical pain was assessed via visual analogue scale (VAS) and short Dutch 
Language Version McGill Pain Questionnaire (sf-MPQ-DLV). Pressure pain thresholds (PPT) 
were measured in dermatome C5, T4, dorsal T10, LI and L4, and the sum of PPT (SOPPT) 
calculated before, at end of, and after infusion. 
Results: Nine patients completed the study. Median pain VAS before infusion was 29mm at 
rest, 32mm during activity; sf-MPQ-DLV score was 4. For the S-ketamine session median 
[IQR] SOPPT change at infusion end was significantly higher than in the placebo session 218 
[116- 527] vs. -123 [-330-24]; P=0.005), and significant vs. pre-infusion values 2109 [964-
3035] vs. 1914 [842-2884] P=0.03). SOPPT was unchanged vs. pre-infusion values and similar 
between groups one hour after infusion end. No significant changes in VAS and sf-MPQ-DLV 
occurred. 
Conclusions: S-ketamine infusion is more effective than placebo in increasing PPT in chronic 
pancreatitis pain patients immediately after infusion. This effect did not outlast the infusion. 
Further research is warranted into S-ketamine use for reducing generalized hyperalgesia and 
chronic pancreatitis 
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Introduction 
Chronic pancreatitis involves progressive inflammatory changes in the pancreas that damage the 
structure of the pancreas, leading to exocrine and endocrine dysfunction (Steer et al. 1995). In 
western countries, alcohol is the main cause of chronic pancreatitis. Upper abdominal pain, 
present in 80-90% of patients, is a dominant feature and the best predictor for health-related 
quality of life (Andren-Sandberg et al. 2002). The relapsing painful attacks and severe pain 
accompanying chronic pancreatitis remain as major therapeutic challenges, often leading to 
opioid dependence, recurrent hospitalization and medical interventions (van Esch et al. 2006). 
The intense visceral nociception in chronic pancreatitis due to inflammation, nerve damage or 
elevated intrapancreatic pressure leads to relapsing painful attacks and often continuous pain 
(Ceyhan et al. 2009). This often leads to central nervous system reorganization and sensitization, 
whose presence has been demonstrated using quantitative sensory testing and 
electroencephalography (Buscher et al. 2006; Drewes et al. 2008a). Central sensitization 
increases excitability of spinal cord nociceptive neurons amplifying signals coming from the 
periphery, manifest as generalized hyperalgesia (Coderre et al. 1993). Another cause of 
hyperalgesia in pancreatitis may be opioid-induced hyperalgesia (OIH) (Simonnet 2005). 
A key mechanism in central sensitization and OIH is that of activation of N-methyl-D-aspartate 
(NMDA) receptors (Woolf and Salter 2000). S-ketamine is a non-competitive NMDA receptor 
antagonist (Adams 1998). Multiple studies have consistently produced positive results regarding 
the use of S-ketamine in (chronic) pain patients with central sensitization and hyperalgesia 
(Subramaniam et al. 2004). We therefore hypothesize that S-ketamine, with its ability to depress 
central nociceptive sensitization and OIH, will positively affect the generalized hyperalgesia 
present in chronic pancreatitis patients (Buscher et al. 2006). At the moment there are no formal 
studies on the use of S-ketamine for this purpose. The aim of this hypothesis-generating 
exploratory study is to investigate the effects of S-ketamine infusion on the generalized 
hyperalgesia present in chronic pancreatitis patients on stable opioid therapy using somatic 
quantitative sensory testing. 
Methods 
Study patients 
The institutional medical ethics committee approved the protocol. All patients gave written 
consent. Patients were eligible if they were at least 18 years of age, had chronic pancreatitis pain, 
had active but clinically stable chronic pancreatitis, and were on stable opioid therapy. Patients 
had no surgically treatable anatomical substrate for chronic pancreatitis pain. Patients with a 
psychiatric disorder or encephalopathy, sufficient to compromise data collection e.g. quantitative 
sensory testing (QST), were excluded. The patients' medical and demographic data were 
obtained from the patient records. Opioid medication for each patient was converted to 
morphine equivalents using the Narcotic Analgesic Converter (Version 2.0, GlobalRPh! Inc.; 
www.Global RPh .com). 
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To confirm the presence of generalized hyperalgesia at baseline in the pancreatitis patients, an 
age and sex matched normal values group consisting of 9 patients without a painful condition 
scheduled for routine gynecologic elective surgery was chosen for comparison from our hospital 
QST database 
Study drug 
S-ketamine (Ketanest-S, Pfizer, Capelle a/d IJssel, The Netherlands) was supplied to the nursing 
ward by the anaesthesiology department A dosage of 2pg/kg/min of S-ketamine is comparable 
with a dosage of 4pg/kg/min for racemic ketamine The blinded syringes contained either a 
solution of 20 ml of Ketanest-S with a concentration of 2 5mg/ml or 20 ml of NaCl 0 9% as 
placebo Experienced doctors administered all study drugs 
Clinical pain assessment 
Mean pain and worst pain was scored by means of a visual analogue scale (VAS, zero mm 
represented no pain and 100 mm unbearable pain) at rest, during activity and during eating 
(only pre-infusion) The short Dutch Language Version of the McGill Pain Questionnaire - sf-
MPQ-DLV - was used to determine intensity and emotional impact of pain at rest The sf-
MPQ-DLV contains 11 items for assessing sensory dimensions of pain and 4 items for affective 
dimensions of pain Only the sum of values for sensory and affective dimensions were used in 
the analysis 
Quantitative sensory testing 
QST took place using a standard temporal test sequence Testing m females was not 
standardized with regard to phase of the menstrual cycle because all were postmenopausal 
Pressure pain tolerance thresholds were tested using a pressure algometer with a 1 0-cm2 probe 
(Somedic Sales AB, Horby, Sweden), at the following sites on the dominant body side lower 
neck (C5 dermatome), sternum (T4 dermatome), pancreatic site (dorsal T10 dermatome), hip 
region (LI dermatome) and knee (L4 dermatome) The sum of pressure pain threshold 
(SOPPT) was chosen for evaluation of generalized hyperalgesia as a simple method of including 
all dermatomes, thus reflecting total body hyperalgesia 
Study design 
This was a blinded and placebo-controlled cross-over trial that evaluated the influence of S-
ketamine on generalized hyperalgesia in patients with chronic pancreatitis at one hospital in the 
Netherlands Sealed envelopes were used for randomization and were opened after data lock 
Eligible patients randomly received placebo or S-ketamme on the first visit and at least one week 
later the opposite regime during the second visit During both sessions, at the same time of the 
day, patients received infusion for 3 hours at a rate equivalent to S-ketamine 2pg/kg/min or 
placebo During the visits patients were only allowed to drink clear fluids without sugar Before 
infusion was started, QST was performed, pain experience was measured by the sf-MPQ-DLV 
and pain intensity by a VAS This was repeated immediately after 3 hours of infusion and one 
hour after the end of infusion Side-effects and hemodynamic parameters were monitored 
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Efficacy end points 
The primary study endpoint was the difference in change vs pre-infusion values of SOPPT 
This was compared for immediately after, or one hour after the end of, the 3-hour infusion for 
the S-ketamine vs placebo group 
Secondary endpoints 
1) Differences in the change vs baseline PPT values in the individual dermatomes before and 
after S-ketamine vs placebo infusion, 
2) Changes in subjective pain sensation measured by VAS scores (at rest or during activity) for 
S-ketamine vs placebo immediately after and one hour after the end of drug infusion, 
3) (Changes in) the sf-MPQ-DLV for S-ketamine vs placebo at the same time points, and 4) 
The observed side effects during study drug infusion 
Statistical analysis 
We performed statistical analysis using Statistica (Release 7 0, Statsoft Ine, Tulsa, OK, USA) 
Statistical significance was set at Ρ < 0 05 We used Mann Whitney U to analyze 1) generalized 
hyperalgesia by comparing the pre-infusion SOPPT of the normal values group and study group, 
2) the change in SOPPT between the S-ketamine and placebo sessions immediately after and 
one hour after infusion, 3) pre-infusion differences in primary and secondary endpoints 
regarding study session (i e placebo vs S-ketamme) and gender, 4) differences in secondary 
endpoints for placebo vs S-ketamine immediately after and one hour after infusion A Wilcoxon 
matched pairs test was performed to determine the difference between SOPPT, VAS and sf-
MPQ-DLV scores pre- vs immediately after infusion or pre- vs one hour after infusion for the 
placebo and S-ketamme sessions The relationship between QST results and VAS scores was 
examined with a Spearman R 
Results 
Study population 
Ten patients were randomized, the study was completed without any incident One patient 
dropped out of the study after randomization for personal reasons All patients (5 women, 4 
men, mean age 53 2 ± 5 7 years) had pain due to chronic pancreatitis and were on a stable 
opioid therapy Their median opioid consumption was 160 (IQR 160 - 315) mg of morphine 
equivalents/day Their median VAS scores pre-infusion were 29 (14 - 48) mm at rest and 32 (23 
- 68) mm during activity The median score of the sf-MPQ-DLV pre-infusion was 4 (2 - 6) 
More demographic data of the study population and normal values group are listed in Table 1 
Baseline pain pressure thresholds 
A significant difference was found in baseline measurements for SOPPT between the normal 
values group (9 patients) 2900 kPa (IQR 2349 - 3461) and the chronic pancreatitis group 1583 
kPa (IQR 1221 - 3191), P=0 04 More patient baseline PPT measurements are listed in Table 1 
Pre-infusion, PPT did not differ significantly between visits or gender 
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I Demographic and baseline data of the chronic pancreatitis group Results are medians and interquartile ranges unless otherwise specified. ΡΡΊ' is pressure pain tolerance threshold. 1 
Age (yr) 
Sex ratio M-F 
Diabetes mellitus 
Pancreatic exocrine insufficiency 
Previous abdominal surgery 
Frey procedure 
Partington-Rochelle procedure 
Whipple procedure 
Stent placement 
Pancreas tail resection 
Aetiology 
Alcohol 
Hypertriglyceridemia 
Unknown 
PPT (dermatome), kPa 
C5 
T4 
1,1 
T10D 
1.4 
Pancreatitis 
(N-9) 
51.6(50.0-57.8) 
4 - 5 
3 
0 
5 
1 
1 
1 
1 
1 
6 
1 
2 
229(198-533) 
280(219-490) 
352(179-564) 
341 (275-568) 
355 (298 - 740) 
Normal values 
(N-9) 
51.9(47.0-55.0) 
4 - 5 
-
-
-
-
-
-
-
-
-
-
-
374 (470 - 740) 
602 (473 - 827) 
5 0 2 ( 4 1 7 - 5 7 6 ) 
666 (446 - 887) 
735 (485 - 875) 
Immediately after end of infusion 
The change in SOPPT was significantly higher in the S-ketamine session immediately after end 
of infusion as compared to the placebo session 218 kPa (IQR 116 - 527) vs. -123 kPa (1QR -
330 - 24); P=0.005 (Figure 1A). Only in the S-ketamine session were SOPPT values 
immediately after end of infusion significantly higher than pre-infusion 2109 kPa (IQR 964 -
3035) vs. 1914 kPa (IQR 842 - 2884) P=0.03. A significantly more positive change in PPT was 
observed in dermatomes LI and L4 in the S-ketamine vs. placebo group immediately after the 
infusion end 121 kPa (IQR 1 - 254) vs. -21 kPa (IQR -97 - 25), P=0.04; and 107 kPa (IQR 68 
- 148) vs. -20 kPa (IQR -97 - -3), P=0.0I; respectively; with the differences for the other 
dermatomes not reaching significance (Figure 2). 
One hour after end of infusion 
One hour after end of infusion, there were no statistically significant differences between sessions 
for PPT (FigurelB). Furthermore, SOPPT at one hour after infusion end was not higher than 
pre-infusion values in either session. 
VAS scores and sf-MPQ-DLV 
Neither session (S-ketamine vs. placebo) nor gender significantly influenced pain VAS scores at 
rest and during activity or sf-MPQ-DLV results pre-infusion. The only exception was that 
maximum pain during eating was significantly higher for men (P=0.016). 
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Changes in VAS scores at rest and with activity and sf-MPQ-DLV immediately and one hour 
after infusion end were similar for both treatment sessions. Furthermore there were no 
significant changes in VAS and sf-MPQ-DLV scores within the sessions immediately after or 
one hour after infusion end as compared to pre-infusion. However, there was a significant 
difference for the sf-MPQ-DLV sensory scores of the placebo group pre- and immediately after 
infusion end (P=0.018). 
No significant correlations between VAS scores, sf-MPQ-DLV scores and the SOPPT were 
found before, immediately after and one hour after infusion end, for both sessions taken 
together or taken separately. 
end infusion 1-hr after infusion 
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The change in SOPPT immediately after end of 
infusion vs. pre-infusion of the trial medication 
compared for the placebo and S-ketamine group. 
The placebo group has a median of-123 kPa 
(1QR -330 - -24) and the S-ketamine group has a 
median of 218 kPa (IQR 116 ~ 527). 
The change in SOPPT vs. pre-infusion one hour 
after the end of infusion of the trial medication 
compared for the pUcebo and S-ketamine group. 
The pUcebo group has a median of 127 kPa 
(IQR -235 - 415) and the S-ketamine group has 
a median of 280 kPa (IQR -51 - 489) Results 
are plotted in a box plot. 
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Side effects 
Side effects during infusion with S-ketamine were categorized as light and providing no reason 
to stop the experiment. Light-headedness was reported by 4 patients and disappeared after the 
infusion ended. One patient felt dizzy at the end of infusion with stable hemodynamic values. 
Another patient mentioned an odd taste that also disappeared after stopping the infusion. No 
side effects were reported during the infusion with placebo. 
C5 T4 T10D LI L4 
I AH measurements for PPT (pain pressure tolerance thresholds) in kPafor all five different dermatomes pre-injusion, 
Β ί ^ Η immediately after end of the infusion and one hour after infusion end oj the trial medication compared for placebo 
B p ^ B and S-ketamine group. Results are medians with interquartile ranges. Results marked with an asterisk are significant. H 
Discussion 
Current treatment concepts for pancreatic pain increasingly target control of hyperalgesia by 
using e.g. tricyclic antidepressants, gabapentin or pregabalin (Drewes et al. 2008b). Opioids 
initially provide analgesia to chronic pancreatitis patients, but have considerable side effects. 
Indeed, opioid usage may induce and maintain hyperalgesia and thus become a part of this 
painful condition (Simonnet 2005). 
I Chapter 10 
Our patients had significantly lower pre-infusion sum of pain pressure thresholds (SOPPT) for 
all dermatomes vs. normal values, compatible with generalized hyperalgesia. Ours is the first 
study to analyze (acute) antihyperalgesic effects of infusion with S-ketamine in chronic 
pancreatitis patients. The study demonstrates the tolerability and short-term effect of S-ketamine 
in the acute treatment of generalized hyperalgesia accompanying the pain of chronic pancreatitis. 
Further studies are necessary to determine optimum indications, treatment paradigms and long 
term effects of S-ketamine in this context. 
Hyperalgesia and ketamine 
Chronic pain is increasingly recognized to be characterized by altered pain processing, including 
spreading (or generalized) hyperalgesia and pro-nocicepdve pain modulation (Apkarian et al. 
2009; O'Neill et al. 2007). This is also the case for chronic pancreatitis where neuroplastic 
changes at spinal and supraspinal sites due to chronic nociceptive input are increasingly being 
demonstrated (Drewes et al. 2008b). Ongoing nociceptive input will ultimately lead to central 
sensitization and loss of descending inhibitory control mechanisms which may end in an 
autonomous pain state (Cervero 2000). In our study we observed a significant increase in 
SOPPT with S-ketamine treatment, suggesting that S-ketamine may be successful in acutely 
treating the generalized hyperalgesia associated with chronic pancreatitis pain (Buscher et al. 
2006; Buscher et al. 2007). This result is compatible with others demonstrating antihyperalgesic 
actions of S-ketamine on central sensitization and chronic pain (Bell et al. 2006; Hocking and 
Cousins 2003). After end of S-ketamine infusion the QST changes disappeared rapidly. This 
may be related to the relatively short infusion period and the low dosage chosen. Studies with 
infusion periods up to days show a more prolonged effect with ketamine (Correli et al. 2004). 
But long-term and high-dose ketamine therapy may have neurotoxic effects, as described in 
animal studies (Correli et al. 2004; Olney et al. 1991), but is unstudied in humans. Available 
human data suggests that low ketamine infusion of up to 7 days are without long-term 
deleterious effects (Kiefer et al. 2008). Unfortunately, studies describing other routes, e.g. oral or 
subcutaneous, have shown limited and unpredictable clinical effects (Blonk et al. 2009; 
Kronenberg 2002). Clearly, further studies are needed to resolve these issues. 
Methodological considerations 
This small hypothesis-generating exploratory study focused on the acute effect of S-ketamine on 
hyperalgesia. A limitation of this study is the short time of infusion and lack of long-term 
follow-up. Thus we could have missed a delayed antihyperalgesic effect of S-ketamine infusion 
in reducing later pain scores and perhaps opioid consumption. Future studies should include 
more patients and document the long term effects of S-ketamine infusion. Alternative 
application routes (e.g. oral, intranasal) or other forms of NMDA receptor blockade (e.g. 
memantine and amantadine) are interesting alternatives. A control group of healthy subjects was 
not included in the trial for the evaluation of the effect of S-ketamine for the simple reason that 
assessment of antihyperalgesic efficacy requires the presence of hyperalgesia - and this is not 
present in healthy subjects. 
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QST provides objective and quantifiable data on pain processing and is a valuable tool for 
observing processes and mechanisms underlying chronic pain and its treatment (Buscher et al. 
2006; Wilder-Smith 2000). In contrast to VAS, QST measures one aspect of pain, sensory 
discrimination. SOPPT change immediately after S-ketamine infusion was not accompanied by 
significant changes in VAS and MPQ scores. However, numerous studies have shown weak 
relationships between VAS and QST (Buscher et al. 2006). 
Conclusions and summary 
Our study provides preliminary evidence that administration of S-ketamine may be more 
effective than placebo treatment in increasing pressure pain thresholds in hyperalgesic painful 
chronic pancreatitis patients. However, this effect is limited to the period of infusion, and no 
improvement was seen in accompanying pain scores. The side effects reported in the S-ketamine 
group were transient and mild. More research is needed regarding the long-term effects of 
infusion, dosage schemes and the relevance of the short-lasting elevation of pain thresholds. 
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Chronic pancreatitis is a disease in which progressive inflammation and fibrosis of the pancreas 
leads to destruction of the pancreas and subsequently to loss of endocrine and exocrine function. 
Chronic pancreatitis is often associated with severe persistent or recurring pain, resulting in a 
poor quality of life and social deprivation. Its management poses a difficult problem for 
physicians involved. The main goal of treatment is to provide sufficient and lasting pain relief, 
preferably without the use of opiates. When conservative measures fail, surgery is often 
unavoidable. Bilateral Thoracoscopic Splanchnicectomy (BTS) is a minimal invasive surgical 
procedure aiming to deafferent the pancreas and thus reduce pain in patients with severe chronic 
pancreatitis. In this thesis, we have described our experience with BTS for treating severe pain in 
patients with chronic pancreatitis. We have explained why pain persists after BTS by studying 
altered central pain processing in these patients. In this context we investigated the impact of 
supraspinal central sensitization expressed as generalized hyperalgesia in maintaining the chronic 
pain state in chronic pancreatitis patients. We have increased our understanding of this topic as 
the basis for a better and more mechanism based approach to the management of pain in 
chronic pancreatitis. 
Chapter 2 
In chapter 2, pain management of chronic pancreatitis is discussed, with emphasis on operative 
techniques and the interruption of nerves bearing afferent pain stimuli. This section includes an 
historical overview of nerve blockade techniques. We report our experience with BTS in the 
twenty-six patients (17 men, 9 women). All patients had chronic pancreatitis, diagnosed by 
means of endoscopic retrograde cholangiopancreatography, computer tomography and/or 
magnetic resonance cholangiopancreatography. The presence of pseudocysts was ruled out. The 
mean interval between onset of pancreatitis and operation was 3.3 years (range 1.6-11.1). In 
most patients alcohol abuse was the cause of pancreatitis. Patient data were collected 
prospectively. Pain was scored with the visual analog score for pain (VAS, 0 is no pain, 10 is 
intractable pain). The mean preoperative VAS was 9 (range 7-10). Twenty-one patients (81%) 
required opiates. Four patients had both endocrine and exocrine pancreatic insufficiency and 
three had only exocrine insufficiency. In all but two procedures splanchnic denervation was 
technically successful (92%). Transient intercostal pain related to the thoracoscopy was 
experienced by almost all patients, which lasted for 1 to 3 days. In three patients intercostal 
neuralgia persisted for a longer period of time but was successfully managed by carbamazepine. 
One patient stayed for 2 days in the ICU for respiratory failure caused by preoperative 
aspiration. Minor complications were encountered in three patients. One pneumothorax had to 
be drained. One patient had a wound infection and one a pneumonia. Twenty-one patients 
(81%) had no complications at all. At follow-up 6 months after operation, pain scores were 
significantly lower (P < 0.01) than preoperative values (mean ± SD VAS; 2.6 ± 3.2 versus 9.1 ± 
0.7). In 6 patients (23%) pain recurred and these procedures were considered as failures. 
Fourteen patients (54%) had no pain medication, six patients (23%) were treated with NSAIDs. 
In summary, an initial success rate of 75 % pain relief was achieved at 6 months postoperatively. 
Based on these early results, we concluded that with regard to the low morbidity rate and the 
effectiveness in pain management 
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BTS appeared an attractive alternative to more invasive surgical approaches (e.g. Frey 
procedure). However, this study provided no data on long term success of more than six 
months. It should be noted that the placebo effect of surgery may have influenced the initially 
high success rate 
Chapter 3 
In chapter 2 we found that BTS is technically feasible in routine clinical practice and alleviates 
pain in patients with chronic pancreatitis. BTS, however, not only disrupts afferent fibres from 
the pancreas that mediate pain but also postganglionic sympathetic fibres which innervate the 
vasculature of the liver, pancreas and the adrenal glands. Therefore it was investigated in chapter 
3 whether and how BTS affects sympathetic noradrenergic and adrenomedullary function in 
patients with chronic pancreatitis. In this study sixteen patients (10 men and 6 women) with 
chronic pancreatitis with the same inclusion criteria as described in the previous chapter, 
underwent autonomic function testing before and 6 weeks after BTS for intractable pain. 
Testing was carried out during supine rest and during sympathetic stimulation when standing. 
We found that supine and standing systolic and diastolic blood pressure were significantly lower 
post BTS as compared to pre BTS (P<0 01). One patient showed orthostatic hypotension after 
BTS. Most likely the hypotensive effect was caused by disruption of the renal sympathetic 
activity by BTS We considered it unlikely that the pain relief was responsible for the blood 
pressure reduction, since chronic pain is not related to blood pressure increase. In addition, not 
all patients were pain free and all but one patient had lower blood pressures after BTS 
Baseline plasma norepinephrine levels and plasma norepinephrine responses to sympathetic 
activation during standing were not reduced by BTS In contrast, supine plasma epinephrine 
levels and responses during standing were significantly reduced (P<0.001). Parasympathetic 
activity was unaffected by BTS. BTS for pain relief in patients with chronic pancreatitis reduced 
adrenomedullary function due to disruption of the efferent sympathetic fibres to the adrenal 
gland Although this effect has been reported in many animal studies, it has not to date been 
reported in humans The clinical significance of this finding is unclear and needs further 
clarification BTS did not affect noradrenergic sympathetic activity. 
Measuring plasma epinephrine before and after nereve blockade might be helpful in assessing 
completeness of deafferentation. New less invasive percutaneous splanchnic ablation techniques 
might benefit from plasma epinephrine measurements because splanchnic nerves are not visible 
and complete deafferentation cannot be assured 
Chapter 4 
The studies in chapter 2 and 3 showed that BTS is a safe procedure without severe morbidity or 
side effects and with good short term pain relief. The aim of the prospective study described in 
chapter 4, was to evaluate the long term pain relief of BTS. Forty-four patients with chronic 
pancreatitis according to the same criteria described in chapter 2 underwent BTS Thirty-six 
patients (82%) required opioids preoperatively. Twenty-eight patients (64%) had undergone 35 
previous pancreatitis related surgical procedures. Median (range) follow up was 36 months (12 
to 60 months) The procedure was technically successful in 40 patients (92%) 
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Thirty six patients (82%) had no complications. Eleven of twenty four patients who had been 
followed up for 24 months or more had a significantly reduced VAS score at two years (8.7 ± 0.8 
vs. 2.6 ± 1.4, p<0.01). The cumulative probability of pain relief was 46% at 48 months after 
splanchnicectomy. Thus, also after a longer period of time BTS alleviates pain in a significant 
number of patients with chronic pancreatitis whilst still being associated with low morbidity and 
no mortality. Pain recurs, however, in approximately 50% in the long run. In this study and in 
the early results study (chapter 2) some patients did not respond at all to splanchnicectomy. It 
may be hypothesized that non-splanchnic pain pathways (e.g. spinothalamic tract, dorsal 
column, vagal nerve) are also involved in transmission of nociception in pancreatitis pain. 
Finally, the study results show that a follow-up of 12 months or more is needed to accurately 
assess pain relief after BTS 
Chapter 5 
Little is known about possible pre-operative risk factors associated with successful pain relief 
after pancreatic surgery in general and splanchnicectomy in particular. In chapter 5, we analyzed 
long-term results of 75 consecutive BTS procedures for CP with a follow up of one year or more 
and identified factors predicting success of splanchnicectomy. Treatment success was analysed 
using Kaplan Meier method, and possible predictive factors (etiology, gender, onset of 
pancreatitis, previous pancreatitis related surgery, opioid use, pathology at imaging, technical 
success and post-splanchnicectomy complications) via Cox regression. We compared patients 
with long-term pain relief, patients who failed the procedure within one year, and those who had 
pain recurrence after more than one year. Further treatments after failed splanchnicectomy were 
also evaluated. Sixty six patients (89%) were on continuous opioids; 47 (62%) had prior 
pancreatitis related interventions. We found that BTS was successful (Reduced VAS together 
with reduced pain medication) in 52% of patients at 12 months, 38% at 24 months, and 28 % 
at 48 months. Twenty-one patients (28%) reported pain relief at the end of follow-up, of whom 
thirteen were completely pain free without any additional treatment. Pancreatic surgery after 
failed splanchnicectomy relieved pain in only 13%. Technical success was the only independent 
factor significantly associated with successful splanchnicectomy outcome (P=0.03). Preoperative 
opioid use showed a strong tendency to be associated with unsuccessful outcome (P=0.07). It 
was concluded that splanchnicectomy offers prolonged (>4 years) benefit in one out of four 
patients with severe chronic pancreatitis pain. Prior opioid use adversely impacts pain relief after 
splanchnicectomy and patients who fail splanchnicectomy are likely to fail other subsequent 
surgical interventions. 
From our work it is evident that chronic opioid use negatively impacts the treatment outcome of 
BTS. A recent unpublished systematic review from our group analyzing the effect of opioid use 
(i.e. percentage of patients using opioids in the study) on pancreatitis pain outcome after 
splanchnicectomy showed significantly less pain relief in BTS studies with high opioid use 
incidences. Thus BTS should not be considered a last resort treatment in chronic pancreatitis 
pain any more - as suggested by the AGA guidelines - but rather deserves an earlier and more 
prominent place in the treatment algorithm, e.g. before opioid use is commenced. 
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Chapter 6 
As we have seen in the previous chapters, even after pancreatic deafferentation the pain of 
chronic pancreatitis can persist or return. This suggests that traditionally favoured pain 
mechanisms such as dilated duct or inflammatory mass are not sufficient to explain the pain in 
these patients. It is known from other pain disorders that ongoing nociceptive input results in 
altered sensory processing by the central nervous system - neuroplasticity - , and that such 
neuroplasticity plays an important role in pain which becomes chronic and abnormal in nature. 
For the pain of chronic pancreatitis, two mechanisms could be postulated to be involved. Firstly, 
persistent pancreatic inflammation may result in ongoing nociceptive input, leading to central 
sensitization and somatic and visceral hyperalgesia. Secondly, continuing visceral nociceptive 
input might at some point lead to changes in central pain processing that are so pathological that 
central pain perception becomes autonomous and thus independent of peripheral pain inputs. 
Quantitative sensory testing (QST) is a tool to make neuroplasticity visible and thus to gain 
insight into pain mechanisms in patients with chronic pain or in patients with visceral pain 
syndromes. QST is a technique in which different standardized stimuli of different modalities 
(e.g. electric, mechanical, thermal or chemical) are applied and the patient's resulting pain 
experience documented in order to characterize the stimulus-response relationship for pain 
processing. This then permits diagnosis of alterations in central pain sensitivity and modulation. 
We studied 10 chronic pancreatitis patients on stable opioid analgesic medication without any 
abdominal surgery or pancreatitis related surgery and scheduled to undergo BTS because of 
severe pain. Ten matched surgical patients without pain served as controls. Pain verbal Numeric 
Rating Scores (NRS) were collected at the time of the testing. Mechanical stimulation thresholds 
were tested using a pressure algometer. The pressure pain thresholds were measured for muscles 
overlying bone at the following sites: lower neck (C5 dermatome), thorax (T4 dermatome), 
pancreatic site (dorsal T10 dermatome), hip region (LI dermatome) and knee (L4 dermatome). 
Thresholds to electric constant current skin stimulation were measured on the right side of the 
body in the same dermatomes as for pressure pain threshold testing. Three thresholds were 
measured: sensation (stimulation just felt), pain detection (stimulation just becomes painful), 
and pain tolerance (painfulness of stimulation just becomes intolerable). Results showed that the 
pancreatitis patients had a median NRS pain score of 5 (range 3-8) at the time of the testing. 
Electric sensation and pain thresholds were significantly increased in the pancreatic region, 
particularly in female pancreatitis patients. Pressure pain thresholds overall were significantly 
lower in pancreatitis patients than in controls, with men tending towards greater generalised 
relative hyperalgesia than women. In conclusion, chronic pancreatitis patients show pronounced 
generalised deep somatic tissue hyperalgesia that is present despite opioid therapy. These signs, 
consistent with central sensitisation, appear relatively more prominent in men than women. 
There is also evidence suggesting that women may have a better segmental inhibitory response 
than men, possibly explaining their relatively less prominent generalized deep tissue hyperalgesia 
compared to men. This hyperalgesia could involve a number of mechanisms. 
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One possibility is supraspinal descending facilitation originating in the rostral ventromedial 
medulla, which can contribute to chronic pain states, and which can be the result of long-term 
chronic visceral nociceptive inputs Failing inhibitory controls, potentially inhibited by opioid 
medication, could also be a contributing factor The presence of autonomous central 
sensitisation, 1 e sensitisation no longer dependent on peripheral nociceptive inputs may also be 
held responsible for the pain Another possible mechanism involves opioid-induced hyperalgesia 
(OIH), in which prolonged exposure of opioids induces neuroplastic changes, in among others, 
facilitatory pathways, leading to hyperalgesia OIH is a phenomena well-described in the context 
of acute as well as chrome opioid analgesic therapy 
Chapter 7 
Using QST, this study investigated whether BTS, performed to reduce nociceptive visceral 
input, altered central sensitisation in chronic pancreatitis patients 
We studied 19 patients with chronic pancreatitis (11 men, 8 women on stable opioid 
medication) and 18 healthy volunteers as preoperative controls Preoperatively and 6 weeks after 
BTS, pain numeric rating scores, opioid medication were documented Thresholds to electric 
skin stimulation and pressure pain were measured at the same sites and in the same manner as 
described previously Treatment success was defined as cessation of opioids 6 weeks after BTS 
We found that BTS was associated with significant increases in sensory and pain thresholds six 
weeks postoperatively (pressure pain +25%, P<0 001, electric+55% [sensation], +34% [pain 
detection], +21% [pain tolerance], P<0 05) For men, who exhibited a trend to generalised 
preoperative pressure hyperalgesia, BTS resulted in generalized hypoalgesia irrespective of 
treatment outcomes Only successfully treated females tended to show segmental hypoalgesia 
postoperatively The number of patients using opioids was significantly reduced after BTS, 
however, without significant pain score reduction BTS treatment success was associated with 
significantly lower preoperative opioid consumption Our results suggest that BIS for reducing 
visceral nociceptive input may be effective in reducing central sensitisation These results in 
combination with the previously demonstrated generalized hyperalgesia also suggest that changes 
in central nervous system function play an important role in this presently therapy-resistant 
group of patients However, we were unable to identify preoperative differences in 
neuroplasticity predictive of successful BTS outcome in this small study 
Chapter 8 
As mentioned earlier (Chapter 4), there are patients who do not benefit from complete 
deafferntation by BTS The fact that such deafferentation is not effective in all patients might 
imply that in some patients, the neuroplastic changes described previously (Chapter 6 & 7) are 
independent of peripheral nociceptive input In chapter 8 we investigated, using QST, whether 
such independence of neuroplastic central alterations from ongoing peripheral nociceptive input 
exists, explaining the failure of splanchmcectomy in some chronic pancreatitis pain patients 
We studied 17 chronic pancreatitis patients (10 men, 7 women on stable opioid medication) 
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Preoperatively and 6 weeks after BTS, pain numeric rating scores, opioid medication, and 
thresholds to pressure pain (PPT, measured in dermatomes T10 (pancreas) and C5 (clavicle) as 
representative site for general hyperalgesia, were documented. We found that an increase in 
pressure pain thresholds after BTS in chronic pancreatitis patients was associated with a 
significant reduction in pain scores six weeks postoperatively. In patients in whom BTS did not 
show any effect on pressure pain thresholds, pain scores were unaltered. In contrast to our 
previous study (Chapter 7) we were now able to link the QST results (presence or absence of 
hyperalgesia) with a clinical effect. A possible reason for this difference may lie in the definition 
of clinical success used. In our previous study, success was defined as ceasing opioids within 6 
weeks after the treatment and in this study a decrease of NRS was used as outcome parameter. In 
retrospect, it is clear that such a clinical endpoint (i.e. reduced opioid consumption) is 
influenced by a multitude of factors, including patterns of opioid use, the presence of opioid 
dependency and associated psychological factors. It thus is evident that opioid use as an 
endpoint is only weakly related to changes in pain processing which can be expected to occur in 
the first weeks after nociceptive deafferentation. The results suggest that in the group of patients 
undergoing BTS without treatment success, central changes in pain processing may have become 
independent of ongoing peripheral nociceptive input, resulting in persisting pain despite 
nociceptive deafferentation via BTS. 
The results in chapter 6,7 and 8 underline the importance of identifying patients who will not 
benefit from BTS - and probably also not from other standard pain treatments based on 
nociceptive deafferentation such as opioids, nerve blocks or surgery. These are patients in whom 
pain perception and processing has become independent from nociceptive input and in whom 
treating the peripheral nociceptive input will not be sufficient. Future strategies should aim at 
identifying these patients early in the therapeutic process to avoid prolonged, costly and 
ultimately futile management strategies from being chosen. 
In summary, accurate and comprehensive diagnosis of altered pain processing (e.g. using QST) 
early in the therapeutic process is thus crucial to achieving successful management for the pain of 
chronic pancreatitis. The presence of altered central pain processing requires specific and 
targeted treatments which are quite different from traditional approaches based on nociceptive 
deafferentation. Inappropriate application of deafferenting therapies carries the risk not only of 
treatment failure and of disappointment, but also further aggravation of central sensitisation 
states, e.g. via opioid-induced hyperalgesia. Directions for future research include further 
improvement in diagnosis of disturbed visceral pain processing (e.g. visceral QST) and associated 
comorbidities (e.g. via EEG or fMRI) and the advances regarding alternative non-drug treatment 
approaches for visceral pain (e.g. transcranial magnetic or electric stimulation; vagus block or 
stimulation). 
Chapter 9 
It is known that in some chronic pain syndromes the autonomous nervous system interacts with 
the somatosensory nervous system, and that this crosstalk may lead to hyperalgesia. 
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The abdomen and its viscera have an extensive autonomous nervous innervation, the enteric 
nervous system, which does not primarily play a role in nociception. It is conceivable that the 
nerve damage in chronic pancreatitis not only affects visceral nociceptive neurons, but also 
neurons of the autonomous nervous system. The aim of this study was to study whether 
evidence exists for "cross-talk" between pain processing and sympathetic activity in patients with 
severe pain caused by chronic pancreatitis. The hypothesis tested was that chronic pancreatitis 
patients with more sympathetic activity exhibit more generalised hyperalgesia. 
In sixteen patients (10 men; 6 women) with severe chronic pancreatitis, sympathetic activity was 
measured by means of venous plasma norepinephrine (NE) levels in the supine and standing 
position. Pain processing was quantified via pressure pain tolerance thresholds (PPT) measured 
in the same way and same dermatomes as previous mentioned. The results showed that five 
patients (4 men and 1 woman) showed increased supine plasma NE levels (NE >3.0 nmol/l) 
ranging between 3.06 -7.68 nmol/l. PPT were lower in patients with increased NE levels (INE) 
compared with patients with normal NE (NNE) (INE: 402 kPa [95% CI, 286-517 kPa] vs. 
NNE: mean PPT 522 kPa [95% CI 444-600 kPa], P=0.042). 
Signs of increased sympathetic activity were found in one third of patients with pain caused by 
chronic pancreatitis; such increased activity was associated with lower pain thresholds supporting 
the hypothesis that the autonomic nervous system may also play a role in the pain of these 
patients. The NE released from sympathetic efferents may directly bind to the adrenoreceptor 
located on the sensory afferent, or may, 'indirectly', trigger the release of other mediators 
(e.g.prostaglandins). By doing so, increased levels of NE may thus sensitize the sensory afférents 
and aggravate the hyperalgesic state found in patients with chronic pain due to chronic 
pancreatitis. 
Venous plasma NE levels only reflect global sympathetic activity and may miss local changes in 
sympathetic activity. This might explain why only a third of the patients showed increased NE 
levels. Also the diabetes or chronic alcoholism, which were frequently present in our group, 
might cause parallel neuronal degeneration and regeneration, leading to decline in NE sensitivity 
and activity. Pain thresholds, however, appeared not to be affected by these factors in our series. 
Chapter 10 
Central sensitization increases excitability of spinal cord nociceptive neurons amplifying signals 
coming from the periphery, manifest as generalized hyperalgesia. Opioid-induced hyperalgesia 
(OIH) may be another cause of hyperalgesia in chronic pancreatitis pain. A key mechanism in 
central sensitization and OIH is that of activation of N-methyl-D-aspartate (NMDA) receptors. 
S-ketamine is a non-competitive NMDA receptor antagonist, which has, reportedly been able to 
reduce central sensitization and hyperalgesia in (chronic) pain patients. We therefore hypothesize 
that S-ketamine, with its ability to depress central nociceptive sensitization and OIH, will reduce 
the generalized hyperalgesia present in chronic pancreatitis patients. In this study we evaluate 
acute effects of S-ketamine in modulating generalized hyperalgesia in chronic pancreatitis pain. 
In a blinded cross-over trial 10 chronic pancreatitis pain patients received S-ketamine for 3 hours 
at 2 microgr/kg/min or placebo infusion at an equivalent rate in randomized order. 
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Clinical pain was assessed via visual analogue scale (VAS) and short Dutch Language Version 
McGill Pain Questionnaire (sf-MPQ-DLV). Pressure pain thresholds (PPT) were measured in 
dermatome C5, T4, dorsal T10, LI and L4, and the sum of PPT (SOPPT) calculated before, at 
end of, and after infusion. Nine patients completed the study. Median pain VAS before infusion 
was 29mm at rest, 32mm during activity; sf-MPQ-DLV score was 4. For the S-ketamine session 
median [IQR] SOPPT change at infusion end was significantly higher than in the placebo 
session (218 [116- 527] vs. -123 [-330-24]; P=0.005), and the SOPPT at end was significantly 
higher vs. pre-infusion values 2109 [964-3035] vs. 1914 [842-2884] P=0.03). SOPPT was 
unchanged vs. pre-infusion values and similar between groups one hour after infusion end. No 
significant changes in VAS and sf-MPQ-DLV occurred. 
It is concluded that S-ketamine infusion is more effective than placebo in increasing PPT in 
chronic pancreatitis pain patients immediately after infusion. However this effect did not outlast 
the infusion. In future, further studies need to be performed investigating the effects of longer 
durations of ketamine infusion in larger patient collectives. The promising results of this study 
also supports the need for studies of other antihyperalgesic medication (e.g. gabapentinoids and 
THC-tetrahydrocannabinoid) for the management of chronic pancreatitis pain. 
Ali ί 
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Chronische pancreatitis (CP) is een ziekte die gekenmerkt is door een progressieve ontsteking en 
fibrose van de alvleesklier hetgeen vervolgens leidt tot beschadiging van de alvleesklier met 
uiteindelijk verlies van endocriene (glucose/suiker metabolisme) en exocnene (afbraak van 
eiwitten en vetten door ezymen) functie Hevige, continue of aanvalsgewijze pijn is een 
belangrijk kenmerk van de ziekte welke leidt tot een slechtere kwaliteit van leven Deze vaak 
onhoudbare en moeilijk te behandelen pijn vormt een groot probleem voor een ieder die bij de 
behandeling is betrokken Het belangrijkste doel van de behandeling is het zorgen voor 
voldoende en blijvende pijnverlichting bij voorkeur zonder het gebruik van opiaten Wanneer 
conservatieve maatregelen falen, is chirurgische behandeling vaak onvermijdelijk Bilaterale 
thoracoscopische splanchnicectomie (BTS) is een minimaal invasieve chirurgische procedure die 
gericht is om de zenuwbanen van de alvleesklier, die de pijn geleiden, door te nemen 
(denervatie) In dit proefschrift beschrijven we onze ervaring met BTS, verricht vanwege hevige 
pijn bij patiënten met chronische pancreatitis We leggen uit waarom, ondanks de complete 
denervatie, de pijn in veel patiënten aanwezig blijft of terugkomt We onderzoeken specifieker, 
wat de rol is van het centrale zenuwstelsel, in het bijzonder de rol van centrale sensitisatie zich 
uitend als hyperalgesie (verlaging van de pijndrempel), bij het in stand houden van de 
chronische pijn in deze patiënten Nieuwe inzichten in deze mechanismen kunnen leiden tot 
betere behandeling die meer op het juiste pijnverwerkingsmechamsme zijn toegespitst In de 
inleiding van dit proefschrift -hoofdstuk 1- worden al deze aspecten uitgebreider beschreven 
Hoofdstuk 2 
In hoofdstuk 2 wordt de historische achtergrond van de zenuwblokkade beschreven met meer 
nadruk op de chirurgische techniek Tevens worden in dit hoofdstuk de eerste ervaringen 
beschreven met BTS bij 26 patiënten met CP (17 mannen en 9 vrouwen) De diagnose 
chronische pancreatitis was bevestigd door endoscopische retrograde cholangio-pancreatografie 
(ERCP), computer tomografie (CT) en/of magnetische resonantie cholangio-pancreatographie 
(MRCP) Patienten met complicaties van CP, die een oorzaak van de pijn konden zijn zoals bv 
pseudocyste, werden uitgesloten De gemiddelde duur van de pancreatitis ten tijde van de 
operatie was 3 3 jaar (spreiding 1 6-11 1) Alcohol was de voornaamste oorzaak van de CP 
Follow up data werden prospectief verzameld Pijn werd geregistreerd met de visual analog scale' 
voor pijn (VAS, 0 is geen pijn, 10 is onhoudbare pijn De gemiddelde preoperatievc VAS was 9 
(range 7-10) Een en twintig patiënten (81%) gebruikten opiaten Vier patiënten hadden zowel 
endocriene als exocnene pancreas msufficientie Op twee patiënten na was de ingreep bij 
iedereen technisch succesvol (92%) Vrijwel iedereen had 1 tot 3 dagen durende intercostale pijn 
als gevolg van de thoracoscopie Bij drie patiënten werd deze pijn succesvol behandeld met 
carbamazepine Een patient verbleef 2 dagen op de intensive care vanwege respiratoire 
msufficientie als gevolg van en aspiratie tijdens de inleiding Drie patiënten hadden mildere 
complicaties, zoals een wond- of luchtweginfectie Een en twintig patiënten (81%) hadden geen 
complicaties Zes maanden na de operatie, waren de gemiddelde pijn scores significant lager (P < 
0 01) dan voor de operatie (VAS, 2 6 ± 3 2 versus 9 1 ± 0 7) Bij 6 patiënten (23%) kwam de 
pijn weer terug en werd de behandeling als niet succesvol beschouwd 
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Veertien patiënten (54%) gebruikten geen pijn medicatie meer, zes patiënten (23%) hadden nog 
een NSA1D tegen de pijn. In deze studie had uiteindelijk 75 % van de patiënten minder tot 
geen pijn na BTS. Er werd geconcludeerd dat vanwege de lage morbiditeit en de goede 
pijnstilling BTS een aantrekkelijk alternatief was voor meer invasieve chirurgische 
behandelingen. Echter een langdurig pijn verminderend effect was bij deze groep nog 
onvoldoende aangetoond en een placebo effect met zo'n korte follow-up periode behoorde nog 
steeds tot de mogelijkheden. 
Hoofdstuk 3 
In hoofdstuk 2 hebben we gezien dat BTS technisch goed uitvoerbaar is met weinig complicaties 
en bij de meeste patiënten met CP de pijn verlicht. Echter bij BTS worden niet alleen de pijn 
afferente vezels vanuit het pancreas doorgenomen maar ook de postganglionaire sympathische 
vezels die de bloedvaten van de lever, de alvleesklier en de bijnieren innerveren. In hoofdstuk 3 
werd onderzocht of en, zo ja, hoe BTS de sympathische noradrenerge activiteit en de bijnier 
functie beïnvloedt bij patiënten met CP. In deze studie hebben zestien patiënten (10 mannen en 
6 vrouwen) met chronische pancreatitis autonome functie testen ondergaan, vóór en 6 weken na 
BTS. Testen zijn uitgevoerd in rust, liggend en bij sympathische activatie tijdens staan. Zes 
weken na de BTS waren de systolische en diastolische bloeddruk, zowel staand als liggend 
gemeten, significant lager dan voor de operatie (P<0.01). Een patiënt had na BTS orthostatische 
hypotensie, maar zonder klachten. De bloeddruk daling werd waarschijnlijk veroorzaakt door de 
onderbreking van de sympatische activiteit naar de nieren. Het was niet aannemelijk dat de 
daling werd veroorzaakt door pijnvermindering. 
Zowel de basale plasma noradrenaline concentratie als de noradrenaline concentratie na activatie 
waren niet veranderd na BTS. De basale plasma adrenaline spiegels en de respons tijdens staan 
waren significant verminderd (P < 0.001). Aangezien de bijnieren de enige bron zijn van plasma 
epinephrine, wordt verondersteld dat deze verstoring van adrenomedullary functie, het gevolg is 
van het doornemen van de efferente sympathische vezels naar de bijnieren. Alhoewel dit effect 
bekend is bij proefdieren, is dit nooit eerder bij mensen vastgelegd. De klinische betekenis van 
deze bevinding is onduidelijk en moet verder worden onderzocht. BTS had geen invloed op 
noradrenergic sympathische activiteit. 
Het meten van epinefrine voor en na zenuwblokkade door een BTS, zou kunnen helpen bij het 
vaststellen van de volledigheid van de procedure. Bij nieuwere minder invasievere technieken 
waarbij de zenuwen niet zichtbaar zijn, kan de epinefrine bepaling extra van waarde zijn om 
volledige blokkade te bewijzen. 
Hoofdstuk 4 
Uit de studies in hoofdstuk 2 en 3 is gebleken dat BTS een veilige procedure is zonder ernstige 
comorbiditeit en goede korte termijn pijn verlichting biedt. In hoofdstuk 4 werd specifiek 
gekeken naar de lange termijn effecten van BTS op de pijn. Vier en veertig CP patiënten 
ondergingen BTS vanwege heftige pijn. Zesendertig patiënten (82%) gebruikten opiaten. 
Achtentwintig patiënten (64%) hadden al in totaal 35 CP gerelateerde ingrepen ondergaan. De 
mediane follow-up was 36 maanden (spreiding 12-60 maanden) 
Samenvatting | 167 
De procedure was technisch succesvol bij 40 patiënten (92%) Zesendertig patiënten (82%) 
hadden geen complicaties Elf van 24 patiënten met een follow up van 24 maanden of meer 
hadden een aanzienlijk lagere VAS na twee jaar (8,7 ± 0,8 versus 2,6 ± 1,4, ρ < 0 01) Het 
cumulatieve percentage pijnreductie of pijnvrij zijn bedroeg 48 maanden na de 
splanchmcectomie, 46% Uit de resultaten bleek dat ook na een langere periode BTS de pijn 
vermindert bij CP patiënten en dat de morbiditeit gering is Echter na BTS hield de pijn aan of 
keerde op de lange termijn terug in ongeveer de helft van de patiënten Zowel in deze studie als 
in de korte termijn studie waren er patiënten bij wie splanchmcectomie geen enkel effect had Er 
wordt verondersteld dat naast de splanchmcus zenuwen ook andere zenuwbanen cq systemen 
(zoals de tractus spinothalamicus, dorsale hoorn, nervus vagus) betrokken 7ijn bij de geleiding 
van nociceptie bij pancreatitis pijn Tenslotte laat deze studie zien dat een follow up van 
tenminste 1 jaar of langer nodig is om de pijnreductie na BTS nauwkeurig te kunnen 
beoordelen 
Hoofdstuk 5 
Er is slechts weinig bekend over factoren die het succes van een chirurgsiche pijnbehandelmg 
beïnvloeden, zowel na pancreas chirurgie in het algemeen als na BTS in het bijzonder In de/e 
studie werden de lange termijn resultaten bestudeerd van 75 opeenvolgende BTS procedures bij 
CP patiënten met pijn, met een follow up van 1 jaar of meer, en werden factoren geïdentificeerd 
die gerelateerd waren aan het succes van BTS Het succes van de behandeling werd geanalyseerd 
met behulp van een Kaplan Meier methode De factoren (enologie, geslacht, duur van de 
pancreatitis, eerdere pancreatitis gerelateerde ingreep, opiaat gebruik, anatomische afwijking, 
technisch succes en postoperatieve complicaties) werden geanalyseerd met een Cox regressie 
analyse Onder primair therapeutisch succes werd pijnverlichting verstaan (een VAS tenminste 2 
punten lager dan voorde BTS) in combinatie met reductie van pijnmedicatie We vergeleken 
patiënten met langdurige pijnreductie (primair therapeutisch succes langer dan 1 jaar), patiënten 
bij wie de behandeling binnen het jaar niet succesvol was, en patiënten bij wie de pijn na een jaar 
of later terugkwam Aanvullende behandelingen na een met succesvolle BTS werden eveneens 
bestudeerd Voor de operatie gebruikten zesenzestig patiënten (89%) iedere dag opiaten, 47 
(62%) hadden eerdere CP gerelateerde interventies ondergaan BTS was succesvol in 52% 
(lagere VAS en minder pijnmedicatie) van de patiënten na 12 maanden, 38% na 24 maanden, 
en 28 % na 48 maanden Eenentwintig patiënten (28%) hadden minder pijn aan het eind van 
de follow-up, van wie er 13 volledig pijnvrij waren zonder extra behandeling Pancreas chirurgie 
na een mislukte BTS was slechts succesvol in 13% van de patiënten Technisch succes was de 
enige factor die significant was geassocieerd met een succesvolle BTS (P=0 03) Preoperatief 
opiaat gebruik tendeerde tot een negatieve uitkomst van de behandeling (1 e geen pijnverlichting 
na BTS, of pijn (inclusief medicatie gebruik) terug op het preoperatieve niveau) Er werd 
geconcludeerd dat BTS lange termijn pijnreductie (>4 jaar) geeft bij 1 op 4 patiënten met 
ernstige CP pijn Opiaat gebruik voor de ingreep beïnvloedde in negatieve zin het effect van 
BTS op de pijn In deze groep bleek dat pancreaschirurgie na een onsuccesvolle BTS meestal ook 
niet leidde tot pijnreductie 
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Chronisch opiaat gebruik had een negatief effect op het resultaat van de BTS. Deze bevinding 
wordt ook gezien in onze recent uitgevoerde review, waarbij het pijnreducerende effect van een 
BTS vanwege chronische pancreatitis pijn, lager was, naar mate de incidentie van opiaat gebruik 
bij patiënten hoger was. We stellen dat BTS geen 'laatste redmiddel' is maar vroeger in een 
behandel algoritme moet worden geplaatst, bij voorkeur voordat wordt gestart met opiaten. 
Hoofdstuk 6 
Zelfs na een volledige denervatie van het pancreas kan de chronische pancreatitis pijn blijven 
bestaan of recidiveren. Traditionele pijn mechanismen zoals de aanwezigheid van een 
gedilateerde ductus of onstekingsmassa zijn ontoereikend om de persisterende pijn te verklaren. 
Het is bekend dat continue persisterende pijnprikkels (nociceptieve input) leidt tot verandering 
in de pijnverwerking door het centraal zenuwstelsel - neuroplasticiteit - en dat deze 
neuroplasticiteit een belangrijke rol speelt in die pijn die uiteindelijk chronisch en abnormaal 
van aard wordt. Tenminste twee mechanismen verklaren de pijn in chronische pancreatitis. Het 
eerste is een continue nociceptive input door een persisterende pancreas infiammane die 
vervolgens leidt tot centrale sensitisatie en viscerale hyperalgesia. Verder kan de continue 
viscerale nociceptieve input op een gegeven moment leiden tot zodanige pathologische 
veranderingen in de pijnverwerking van het centrale zenuwstelsel dat deze verstoorde 
pijnverwerking autonoom wordt en dus onafhankelijk is van perifere pijn input. 
Quantitative sensory testing (QST) is een instrument om neuroplasticiteit te meten en zodoende 
meer inzicht te krijgen in pijn mechanismen bij patiënten met chronische pijn, neuropathische 
pijn of patiënten met viscerale pijn syndromen. Bij deze techniek kunnen verschillende soorten 
prikkels (mechanisch: druk, haren van Frey, 'pin-prick', chemisch: capsaïcine, thermisch: koude 
of warmte of electrisch) met verschillende gestandaardiseerde sterktes op verschillende plaatsen 
worden toegediend. De pijnreactie van patiënt wordt vastgelegd om zo een prikkel respons te 
relateren aan de pijnverwerking (lees pijndrempels). Hiermee kunnen ook veranderingen in 
pijnverwerking worden gemeten. 
In deze studie werden 10 CP patiënten getest die ingesteld waren op opiaat medicatie en gepland 
stonden voor een BTS. De diagnose chronische pancreatitis was bevestigd door endoscopische 
retrograde cholangio-pancreatograPie (ERCP), computer tomografie (CT) en/of magnetische 
resonantie cholangio-pancreatograPie (MRCP). Geen van de patiënten was eerder geopereerd of 
had een pijnbehandeling ondergaan vanwege CP. Tien chirurgische patiënten zonder pijn 
vormden de controle groep. De verbale pijn Numerical Rating Scores (NRS) werden afgenomen 
op het moment van de QST. Mechanische pijn drempels werden bepaald met een druk 
algometer op een spier gelegen over een bot ter plaatse van de lage nek regio (C5 dermatoom), 
de thorax (T4 dermatoom), de pancreas regio (T10 dermatoom dorsaal), de heup regio (LI 
dermatoom) en de knie (L4 dermatoom). Electrische pijndrempels werden bepaald op de rechter 
lichaamshelft in dezelfde dermatomen als die voor de mechanische drempels. Drie drempels 
werden gemeten: sensatie (stimulatie net waarneembaar), pijndetectie (stimulatie die net pijnlijk 
is) en pijntolerantie (stimulatie die te pijnlijk is om vol te houden). Ten tijde van het testen 
bedroeg de mediane NRS 5 (bereik 3-8). QST resultaten lieten zien dat elektrische sensatie en 
pijn drempels significant waren verhoogd in het pancreas dermatoom. 
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Dit was meest opvallend bij vrouwelijke patiënten. De druk pijndrempels waren aanzienlijk lager 
in pancreatitis patiënten in vergelijking met de controle groep, met bij mannen een sterkere 
tendens naar gegeneraliseerde hyperalgesia dan bij vrouwen. Chronische pancreatitis patiënten 
lieten dus een uitgesproken gegeneraliseerde hyperalgesia zien ondanks opiaat therapie. Deze 
gegeneraliseerde hyperalgesie, passend bij centrale sensitisatie, was relatief duidelijker bij mannen 
dan bij vrouwen. Er waren ook aanwijzingen dat vrouwen een beter segmentale inhibirende 
respons hadden dan mannen. Dit verklaart waarschijnlijk waarom zij een minder uitgesproken 
gegeneraliseerde diep weefsel hyperalgesia hebben in vergelijking met mannen. Bij de 
hyperalgesie kunnen meerdere mechanismen betrokken zijn. Neerwaartse zenuwbanen vanuit 
het supraspinale zenuwstelsel kunnen, als gevolg van de continue viscerale nociceptie, een 
toegenomen stimulus versterkende activiteit (faciliterend) hebben die bijdragen aan de 
chronische pijntoestand van deze patiënten. Ook de zenuwsystcmen die van nature remmende 
(inhiberend) invloed hebben op de pijnperceptie kunnen o.a. door opiaten negatief zijn 
beïnvloed en zodoende bijdragen aan de hyperalgesie. Evenzeer kan de aanwezigheid van 
autonome sensitisatie (sensitisatie die niet langer afhankelijk is van nocicepticve input) 
verantwoordelijk zijn voor de pijn. Een ander mogelijk mechanisme betreft "opiaat geïnduceerde 
hyperalgesie" (Opioid induced hyperalgesia - OIH), waarbij het gebruik van opiaten 
veranderingen in de faciliterende zenuwbanen veroorzaken die leiden tot hyperalgesie. OIH is 
een bekend fenomeen in de acute en chronische pijn behandeling met opiaten. 
Hoofdstuk 7 
In deze studie werd met behulp van QST onderzocht of BTS in staat is om de veranderde 
centrale sensitisatie in chronische pancreatitis patiënten te reduceren. 
Negentien patiënten met CP (11 mannen, 8 vrouwen en allen ingesteld op opiaat medicatie) en 
18 gezonde vrijwilligers zonder pijn (preoperatieve controle groep) ondergingen QST. De 
patiënten werden zowel preoperatief als 6 weken na BTS getest. Pijn Ν RS en opiaat gebruik 
werden daarbij vastgelegd. Voor de QST werd hetzelfde protocol toegepast als beschreven in 
hoofdstuk 6. De BTS werd succesvol genoemd als de opiaatmedicatie na 6 weken volledig was 
gestopt. We vonden dat BTS geassocieerd was met een significante verhoging van de sensorische 
en pijndrempels (druk pijn: + 25%, Ρ < 0.001; elektrische: + 55% [sensatie], +34% [pijn 
detectie], +21% [pijn tolerantie], Ρ < 0.05). Bij mannen die vooraf een gegeneraliseerd 
hyperalgesie patroon vertoonden, leidde BTS tot een gegeneraliseerde hypoalgesie onafhankelijk 
van het klinische resultaat van de behandeling. Daarentegen hadden alleen vrouwen met een 
therapeutisch succesvolle BTS een segmentale hypoalgesie. Na BTS gebruikten significant 
minder patiënten opiaten, alhoewel dit niet gepaard ging met een lagere Ν RS. Een succesvolle 
behandeling was geassocieerd met een significant lager pre operatief opiaat gebruik. Onze 
resultaten suggereren dat BTS effectief is in het verminderen van de centrale sensitisatie. Deze 
resultaten in combinatie met de reeds eerder aangetoonde gegeneraliseerde hyperalgesie laten 
zien dat veranderingen in het centrale zenuwstelsel een belangrijke rol spelen in deze therapie 
resistente patiënten groep. Het was helaas niet mogelijk, om in deze betrekkelijk kleine studie, 
het succes van de behandeling te voorspellen aan de hand van specifieke patronen van 
neuroplasticiteit zoals aanwezigheid of afwezigheid van hyperalgesie. 
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Hoofdstuk 8 
Het feit dat volledige deafferentiatie door BTS niet effectief is in alle patiënten (hoofdstuk 4) zou 
erop kunnen wijzen dat in sommige patiënten de neuroplastische veranderingen (beschreven in 
hoofdstuk 6 & 7) onafhankelijk zijn van de perifere nociceptieve input wat het falen van BTS in 
deze patiënten kan verklaren. Om dit te onderzoeken werden 17 CP patiënten (10 mannen, 7 
vrouwen op stabiele opiaat medicatie) getest. Preoperatief en 6 weken na BTS werden pijn NRS, 
opiaat gebruik en mechanische pijn drempels (gemeten in dermatomes TIO (pancreas) en ter 
hoogte van C5 als representatieve plaats voor gegeneraliseerde hyperalgesia) gemeten. Wij 
vonden dat een verhoging van de pijn drempels 6 weken na BTS gepaard ging met een 
significante verlaging in pijnscores. Bij patiënten zonder effect van de BTS op de pijndrempels 
waren de pijnscores eveneens onveranderd. Dus in tegenstelling tot de bevindingen in ons vorige 
onderzoek (hoofdstuk 7) konden wij nu wel de QST resultaten (aan- of afwezigheid van 
hyperalgesia) koppelen aan een klinisch effect. Een mogelijke reden voor dit verschil kan liggen 
in het verschil in definitie van klinisch succes. In onze vorige studie was succes gedefinieerd als 
het stoppen van opiaten binnen zes weken na de behandeling en in deze studie werd de afname 
van NRS als eindparameter gebruikt. Achteraf gezien is het duidelijk dat een klinisch eindpunt 
als opiaatgebruik beïnvloed wordt door een groot aantal factoren, zoals bijvoorbeeld hoeveelheid, 
duur van gebruik of opiaat afhankelijkheid. Opiaat gebruik als eindpunt is ook niet of 
nauwelijks gerelateerd aan de veranderingen in pij η verwerking die waarschijnlijk in de eerste 
weken na de deafferentiatie optreden. Deze studie laat zien dat in een subgroep van patiënten, 
centrale veranderingen in pijn verwerking mogelijk onafhankelijk zijn geworden van continue 
perifere nociceptive input, waardoor pijn persisteert ondanks deafferentatie door BTS. 
Samenvattend is uitgebreide en nauwkeurige analyse van de veranderde pijnverwerking (bijv. 
met behulp van QST) vroeg in het behandeltraject zeer belangrijk voor een succesvolle 
behandeling van de pijn bij chronische pancreatitis. De behandeling van veranderde centrale 
pijnverwerking vereist een andere doelgerichte en specifiekere benadering dan de traditionelere 
behandelingen gebaseerd op nociceptive deafferentiatie. Onjuiste toepassing van deze 
behandelstrategieën leidt niet alleen tot teleurstellende resultaten maar kan ook de centrale 
sensitisatie verergeren o.a. via opiaat geïnduceerde hyperalgesie. Verder onderzoek zal zich 
moeten richten op het verbeteren van diagnostiek naar veranderde viscerale pijnverwerking (bijv. 
viscerale QST) en de hiermee geassocieerde comorbiditeit (o.a. d.m.v. EEG or fMRI) en naar 
alternatieve behandelingen zoals transcraniële magnetische of electrische stimulatie of vagus 
blokkade dan wel stimulatie 
Hoofdstuk 9 
Het is een bekend dat in sommige chronische pijnsyndromen een interactie (i.e. "cross-
talk'Vkortsluiting) bestaat tussen het autonome en het somatosensorische zenuwstelsel die tot 
hyperalgesie kan leiden. De buikorganen worden zeer uitgebreid geïnnerveerd door het 
autonome zenuwstelsel, het zogenaamde enterale zenuwstelsel, wat geen primaire rol speelt bij de 
nociceptie. Het is niet ondenkbaar dat de zenuwschade veroorzaakt door chronische pancreatitis 
zich niet beperkt tot de somatische pijnneuronen maar ook het autonome zenuwstelsel 'aantast'. 
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Het doel van dit onderzoek was om te bekijken of een dergelijke "cross-talk" tussen sympatische 
activiteit en pijnverwerking bestaat De hypothese was dat chronisch pancreatitis patiënten met 
meer sympathisch activiteit meer gegeneraliseerde hyperalgesie vertonen 
In zestien patiënten (10 mannen, 6 vrouwen) met ernstige chronische pancreatitis, werd de 
sympathische activiteit gemeten door middel van het meten van veneuze plasma norepinefrine 
(NE) concentraties in liggende positie (rust) en na activatie (staan) Pijnverwerking werd 
gemeten aan de hand van de drukpijn tolerantie drempels (PPT) op dezelfde wijze en in dezelfde 
dermatomen zoals in vorige hoofdstukken is beschreven De resultaten lieten zien dat vijf 
patiënten (4 mannen en 1 vrouw) significant verhoogde plasma NE concentraties hadden (NE 
>3 0 nmol/1) tussen 3,06 - 7 68 nmol/1 PPT was lager bij patiënten met een verhoogde NE 
spiegel (INE) in vergelijking met patiënten met een normale NE spiegel (NNE) (INE mean 
PPT 402 kPa [95% Cl, 286-517 kPa] vs NNE mean PPT 522 kPa [95% Cl 444-600 kPa], Ρ 
= 0 042) In een derde van de patiënten met pijn bij chronische pancreatitis werd aanwijzingen 
gevonden voor verhoogde sympathische activiteit Deze verhoogde activiteit was geassocieerd 
met lagere pijndrempels, hetgeen de hypothese ondersteunt dat het autonoom zenuwstelsel een 
rol in de pijn van deze patiënten kan spelen De NE kan hierbij direct via de adrenoreceptor 
aanwezig op de sensorische afferente zenuw stimuleren, of indirect via de release van mediatoren 
(o a Prostaglandines) Zo kan NE de sensorische zenuwen sensitiseren en de hyperalgesie bij 
patiënten met chronische pancreatitis pijn versterken 
Met veneuze NE monsters wordt alleen de globale sympatische actirviteit bepaald en subtiele 
lokale veranderingen in sympatische activiteit worden niet gemeten Dit zou een verklaring 
kunnen zijn voor het feit dat slechts een derde van de patiënten verhoogde NE concentraties in 
het plasma hebben Ook kunnen diabetes en chronisch alcohol gebruik, in onze groep patiënten 
vaak voorkomend, zenuwschade veroorzaken waardoor zowel de NE gevoeligheid als 
sympatische activiteit verstoord zijn De pijndrempels waren overigens met anders bij patiënten 
met diabetes en chronisch alcohol gebruik 
Hoofdstuk 10 
Activatie van de N-methyl D-Aspartaat (NMDA) receptor speelt een belangrijke rol bij het 
optreden van gegeneraliseerde hyperalgesia en OIH Beide spelen een rol in het ontstaan van 
hyperalgesie bij chronische pancreatitis pijn In deze studie evalueerden wij de effectiviteit van S-
ketamine, een met competitieve NMDA antagonist, in het verminderen van de gegeneraliseerde 
hyperalgesie in chronische pancreatitis pijn 
In een geblindeerde cross-over trial kregen 10 chronische pancreatitis patiënten met pijn in een 
willekeurige volgorde een S-ketamine of placebo infuus S-Ketamine werd toegediend als 
continu infuus van 2 microg/kg/min De totale duur van de S-ketaminc en placebo infusie was 3 
uur Pijn werd geregistreerd met de Visual Anologue Scale voor pijn (van 0=geen pijn tot 
10=onhoudbare pijn) en de verkorte Nederlandse Versie van de McGill Pain Questionnaire - sf-
MPQ-DLV Zowel electnsche pijndrempels (EPT) als druk pijndrempels (PPT) werden 
gemeten volgens een eerder beschreven protocol (Hoofdstuk 6) en de som van PPT(SOPTT) 
werd berekend voor de start van het infuus, aan het eind en na het infuus Negen patiënten 
voltooiden het onderzoek 
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De mediane VAS voor het infuus was 29 mm en 32 mm tijdens het infuus; de sf-MPQ-DLV 
score was 4. De PPT [IQR] verandering aan het eind van het infuus was significant hoger bij S-
ketamine infusie in vergelijking met placebo (218 [116- 527] vs. -123 [-330-24]; P=0.005). Ook 
was de SOPPT significant hoger in vergelijking met pre-infusie waarden, 2109 [964-3035] vs. 
1914 [842-2884] P=0.03). De SOPTT een uur na infuus verschilde niet met die van voor 
infusie en was niet significant verschillend tussen beide groepen. Er deden zich geen significante 
veranderingen voor in de VAS en de sf-MPQ-DLV. 
Een S-ketamine infuus van 3 uur is aan het eind van de infusie effectiever in het verhogen van de 
PPT dan een infuus met placebo bij chronische pancreatitis pijn. Dit effect verdwijnt vrijwel 
direct nadat het infuus is beëindigd. Studies met meer patiënten en een langere behandelduur 
zouden kunnen uitwijzen of er een langer durend effect op de PPT optreedt. De positieve 
resultaten met S-Ketamine ondersteunen het belang van studies naar de toepassing van andere 
anti-hyperalgetische medicatie (o.a. gabapentoiden en T H C (tetrahydrocannabinoid)) bij de 
behandeling van chronische pancreatitis pijn. 
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Stellingen behorende bij het proefschrift 
Bilateral Thoracoscopic Splanchnicectomy for chronic pancreatitis pain: 
Unraveling the effects on pain processing and outcomes. 
Bilaterale Thoracoscopische Splanchmcectomie (BTS) is een veilige, minimale invasieve 
behandeling voor chronische pancreatitis pijn met een beperkt lange termijn effect 
(dit proefschrift) 
Preoperatief opiaat gebruik beïnvloedt het effect van BTS op pijnverhchting in 
negatieve zin (duproefschrift) 
Chronische pancreatitis patiënten hebben een uitgesproken gegeneraliseerde 
hyperalgesie, passend bij centrale sensitisatie, welke meer uitgesproken is bij mannen 
dan bij vrouwen (dit proefschrift) 
BTS vanwege chronische pancreatitis pijn is effectief in het verminderen van de centrale 
sensitisatie (ditproefschrift) 
In een subgroep van patiënten zijn centrale veranderingen in pijn verwerking 
onafhankelijk geworden van continue perifere nociceptieve input, waardoor pijn 
persisteert ondanks deafferentiatie door BTS (ditproefschnfi) 
BTS moet vroeger in het behandel algoritme van chronische pancreatitis pijn worden 
geplaatst, bij voorkeur voordat wordt gestart met opiaten 
De behandeling van patiënten met acute necrotiserende pancreatitis en chronische 
pancreatitis moet m Nederland in snel tempo worden gecentraliseerd om de kwaliteit 
van zorg en prognose van deze relatief zeldzame aandoeningen te verbeteren 
De QST is betrouwbaarder dan de veel gebezigde uitspraak van de patient met 
chronische pijn 'ik heb een hoge pijndrempel' 
Het gebruik van het LPD in de spreekkamer leidt tot afname van de kwaliteit van de 
consultvoering en een toename van nekklachten bij de specialist 
Het met vergoeden van de behandeling van C2 varices draagt niet bij tot verbetering 
van de kwaliteit van zorg en zal ook met leiden tot kostenbesparing Hooguit ontstaat 
een toename van avondspreekuren en C3 varices 
Omdat het luisteren naar muziek van Mozart pijn vermindert en de concentratie 
verhoogt (het 'Mozart effect') zou Mozart muziek verplicht moeten worden gesteld op 
de pijn poli 
Het is dé alvleesklier en hét pancreas 
Marktwerking in de zorg leidt tot een markt waarin de zorg met werkt 
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